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In addition to white and brown adipose tissue (WAT and BAT, respectively), there is 
a third major adipose depot, called bone marrow adipose tissue (BMAT), the 
formation and function of which is poorly understood. In healthy adults, BMAT 
accounts for up to 70% of bone marrow (BM) volume and further increases during 
various conditions, such as ageing, osteoporosis, obesity, oestrogen deficiency, 
glucocorticoid (GC) therapy and, most surprisingly, during caloric restriction (CR) in 
animals and anorexia nervosa (AN) in humans. Furthermore, such BMAT expansion 
often coincides with bone loss. However, the mechanisms regulating BMAT 
expansion in these adverse conditions remain incompletely understood.  
 
One possibility is that GCs contribute to BMAT expansion and bone loss during CR 
and ageing. Long-term GC treatment can induce bone loss and BMAT expansion. 
One recent study found that CR is associated with elevated circulating GCs in mice, 
but not in rabbits; the mice also have increased BMAT, whereas the rabbits do not. 
Furthermore, GCs have been reported to increase during starvation or AN in humans, 
followed by BMAT expansion. Tissue regeneration of GCs is regulated by 11-
hydroxysteroid dehydrogenase (11-HSD1), which generates active cortisol in 
humans and corticosterone in rodents, from inactive cortisone and 11-
dehydrocorticosterone (11-DHC), respectively. Notably, 11-HSD1 KO mice resist 
the Cushingoid effects of GC excess. Thus, the hypothesis for this thesis is that GC 
excess contributes to BMAT expansion and bone loss during CR and ageing, and that 
11-HSD1 KO mice would therefore resist these effects. Herein, I addressed this 
hypothesis by characterising the BMAT and bone phenotypes of control and 11-
HSD1 KO mice in response to CR and ageing. 
 
To investigate the effects on BMAT and bone remodelling during CR, male and female 
C57BL/6J mice lacking 11-HSD1 (KO) or littermate controls (WT) were fed ad libitum 
(AL) or 70% of AL intake (CR) from 9-15 weeks of age. Whereas, to investigate the 
effects of ageing on BMAT and bone remodelling, KO and WT mice of both sexes 
were characterised at 15, 42 and 70 weeks of age. 
 
 IX 
Following CR, all mice had decreased body mass and increased plasma and BM 
corticosterone concentrations. Cortical bone loss was present with CR in all mice, and 
CR significantly increased BMAT in WT males and females, and in KO females. 
However, KO males resisted CR-induced BMAT expansion. Unexpectedly, the KO 
males also had significantly increased circulatory and BM progesterone, suggesting 
that this hormone might be a potential candidate. The aged mice exhibited increased 
circulating corticosterone and BMAT, and decreased bone mass, compared to young 
mice. However, unlike during CR, KO males did not resist age-related BMAT 
expansion, suggesting that the mechanisms for this differ to those responsible for 
BMAT expansion during CR. Correlation data between BMAT, bone parameters and 
GCs suggest these factors may be linked, but do not inform cause and effect. 
Although 11-HSD1 may play a role in BMAT expansion, the physiological 
significance remains unknown. 
 
These findings suggest that local corticosterone regeneration might mediate BMAT 
expansion during CR in males only. However, another possibility is that progesterone 
might influence the blockade of BMAT, since progesterone is the precursor to 
oestradiol, and oestradiol blocks BMAT formation. Given the sexual dimorphism, in 
females other mechanisms likely influence BMAT expansion during CR. Bone loss 
was observed in all mice, suggesting a limited role for 11-HSD1 in bone formation. 
Results in the aged mice suggest that 11-HSD1 does not influence BMAT expansion 
in this context. However, ageing-associated corticosterone and BMAT expansion did 
demonstrate a correlation with bone loss, while corticosterone was positively 
associated with BMAT volume in aged females.   
 
To conclude, 11-HSD1 activity is required for CR-induced BMAT expansion in 
males, and GC excess might contribute to ageing-associated BMAT expansion in 
females. Considering the broad physiological and pathological implications of BMAT, 
it will be important for future studies to further dissect the relationship between GC 
excess, BMAT expansion and bone loss. 
 X 
Lay summary  
 
Fat is a complex tissue whose main role is to store energy. The ability of our bodies 
to store fat is important, because it acts as an energy reserve in times of food scarcity. 
However, in modern times, the ready availability of energy-rich food has driven the 
increased prevalence of obesity. This disease is defined by the excessive 
accumulation of fat. Because of the health burden of obesity, there has been much 
interest in better understanding the functions of fat in normal health and disease.  
 
Mammalian fat is classed as two distinct subtypes, white and brown fat. It is the white 
fat that is specialised for fat storage and that accumulates excessively in obesity; in 
contrast, brown fat is specialised for generating heat. There is also a third fat subtype, 
called bone marrow fat (BMAT), which is present within the bone marrow. BMAT also 
expands during various clinical conditions such as ageing, bone loss, obesity, cancer 
treatment, oestrogen deficiency, and following treatment with glucocorticoids (GCs). 
GCs are a class of hormones that control stress responses. Most surprisingly, BMAT 
accumulates during caloric restriction (CR) in animals and anorexia nervosa (AN) in 
humans. CR has many health benefits, such as increased lifespan and decreased 
risk of diseases, but it can also promote bone loss. Thus, one possibility is that BMAT 
contributes to these beneficial and detrimental effects of CR. Similarly, BMAT 
expansion has been suggested to promote bone loss with ageing and in osteoporosis. 
Therefore, BMAT could be used as a potential drug target to prevent age-induced 
bone loss. However, there is a lack of knowledge in this field, and the factors 
responsible for the expansion of BMAT remain incompletely understood.  
 
One factor that might cause BMAT expansion and bone loss during CR and ageing 
is GCs. Patients on long-term GC treatment often have bone loss and BMAT 
expansion. A recent study revealed that CR-fed mice have increased BMAT as well 
as GCs; while CR-fed rabbits had neither of these. Furthermore, GCs and BMAT both 
increase during starvation or AN in humans, as well as during ageing; each of these 
conditions is also often accompanied by bone loss. These findings suggest that 
increases in GCs are required for BMAT accumulation during CR and might also 
contribute to BMAT expansion and bone loss as we age. 
 
 XI 
GCs are released by the same glands that produce adrenaline; however, GCs can 
also be regenerated inside tissues by an enzyme called 11-hydroxysteroid 
dehydrogenase 1 (11-HSD1). This enzyme amplifies GC action by converting 
inactive GCs into their active forms. The effects of this enzyme have been studied by 
analysing mice that lack this enzyme, known as 11-HSD1 knock out (KO) mice, and 
comparing these to normal, ‘wild-type’ (WT) mice, that retain this enzyme’s function. 
Such studies have shown, importantly, that KO mice resist the effects of excess 
amounts of GCs. Therefore, the hypothesis for my thesis is that GC excess controls 
BMAT expansion and bone loss during CR and ageing, and that 11-HSD1 KO mice 
will resist these effects.  
 
To investigate the effects of CR on BMAT and bone, WT and KO male and female 
mice were fed either a control diet or 70% of control intake (CR) from 9-15 weeks of 
age. The mice on CR had decreased body mass but increased circulatory and BM 
GC concentrations. CR also caused bone loss and increased BMAT in female WT 
and KO mice, and in WT males; however, KO males did not have BMAT expansion. 
The KO males also had significantly increased levels of progesterone in their BM and 
blood. Progesterone is a hormone that influences fertility in females, while in men it 
regulates sperm formation. This finding suggests that progesterone might be involved 
in BMAT formation, but this new possibility remains to be further investigated. 
 
To determine the effects of ageing on BMAT and bone, KO and WT mice of both 
sexes were examined at 15, 42 and 70 weeks of age. Older mice had increased BMAT 
and greater GC levels in their blood, along with decreased bone compared to young 
mice. GC levels were positively associated with BMAT volume in aged females, while 
BMAT was associated with bone loss in both males and females. Therefore, it 
remains possible that BMAT accumulation contributes to ageing-associated bone 
loss. To conclude, 11-HSD1 activity is necessary for CR-induced BMAT expansion 
in males only, whereas GC excess might contribute to BMAT expansion in aged 
females. Considering the role of BMAT in health and disease, it will be important for 
future studies to further understand the relationship between GC excess, BMAT 
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Chapter 1. Introduction  
 
 
1.1. Adipose tissue  
 
Adipose tissue (AT) is a complex tissue with profound effects on physiology and 
pathophysiology. Mammalian AT is generally classed into three distinct subtypes, 
white AT (WAT), brown AT (BAT) and beige/brite AT (Petrovic et al., 2010; Berry et 
al., 2013). AT is primarily composed of adipocytes, cells that are specialised for 
storing energy as fat. Besides adipocytes, AT also contains the stromal vascular 
fraction (SVF) consisting of cells such as pre-adipocytes, fibroblasts, vascular 
endothelial cells and also numerous immune cells (Ahima and Flier, 2000; Coelho, 
Oliveira and Fernandes, 2013). AT also serves mechanical and protective functions, 
for example in the heel fat pad and around the kidneys, and provides insulation from 
heat and cold (Rosen and Spiegelman, 2014). 
 
The most abundant human fat, WAT, plays a vital role in energy homeostasis: in times 
of a positive energy balance (i.e. energy intake > energy expenditure) WAT stores the 
excess energy as triacylglycerol, whereas in times of negative energy balance (e.g. 
fasting, starvation) WAT releases fatty acids (FAs) and glycerol to be used for beta-
oxidation or gluconeogenesis, respectively. WAT is now also established as a major 
endocrine organ (Rosen and Spiegelman, 2014). This concept originated with the 
discovery of adipose-derived circulating factors, called “adipokines”, which include 
hormones and cytokines such as leptin  (Zhang et al., 1994), TNF- and IL-6 
(Cianflone, Xia and Chen, 2003), adiponectin (Scherer et al., 1995; Hu, Liang and 
Spiegelman, 1996; Maeda et al., 1996; Nakano et al., 1996) and adipsin (Cianflone, 
Xia and Chen, 2003). Through release of these adipokines, WAT can exert diverse 
systemic effects, not only on energy homeostasis but also on other aspects of 
physiology such as blood pressure, immune function, and fertility (Michalakis et al., 
2013). Thus, WAT performs many essential physiological functions beyond energy 
storage and release. 
 
Much of the interest in WAT has been motivated by the increasing prevalence of 
obesity and associated metabolic diseases, such as type 2 diabetes (T2D), and 
dysregulated WAT function contributes to the pathogenesis of these diseases. WAT 
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is found viscerally as well as subcutaneously. Visceral WAT build-up is associated 
with increased cardio-metabolic risk (Grauer et al., 1984), while subcutaneous WAT 
build-up has fewer deleterious effects on health (Snijder, Dekker, Visser, Bouter, et 
al., 2003; Snijder, Dekker, Visser, Yudkin, et al., 2003). Therefore, understanding the 
mechanisms that influence the development of different AT depots may identify new 
strategies to treat metabolic diseases. 
 
In contrast to white adipocytes, which store energy, brown adipocytes burn it (Cannon 
and Nederfaard, 2004). This process is called non-shivering thermogenesis, i.e. the 
production of heat. This is possible with the help of a BAT-specific protein located 
within the mitochondria, uncoupling protein-1 (UCP-1) (Aquila, Link and Klingenberg, 
1985). Adults have increased BAT activity if exposed to chronic cold, as shown in 
Scandinavian outdoor workers (Huttunen, Hirvonen and Kinnula, 1981). Furthermore, 
since BAT burns energy, it has been considered a potential target to treat obesity and 
associated metabolic dysregulation (Dong et al., 2018; Moonen, Nascimento and van 
Marken Lichtenbelt, 2019). Prolonged cold exposure in rodents can also alter white 
adipocytes by causing them to develop a brown-fat-like morphology. These cells have 
been named “beige” adipocytes and have overlapping but distinct gene expression 
patterns compared to BAT, as well as having distinct developmental origins to brown 
adipocytes (Wu et al., 2012; Shan et al., 2013). Brown adipocytes have higher 
expression of UCP-1 and a greater capacity for uncoupled respiration than beige fat 
(Wu et al., 2012). In addition, beige AT can also increase energy expenditure, and 
therefore there has been a large interest in targeting adipocyte ‘beiging’ as another 
potential strategy to treat obesity (Wu et al., 2012; Shabalina et al., 2013; Phillips, 
2019). However, the development of these adipocytes and their mechanism of 
thermogenic stimulation needs to be better understood. 
 
In addition to WAT, BAT and beige AT, there is also a fourth major depot, called bone 
marrow adipose tissue (BMAT). BMAT is altered in various physiological and 
pathological conditions, but, compared to WAT, BAT and beige AT, the formation and 
function of BMAT is poorly understood. Unlike the other adipose depots, BMAT 
research has been relatively limited. Therefore, an overarching goal of my PhD 
research has been to elucidate the mechanisms that regulate BMAT formation, and 




1.2. BMAT  
 
Whilst WAT and BAT have received much research focus, BMAT has been largely 
ignored. Nonetheless, since mid 2000, the interest in BMAT research has expanded 
(Bravenboer et al., 2019). BMAT accounts for up to 70% of bone marrow (BM) volume 
and about 10% of total fat mass in healthy lean humans (Fazeli et al., 2013; Cawthorn 
et al., 2014). Furthermore, BMAT expands during various conditions including in 
ageing (Griffith et al., 2005, 2006; Yeung et al., 2005; Di Iorgi et al., 2008, 2010; Shen 
et al., 2012; Schwartz et al., 2013), in mice fed a high-fat diet (HFD) (Doucette et al., 
2015; Tencerova et al., 2018), obesity in humans (Bredella et al., 2011; Ambrosi and 
Schulz, 2017; Ambrosi et al., 2017), osteoporosis (Yeung et al., 2005; Rosen and 
Bouxsein, 2006; Zhao et al., 2008; Fazeli et al., 2013), in animal models of type 1 
diabetes (T1D) (Botolin et al., 2005; Botolin and McCabe, 2007; Slade et al., 2012), 
oestrogen deficiency (Syed et al., 2008; Veldhuis-Vlug et al., 2015), chronic kidney 
disease (Woods et al., 2018) and with glucocorticoid (GC) treatment (Vande Berg et 
al., 1999; J. Li et al., 2013). Perhaps most surprisingly, BMAT also expands during 
caloric restriction (CR) in animals (Devlin et al., 2010; Cawthorn et al., 2014) and 
anorexia nervosa (AN) in humans (Bredella et al., 2009, 2014; Ecklund et al., 2010), 
conditions in which WAT is depleted. The function of BMAT is still to be completely 
understood, although it is now clear that BM adipocytes (BMAds) are not just space 
fillers. Naveiras et al., showed that BMAds are negative regulators of the BM 
microenvironment, suppressing haematopoiesis. Whereas, the lack of BMAds 
accelerates haematopoietic recovery post-BM transplantation (Naveiras et al., 2009). 
In addition, just like WAT, BMAT has been identified as a source of adiponectin, 
highlighting its potential as an endocrine organ with systemic effects (Cawthorn et al., 
2014). Furthermore, BMAT expansion is associated with bone loss, increasing the 
risk of developing osteoporosis (Devlin and Rosen, 2015; Veldhuis-Vlug and Rosen, 
2018). These examples underscore the need to better understand BMAT formation 
and function, issues that are discussed further in the following sections. In addition to 
the association between bone and BMAT, bone remodelling is also highly regulated 
by hormones, including leptin (Karsenty, 2006), osteocalcin (Lee et al., 2007; Oury et 
al., 2011) and sex hormones  (Khosla et al., 2001; Nakamura et al., 2007) (Figure 
1.1). Leptin, an adipose-derived hormone acts on osteoblasts to regulate bone 
remodelling (Karsenty, 2006). Besides bone regulation, osteocalcin, an osteoblast 
specific protein also regulates metabolic functions (Figure 1.2). Uncarboxylated 
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(active) osteocalcin acts as a hormone to promote -cell proliferation, insulin secretion 
and sensitivity as well as energy expenditure (Lee et al., 2007). Carboxylated 
(inactive) osteocalcin directly binds calcium and resides in the bone. This inactivation 
is regulated by a different gene expressed in osteoblasts; Esp (Ferron, Wei, 
Yoshizawa, Del Fattore, et al., 2010; Fulzele et al., 2010). In addition to osteocalcin 
metabolic and bone functions, it was revealed that it also regulates male fertility (Oury 
et al., 2011). Undercarboxylated osteocalcin directly acts on Leydig cells to produce 
and secrete testosterone, a steroid hormone required for testicular function and 
fertility (Figure 2). In contrast, osteocalcin does not affect female fertility. Testosterone 
itself can also regulate bone remodelling by directly promoting osteoblast 
differentiation. Similarly, oestrogen also aids bone formation (further reviewed 
(Mohamad, Soelaiman and Chin, 2016)). This highlights osteocalcin as an endocrine 
factor from bone. Research regarding osteocalcin effect on BM adiposity or vice versa 







Figure 1.1. The differentiation mechanisms of adipogenesis and osteoblastogenesis. Mesenchymal stem cells (MSCs) can 
differentiate towards adipocytes and osteoblast. The master regulators of adipogenesis and osteoblastogenesis differ as seen in the figure. 
GCs can directly affect both pathways. GCs can promote adipogenesis and osteoblastogenesis. Although, excessive GCs leads to increased 
differentiation towards adipocytes rather than osteoblasts. Furthermore, sex hormones, such as progesterone, oestrogen and testosterone 
can promote bone formation.  However, oestrogen can also promote adipogenesis, whereas, testosterone inhibits it. WNT signalling pathway 
also inhibits adipogenesis, whereas TWIST, a transcription factor, inhibits osteoblastogenesis. The “+” indicates promotion. The “++” 




Figure 1.2. Effects of osteocalcin on metabolic functions. Osteocalcin, an 
osteoblast secreted bone protein can induce endocrine regulation of energy 
metabolism and male reproduction. Osteocalcin can promote -cell proliferation and 
insulin secretion, which further promotes osteocalcin. Furthermore, osteocalcin also 
promotes male reproductive function by stimulating testosterone production. In 
addition, testosterone, just like insulin, promotes osteocalcin release and supports 
bone growth, maturation and maintenance. Adapted from Karsenty and Oury, 2014. 
 
 
1.2.1. Origins, development and subtypes of BMAT 
 
The observation that BMAT expands during CR/AN is striking due to the fact that WAT 
decreases under the same conditions, suggesting that these two fat depots are 
developmentally and/or functionally distinct. Like WAT, BMAds gather lipid that 
accumulates into a unilocular droplet (Fazeli et al., 2013). WAT is derived from Myf5-
/Pax7- progenitor cells, whereas BAT derives from Myf5+/Pax7+ progenitor cells 
(Lepper and Fan, 2010). However, BMAds have developmental origins distinct to 
WAT and BAT. One of these distinctions relates to the expression of osterix (Osx), a 
transcription factor implicated in osteoblast development (Chen et al., 2014). Apart 
from lineage-tracing to osteoblasts and osteocytes, Osx-Cre also targets stromal 
cells, adipocytes and perivascular cells explicitly within the BM. This indicates a 
different origin of BMAds compared to white or brown adipocytes which are not traced 
by Osx-Cre (Chen et al., 2014). An independent study also revealed similar results 
using a different approach, where sorted stromal cells from BM cultures from pups of 
Osterix-EGFPCre/Ai9 matings were shown to be able to differentiate into not only 
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osteoblasts, but also adipocytes (Liu et al., 2013). These results further suggest that 
BMAds can be derived from cells expressing Osx.  
 
Besides lineage tracing, BMAd progenitors in mice recently have been characterised 
by flow cytometry using cell markers within the BM (CD45-, CD31-, Sca1+ and CD24+) 
and identifying progenitor populations that have adipogenic potential (CD45 -CD31-
Sca1+CD24-). These adipocytic lineages further respond to diet and age: the 
expression of the adipogenic marker Pparg is increased with age (25-month-old 
mice), whereas the osteogenic marker Osx/Sp7 is decreased. Moreover, aged mice 
on 10-day HFD have an increased proportion of the adipogenic CD45-, CD31-, Sca1+ 
and CD24+ population, associated with increased BMAT (Ambrosi et al., 2017). These 
findings suggest that age-and obesity-related BMAT accumulation is related to effects 
on progenitors in mice; however, the lineage development of BMAT is complex and 
additional studies are necessary to uncover it further, including in humans. 
 
1.2.1.1. BMAT development in humans  
 
In humans, at birth, the BM mostly contains haematopoietic cells, and is therefore 
referred to as red marrow due to its colour from erythroid cells. During postnatal 
growth, between 4 and 8 weeks of age, BMAds increase in number, resulting in less 
red marrow and more adipocyte-rich ‘yellow’ marrow (Scheller and Rosen, 2014). 
With ageing, the size of the BMAds also increases (Allen et al., 1995). Marrow 
conversion from red to yellow occurs from distal to proximal BM sites, with the 
adipocytes in the distal bone developing more rapidly in comparison to the proximal 
bone. By the mid-20s, the red marrow in the appendicular/distal skeleton of humans 
is almost entirely converted into yellow marrow; however, in the axial/proximal 
skeleton, the red marrow persists into adulthood (Kricun, 1985; Scheller et al., 2015), 
with a slower conversion throughout the rest of life (Justesen et al., 2001). The 
proximal bones display this slow conversion towards an increase in BMAds 
throughout life and therefore contains a greater proportion of haematopoietic red 
marrow compared to distal bone (Scheller et al., 2015). As a result of a slower 
conversion towards BMAds, the existing BMAds are more interspersed within the 
haematopoietic BM compared to distal BMAds. BMAT development further differs 
between men and women. Compared to premenopausal women, postmenopausal 
women have a sharp increase in BMAT volume, resulting in 10% more BMAT volume 
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than age-matched men (Griffith et al., 2012; Pansini et al., 2014). This highlights the 
influence of sex hormones on BMAT development and will be reviewed in more detail 
in Section 1.2.2.1. 
 
1.2.1.2. BMAT development in rodents  
 
Although it has been assumed that all BMAds are equivalent, a study in 1976 
proposed that the characteristics of adipocytes within the proximal bones differ to 
those within the distal skeleton (Tavassoli, 1976). In rodents, the differences between 
distal and proximal BMAds are more readily observed than in humans. Distal BMAds 
have an increase in unsaturated FAs and the adipocytes are larger (Scheller et al., 
2015). Just like in humans, these adipocytes develop soon after birth. By light 
microscopy, distal BMAds appear morphologically similar to WAT, storing lipid in 
large, unilocular droplets. Once the distal skeleton is accumulated with these mature 
BMAds there is less haematopoietic activity, owing to displacement of the 
haematopoietic red marrow. Following this initial stage, BMAds continue to form 
throughout life within the hematopoietic marrow, i.e. the proximal BMAds within the 
red marrow in the axial/proximal skeleton (Kricun, 1985). Proximal BMAds are 
characterised by an increased proportion of saturated FA and are smaller in size 
compared to the distal BMAds (Scheller et al., 2015). Other vertebrate species, like 
rabbits, have a similar pattern of BMAT development (Bigelow and Tavassoli, 1984). 
 
1.2.1.3. BMAT subtypes 
 
These observations in humans and other mammals reveal that BMAT is present 
throughout the skeleton and that BMAds properties show site-specific differences. 
This suggests that the function and/or formation of BMAds differ based on their 
location within the skeleton. Indeed, it has been proposed that two subtypes of BMAT 
exist, designated regulated and constitutive BMAT (rBMAT and cBMAT, respectively) 
(Scheller et al., 2015; Craft et al., 2018) (Figure 1.3). The anatomical location within 
the BM, development, morphological, molecular and functional characteristics differ 
between rBMAT and cBMAT (Craft and Scheller, 2017). cBMAds are larger than 
rBMAds and exist as contiguous clusters of adipocytes, similar to adipocytes within 
WAT. They also develop early in life and are resistant to expansion and breakdown. 
Whereas, rBMAds are present as smaller, discrete adipocytes that are interspersed 
within the haematopoietic environment. In rodents, cBMAT and rBMAT are more 
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readily distinguished by their anatomical location (distal-to-proximal), whereas in 
humans these two subtypes can exist adjacent to each other at a given BM site 
(Scheller et al., 2015; Craft et al., 2018). However, both rodents and humans display 
molecular and developmental differences between these subtypes. For example, 
compared to cBMADs, rBMAds have a greater proportion of saturated FAs and 
develop later in life. The rBMAds also further increase under different circumstances, 
including the adverse conditions described at the beginning of section 1.2; this will be 
further reviewed in Section 1.2.2 (Scheller et al., 2015, 2016, 2019; Craft et al., 2018). 
Additional molecular and functional distinctions have been found between these two 
subtypes (reviewed in (Craft et al., 2018)); however, further work is necessary to 




Figure 1.3. Subtypes of BMAT: rBMAT versus cBMAT. rBMAT = regulated BMAT. 







1.2.2. BMAT expansion in health and disease  
 
1.2.2.1. Ageing, osteoporosis and sex hormones 
 
Osteoporosis, i.e. the loss of bone tissue, is commonly observed with ageing. 
Numerous publications  report an inverse correlation between bone mass and BMAT 
in young and old men and women (Griffith et al., 2005, 2006; Yeung et al., 2005; Di 
Iorgi et al., 2008, 2010; Shen et al., 2012; Schwartz et al., 2013) (Figure 1.4). A 
different study did not find the same association, but instead suggested that increased 
BMAT could be used to diagnose bone weakness and fragility almost as well as 
measurements of bone mineral density (BMD) (Schellinger et al., 2004). Cross-
sectional results have revealed that associations between bone and BMAT expansion 
differ by sex. Increased BMAT volume is associated with lower trabecular, but not 
cortical bone mass in older women, but not in men. Furthermore, higher BMAT is 
instead negatively associated with BMD in men only (Schwartz et al., 2013). Beyond 
bone morphology, BMAT accumulation also differs between men and women and this 
relationship differs pre- vs post-menopause. Premenopausal women have lower 
BMAT volume than age-matched men whereas, post-menopause, BMAT volume 
sharply increases, such that postmenopausal women have 10% more BMAT 
compared to age-matched men (Griffith et al., 2012; Pansini et al., 2014). These sex 
differences are explained by the decrease of oestrogen post menopause, resulting in 
BMAT expansion (Syed et al., 2008; Limonard et al., 2015). Oestrogen therapy in 
women can also prevent the increased BMAds (Syed et al., 2008). Although men also 
have oestrogen, it is not their main reproductive hormone and is therefore likely to 
have less influence over BM adiposity in males. In addition, ovariectomised rats are 
more obese, have decreased bone mass and increased BMAT (Sottile, Seuwen and 
Kneissel, 2004). Although, similarly to humans, oestrogen replacement can reverse 
BMAT expansion in ovariectomised young and aged female mice (Elbaz, Rivas and 
Duque, 2009). Besides oestrogen, the ovaries also secrete testosterone and 
progesterone, suggesting that lack of oestrogen might not be the sole mediator of 
BMAT expansion post-ovariectomy. Indeed, testosterone administration in female 
rats decreases fat content in the BM (Tamura et al., 2005), supporting the possibility 
that other sex steroids influence BM adiposity. A recent cross-sectional study showed 
a negative association in aged men and women between BMAT and 
oestrogen/testosterone (Mistry et al., 2018). Besides BMAT, androgens can also 
regulate bone remodelling as previously mentioned in Section 1.2. Undercarboxylated 
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osteocalcin secreted from bone directly regulates the production on testosterone in 
men, but not in females. However, if osteocalcin regulates in/directly the formation of 
BMAT is unknown. Recent preprint publication shows that the global deletion of Bglap 
and Bglap2, meaning an osteocalcin KO mouse, does not have a different bone 
phenotype compared to control mice (Diegel et al., 2019). This would suggest that it 
might not affect BMAT either, although it cannot be excluded. Indeed with ageing, 
osteocalcin levels decrease (Vanderschueren et al., 1990; Obri et al., 2018) but it is 
yet to be revealed if this is associated with other hormones such as oestrogen, which 
is known to impact BMAT formation. These findings suggest that sex hormones do 
play a role in regulating BM adiposity with ageing. It therefore important to further 
understand the regulation of age-induced BMAT expansion, as BMAT may be a 




Figure 1.4. The outcome of ageing/osteoporosis on bone morphology and 
BMAT. Comparison between healthy and aged/osteoporosis trabecular bone. Bone 
morphology worsens as trabecular spacing increases and the bone formation 
decreases. BMAT subsequently expands as the bone regenerative potential 
decreases. Adapted from (Ambrosi et al., 2017). 
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1.2.2.2. Obesity and HFD-induced obesity  
 
BMAT accumulation does not occur only with ageing, but also with obesity and HFD. 
A positive association between BMAT and visceral AT was found in obese 
premenopausal women (Bredella et al., 2011). Similar association was found in 
healthy women (18-88 years old), with positive but not statistically significant 
association between BMAT and total body fat. BMAT was instead significantly 
associated with visceral WAT, but not after adjusting for age and menopause (Shen 
et al., 2007). In a different study, a positive and significant association was found 
between BMAT and visceral WAT in premenopausal women (Bredella et al., 2011). 
These observations show that BMAT can increase in human obesity, although the 
associations are complex and may depend on age and sex. 
 
Obesity can also increase the risk of developing diabetes in humans, and the 
association between BMAT and adiposity in diabetic patients has shown contradicting 
results. Past publications have found a positive association between BMAT and 
subcutaneous and abdominal AT in T2D postmenopausal women compared to 
healthy age-matched controls (Baum et al., 2012). However, BMAT significantly 
increases post menopause; hence, the elevated BMAT volume could have resulted 
from reduced oestrogen. Men with T2D also exhibit increased BMAT compared to 
age-matched controls, but overall adiposity was not included in the study (Sheu et al., 
2017). However, no significant differences in BM adiposity were found between 
healthy and diabetic patients in regard to body weight and body mass index (BMI). A 
past publication reported that BMAT positively correlated with body adiposity in 
control and diabetic women (Baum et al., 2012), whereas a different publication found 
no correlations between these parameters (de Araújo et al., 2017). In rodent models, 
T1D markedly increases BMAT but this is not observed in T1D patients (Slade et al., 
2012). Instead, in T1D humans the variation in BMAT is associated with changes in 
blood lipid levels. The lack of increase in BMAT in T1D humans may be due to insulin 
treatment, given that animal models of T1D go untreated. However, further research 
is necessary to understand the mechanism of BMAT expansion in diabetes. 
 
Mice on HFD exhibit a sharp increase in BMAT, with one study showing no changes 
in trabecular nor cortical bone parameters (Doucette et al., 2015). However, a more 
recent publication showed that HFD induced not only BMAT expansion, but also bone 
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loss (Tencerova et al., 2018). With diet-induced obesity, BMAds in young (6 months) 
and aged (14 months) mice had altered gene expression at each age, but the effects 
of obesity on the transcriptome were even greater in white adipocytes (Liu et al., 
2013). This demonstrates that obesity exerts differential effects on BMAds and white 
adipocytes, raising the possibility that BMAds may play distinct roles in obesity-related 
metabolic dysfunction.  
 
Overall, these results demonstrate an association between whole-body adiposity and 
BMAT. However, it is yet to be confirmed if overall adiposity with obesity initiates 
BMAT expansion, or if other factors are involved.  
 
1.2.2.3. Iatrogenic BMAT expansion  
 
Besides the above-mentioned conditions, BMAT can also increase in iatrogenic 
contexts. For example, following thiazolidinedione treatment (antidiabetic drugs), 
chemo/radiotherapy, GC therapy and beyond.  
BMAT significantly increases following chemo/radiotherapy in rodents (Georgiou et 
al., 2012; Fan et al., 2016; Horowitz et al., 2017; Wang et al., 2018; Lee et al., 2019) 
and humans (Georgiou, Hui and Xian, 2012; Cawthorn et al., 2014; Mostoufi‐Moab et 
al., 2015; Veldhuis-Vlug and Rosen, 2018). Increased BMAT and bone loss is also 
evident following thiazolidinedione treatment in mice (Schwartz and Sellmeyer, 2007; 
Piccinin and Khan, 2014; Sulston et al., 2016; Tencerova and Kassem, 2016) and 
humans (Grey et al., 2012; Pop et al., 2017). Although one study in humans showed 
the opposite results, with decreased bone loss and BMAT in the spine (Harsløf et al., 
2011), the balance of evidence shows that thiazolidinediones increase BMAT in 
rodents and humans. GCs are frequently used as anti-inflammatory drugs (Coutinho 
and Chapman, 2011). However, long-term usage often results in bone loss and 
increased risk of osteoporosis (LoCascio et al., 1990; Kim et al., 2006). Another 
outcome of increased GC action with drugs or hormones is BMAT expansion (Vande 
Berg et al., 1999). GCs are a key subject of this thesis as potential regulators of 
BMAT, and will therefore be further discussed in Section 1.3. 
 
Overall, these iatrogenic conditions result in increased BMAT in rodents and humans, 
suggesting that BMAT may contribute to other side effects of these therapeutic 
interventions. However, in each case the mechanism behind this effect remains to be 
identified.  
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1.2.2.4. CR and AN  
 
As mentioned above, during CR in animals (Devlin et al., 2010, 2016; Cawthorn et 
al., 2016) and AN in humans (Bredella et al., 2009, 2014; Ecklund et al., 2010), BMAT 
surprisingly increases. This is odd, as other adipose depots simultaneously decrease. 
This is also in stark contrast to obesity, when both overall body adiposity and BMAT 
increase (Shen et al., 2007; Bredella et al., 2011; Baum et al., 2012; L. Liu et al., 
2013; Doucette et al., 2015). This suggests that, unlike for WAT, the increase in BMAT 
does not always require excess calories and is likely mediated by different 
mechanisms in these two adverse conditions. CR without malnourishment, in which 
there is provision of adequate vitamins and minerals, has been shown to have 
beneficial effects on the ageing process and can extend lifespan in numerous species 
(Masoro, Yu and Bertrand, 1982; Lin, Defossez and Guarente, 2000; Houthoofd et 
al., 2002; Bodkin et al., 2003). With CR, a decrease in body mass, blood pressure, 
insulin, fasting glucose and serum total cholesterol levels are also observed 
compared to healthy age-matched controls (Fontana et al., 2004; Meyer et al., 2006). 
Besides these beneficial metabolic effects of CR, it is also of interest as potential 
therapeutic strategy to prevent and treat other chronic diseases, including 
Alzheimer’s, asthma, arthritis and cancer. Whether CR-induced BMAT expansion 
plays a role in these conditions remains to be determined. 
  
In contrast to CR, AN is an eating disorder that is characterised by malnourishment 
(lack of nutrition), resulting in weight loss and WAT depletion. However, unlike CR, 
AN has adverse health effects, including bone loss, increased fracture risk, 
immunosuppression and increased risk of mortality. For both AN and CR, why or how 
reduced food intake mediates BMAT expansion still remains indefinite. Past 
publications have demonstrated that women with AN have increased lumbar and 
femoral BMAT compared to age-matched controls. Moreover, increased BMAT in AN 
women was inversely correlated with BMD (Bredella et al., 2009, 2014). Adolescent 
women (between 13 and 18 years old) with AN have a greater risk of developing 
osteoporosis. By analysing the distal femur and proximal tibia from MRI scans of 
adolescent women with AN, it was revealed that they exhibit premature replacement 
of haematopoietic to adipose cells in the marrow. This is most likely owing to the 
increase of adipogenesis at the expense of osteoblast differentiation (Ecklund et al., 
2010). Furthermore, GCs are not only elevated during CR in animals (Sabatino et al., 
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1991; Chacón et al., 2005; Levay et al., 2010; Pankevich et al., 2010; Cawthorn et al., 
2016) but also in AN patients (Boyar et al., 1977; Walsh et al., 1978; Misra et al., 
2004; Lawson et al., 2009). This suggests an association between increased GC and 
BMAT expansion in these conditions.  
 
It is still debatable whether BMAT expansion with CR is good or bad. As CR results 
in increased BMAT and often bone loss, bone biologists see BMAT expansion as 
detrimental. However, BMAT has been shown to secrete the adipose-derived 
hormone adiponectin at higher concentrations than WAT, such that BMAT expansion 
contributes to hyperadiponectinaemia during CR (Cawthorn et al., 2014). This 
suggests potential beneficial effects of BMAT, because adiponectin can promote 
insulin sensitivity and exert other health benefits (further reviewed in section 1.2.3.3). 
Furthermore, BMAT-derived adiponectin has been implicated with CR-associated 
metabolic adaptations in skeletal muscle, suggesting that BMAT might have systemic 
effects (Cawthorn et al., 2014). It is therefore important to understand what regulates 
CR-induced BMAT expansion, as this understanding may further allow us to 
comprehend the functions of BMAT in normal physiology and disease. In addition, 
understanding what regulates CR-induced BMAT expansion, and the role of BMAT 
during CR, can aid out understanding if BMAT contributes to the health benefits of 
CR. For example, if and/or how BMAT expansion during CR contributes to the 
enhanced breakdown of visceral adiposity and the lower risk of developing 
cardiovascular disease. As of now, this still remains to be revealed.  
 
1.2.3. Functions of BMAT 
 
In section 1.2.2, different conditions were reviewed where BMAT expands in both 
health and disease. In the present section I focus on the proposed functions of BMAT 
during these conditions and in normal physiological contexts. 
 
1.2.3.1. BMAT and bone remodelling 
 
As mentioned in Section 1.2.2.1, BMAT expands in conditions such as ageing, which 
is also accompanied by bone loss. This has led to the concept that BMAT expansion 
occurs at the expense of bone formation, but this is not always the case. For example, 
during postnatal development in rabbits, BMAds accumulate as soon as the third to 
fourth weeks of life, which occurs at the same time as bone growth (Sabin et al., 
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1936). Bone formation and BMAT accumulation also coincide in armadillos (Weiss 
and Wislocki, 1956). A similar finding has been observed in young girls (4-10 years 
of age) (Newton et al., 2013), suggesting that BMAT accumulation is important for 
bone growth. However, other human studies have found negative associations 
between BMAT and bone (boys and girls, 5-17/18 years of age) (Shen et al., 2014; 
Gao et al., 2015). The variance in the results could be due to the age and sex of the 
children and to the skeletal sites analysed; indeed, inverse associations between 
BMAT and bone mass are often observed in the proximal BMAT, but not in the distal 
BMAT. 
 
BMAT volume and bone mass also differ in different mouse strains. For example, in 
C3H/HeJ mice, bone mass and BMAT volume are greater than in C57BL/6J mice 
(Scheller et al., 2015). Moreover, in C57BL/6J mice trabecular bone loss is apparent 
around 8 weeks of age, but BMAT volume does not increase until much later in life 
(Devlin and Rosen, 2015). Altogether, these observations suggest that BMAT 
accumulation and bone loss are not always inversely associated, and although 
increased BMAT is associated with bone loss in some pathological conditions, this 
likely does not reflect the physiological role of BMAds in healthy bone. Further insights 
are gained from the observation that, in bony fish, haematopoiesis occurs outwith the 
skeleton, and yet BMAds are still present (Craft and Scheller, 2017). This suggests 
that BMAds have physiological functions that are independent of haematopoietic 
regulation and instead relate to bone remodelling and function (Craft and Scheller, 
2017). 
 
While the above findings provide insights into the physiological interplay between 
BMAds and bone, further data support the concept that BMAds may play detrimental 
roles in skeletal pathologies. One such context is metastatic bone disease. For 
example, breast cancer cells spread preferentially to BMAT-rich regions of BM 
(Templeton et al., 2015). Moreover, mice fed a HFD with prostate tumours have 
increased tumour growth, and the increased BMAT promotes the proliferation and 
invasion of these tumour cells (Herroon et al., 2013). In addition, the anatomical 
location of BMAds also seems to matter, as tumour cells prefer to metastasize to the 
proximal part of the bone (Kricun, 1985). rBMAds are also more lipolytic compared to 
cBMAds (Scheller et al., 2019), with an increased supply in FA possibly further aiding 
tumour cell growth/survival. 
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The interactions between BMAds and tumours also extend to haematological 
malignancies, such as multiple myeloma and acute myeloid leukaemia. As previously 
mentioned, chemo/radiotherapy often results in increased BMAT, suggesting that 
BMAds could either promote and/or inhibit metastasis and/or tumour progression 
within bone. Previous research showed that BMAT expansion during multiple 
myeloma interacts with tumour cells in the BM, promoting tumour cell growth and 
survival (Trotter et al., 2016). BMAds can act as energy sources for tumour cells. The 
release from BMAds of growth factors (IL-6, TNF-, insulin-like growth factor 1 (IGF-
1), etc.), free FAs (FFAs) and numerous hormones, including adiponectin and leptin, 
may promote tumour cell survival and protect the tumour cells from chemotherapy-
induced apoptosis (further reviewed (Falank, Fairfield and Reagan, 2016). Altogether, 
the increase in BMAT is not aiding health in these conditions. Suppressing BMAT 
expansion might be an alternative to diminish the consequences of these conditions.  
 
Many studies have shown that osteoporotic patients have increased BMAT (Meunier 
et al., 1971; Justesen et al., 2001; Verma, 2002; Griffith et al., 2005; Yeung et al., 
2005; Tang et al., 2010; Devlin and Rosen, 2015; Cordes et al., 2016; Veldhuis-Vlug 
and Rosen, 2018). Patients with increased BMAT also tend to have a decrease in 
BMD compared to healthy age-matched controls (Griffith et al., 2012). Furthermore, 
increased BMAT is associated with higher risk of vertebral fracture in men, 
independent of BMD (Schwartz et al., 2013), and potentially with bone weakening 
(Schellinger et al., 2004). 
 
Due to bone loss often occurring with CR in animals and AN in humans, alongside 
BMAT expansion, studies have often focused on the supplementation of vitamin D. 
Furthermore, vitamin D is an important regulator of calcium absorption, hence the 
effects of vitamin D supplementation often include its effects on calcium, or vice versa, 
as well as the effects on PTH. CR reduced calcium absorption, however urinary 
calcium does not differ between postmenopausal women on a diet compared to age-
matched controls. Nonetheless, PTH decreases with vitamin D treatment. The 
decrease in calcium absorption could be a contributor to bone loss associated with 
weight loss during CR, hence calcium supplementation might be necessary alongside 
vitamin D (Shapses et al., 2013). A different study further showed that vitamin D 
supplementation and CR affect serum osteocalcin concentrations followed by 
enhanced insulin sensitivity. Although, in this study, PTH was unaltered between the 
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groups (Sukumar, Shapses and Schneider, 2015). Although, vitamin D is decreased 
with obesity, it increases with weight loss (further reviewed (Himbert et al., 2017)). 
Healthy non-obese volunteers underwent 25% CR for two years, and compared to 
age-matched controls, PTH did not differ at any point throughout the study. The CR 
group had significantly increased vitamin D, cortisol and adiponectin (Villareal et al., 
2016). Although patients with AN have reduced nutrient intake, one study showed 
that it most likely does not contribute to the low bone mass. Misra et al., (2006) 
published that girls with AN consume more calcium and vitamin D via supplements 
compared to normal-weight girls (Misra et al., 2006). Similar results were published 
for adolescent girls with AN (Misra et al., 2006; Haagensen et al., 2008; DiVasta et 
al., 2011). PTH concentration was however decreased in adolescents with AN 
(Haagensen et al., 2008; Lenherr-Taube et al., 2020). Overall, these results show that 
with CR there is an increase in vitamin D, but not during AN. Calcium remains 
unaltered during 25% CR, but it decreases during AN. How vitamin D and calcium are 
associated with BMAT expansion and bone loss during these conditions is still to be 
revealed. Although many studies have focused on the effect of vitamin D and calcium 
on bone, none have yet to include BMAT as a factor. Overall, these pathological 
functions of BMAT are not aiding health. However, it is vital to understand the 
mechanisms and pathways behind this for potential treatments. Additional research 
is also necessary to understand and determine the relevance of BMAds to not only 
these diseases, but also other bone diseases. 
 
1.2.3.2. BMAT and haematopoiesis 
 
The BM niche is the primary site of haematopoiesis. Changes to the BM, such as 
those that occur with increased adiposity, affect haematopoietic maintenance and 
differentiation (Adler, Kaushansky and Rubin, 2014). Furthermore, BMAds act as 
negative regulators of the BM niche in mice (Naveiras et al., 2009). However, a more-
recent publication found that human BMAds exhibit a positive regulation on the 
haematopoietic system (Mattiucci et al., 2018). Similar results were found in mouse 
BM, where mice lacking BMAds had slow haematopoietic regeneration post-
irradiation (Zhou et al., 2017). In addition, besides adiponectin, BMAds also express 
stem cell factor which aids the regeneration of the haematopoietic stem cells post-
irradiation (Zhou et al., 2017). Thus, the precise function of BMAds in regenerative 
haematopoiesis remains inconclusive. 
 19 
Additional insights are provided by studies of BMAT in AN, obesity and ageing. As 
previously discussed, BMAT accumulates in patients with AN (Section 1.2.2.4). 
However, in severe cases of AN, BMAT actually decreases and this is associated with 
decreased haematological function; post recovery, BMAT accumulates and the 
haematopoietic system regains its normal function (Geiser et al., 2001; Abella et al., 
2002; Fazeli and Klibanski, 2019). This further suggests that the presence of BMAT 
is beneficial for the haematopoietic system. 
 
With obesity and ageing, mesenchymal stem cells (MSCs) are mostly committed to 
the adipogenic linage (Tencerova et al., 2018), which does not only inhibit bone 
formation, but it also reduces the haematopoietic reconstitution in mice (Ambrosi et 
al., 2017). These results suggest that BMAT expansion contributes to age-and 
obesity-related dysfunctions of the BM microenvironment, which can potentially be 
involved in numerous other processes that interfere with the maintenance of bone and 
the haematopoietic system (Ambrosi et al., 2017). The number of haematopoietic 
stem cells also decreases with ageing in humans, and this is correlated with increased 
BMAT (Tuljapurkar et al., 2011). Iatrogenic expansion of BMAT following 
chemo/radiotherapy in rodents and humans can also alter the haematopoietic 
environment, as previously mentioned in section 1.2.2.3.  
 
Although HFD increases BMAT, BMAds do not exhibit a pro-inflammatory nor an 
insulin resistance phenotype, compared to white adipocytes (Tencerova et al., 2018). 
This suggests that although BMAds have a deleterious effect on the skeleton and can 
reduce haematopoietic reconstitution, obesity-induced BMAT expansion might not be 
entirely detrimental. 
 
Overall, the literature presents contradictory findings regarding the interplay BMAds 
and the haematopoietic system. Accordingly, more research is necessary to 
understand the association between BMAT and the haematopoietic system in various 
adverse conditions.  
 
1.2.3.3. BMAT metabolism and endocrinology 
 
BMAds are capable of secreting adipokines, such as adiponectin and leptin 
(Laharrague et al., 1998; Cawthorn et al., 2014), suggesting that BMAT may have 
endocrine functions similar to WAT (Scherer et al., 1995). The circulatory 
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concentration of adiponectin is decreased with obesity (Hu, Liang and Spiegelman, 
1996; Arita et al., 1999) but increased with CR (Zhu et al., 2004). Similarly, in patients 
with AN, adiponectin is often increased compared to age-matched controls (Bosy-
Westphal et al., 2005; Dolezalova et al., 2007; Modan-Moses et al., 2007); however, 
this increase is not always observed (Iwahashi et al., 2003; Tagami et al., 2004) and 
may depend on the duration and severity of the disease. Why circulating adiponectin 
concentrations increase in CR and AN still remains incompletely understood. A study 
showed that although adiponectin expression is increased with CR in WAT, 
adiponectin protein is decreased (Wiesenborn et al., 2014). Whereas, a different 
study in humans showed that circulating adiponectin is not associated with 
adiponectin secretion from WAT during CR (Wang et al., 2015). These findings 
motivated studies of other possible sources of adiponectin secretion, such as BMAT. 
 
As previously mentioned, both adiponectin and BMAT increase during CR in animals 
and AN in humans, suggesting an association between BMAT and circulating 
adiponectin concentrations. It has also been reported that adiponectin transcripts and 
protein are expressed in whole BM of long bones in mice (Berner et al., 2004; Shinoda 
et al., 2006; DiMascio et al., 2007), as well as in cultured BMAds derived from human 
femurs (Modan-Moses et al., 2007). BMAT from the rodent caudal vertebrae 
expresses adiponectin protein at similar levels as WAT (Cawthorn et al., 2014), 
whereas other adipocyte markers such as PPAR, fatty-acid-binding protein 4 
(FABP4), hormone-sensitive lipase (HSL) and perilipin A are expressed at much lower 
levels in the BMAds compared to WAT (Liu et al., 2011; Cawthorn et al., 2014). This 
suggests that, relative to other adipocyte markers, BMAds have greater adiponectin 
production than white adipocytes. To test if BMAT directly contributes to circulating 
adiponectin, studies were done in Ocn-Wnt10b mice, which resist BMAT expansion 
during CR. These mice were also found to resist CR-associated increases in 
circulating adiponectin, despite unaltered expression and protein in WAT (Cawthorn 
et al., 2014). 
 
This suggests that the differences in circulating adiponectin concentrations were not 
a result of altered adiponectin production from WAT and instead resulted from 
suppressed BMAT expansion. This was further confirmed during CR in rabbits, which 
decreased adiposity but did not cause BMAT expansion or hyperadiponectinemia 
(Cawthorn et al., 2016). These observations suggest that BMAT expansion is 
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necessary for hyperadiponectinaemia during CR, underscoring the conclusion that 
BMAT is an endocrine organ (Cawthorn et al., 2016).  
 
Besides adiponectin, leptin is also an adipose-derived hormone regulating food intake 
and energy expenditure (Hussain and Khan, 2017). Circulating leptin concentrations 
are associated with total AT mass, such that concentrations are increased with 
obesity (Heymsfield et al., 1999; Ahima, 2008) and decreased with CR/AN (Zgheib et 
al., 2014; Cawthorn et al., 2016). It has previously been reported that, as in WAT, 
leptin expression in BMAT is inhibited in response to CR (Cawthorn et al., 2016). 
Thus, while WAT and BMAT differ during CR in terms of their amount and effects on 
adiponectin, in terms of leptin expression they may share a common endocrine 
function. However, whether BMAT contributes to circulatory leptin concentration, and 
thereby influences downstream functions of leptin, still remains to be defined.  
 
1.2.4. Candidate regulators of BMAT formation   
 
BMAT increases and decreases in numerous adverse physiological and clinical 
conditions. For this reason, many studies have investigated possible regulators that 
might promote BMAT development. Prominent candidates include preadipocyte 
factor-1 (Pref-1), ghrelin, leptin, sex hormones and GCs (Figure 1.5). 
 
Pref-1 is a skeletal stem cell regulator (Abdallah et al., 2004). AN women in recovery 
have decreased BMAT, but also decreased Pref-1 levels (Fazeli et al., 2012). A 
positive association was also found between Pref-1 and proximal femur BMAT (Fazeli 
et al., 2010). This suggests that Pref-1 might have distinct effects during AN compared 
with nutritional abundance.  
 
Another hormone that might mediate CR/AN-induced BMAT expansion is ghrelin. 
Ghrelin is secreted by enteroendocrine cells in the stomach and is significantly 
elevated in AN individuals compared to normal weight subjects (Misra et al., 2005; 
Germain et al., 2007; Monteleone et al., 2008). BMAT was measured in women 
administrated ghrelin receptor agonist, and although the results were not significant, 
there was a trend for a decrease in BMAT. Whereas, in rodents, infusion of ghrelin in 
tibial BM promotes BMAT accumulation (Thompson et al., 2004). These findings 
suggest that ghrelin is playing an important role in BMAT development, but more 
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research is necessary to understand the mechanism behind it and the role of ghrelin 
in regulating physiological and pathological BMAT formation. 
 
Decreased leptin is correlated with increased BMAT in leptin deficient mice (Hamrick 
et al., 2004). However, leptin administration decreases BMAT volume in mice and rats 
(Hamrick et al., 2005, 2006; Devlin et al., 2016). Furthermore, decreased 
concentrations of leptin are associated with CR-induced BMAT expansion (Devlin, 
2011). Conversely, a different publication showed that decreased concentrations of 
leptin are neither necessary nor sufficient for CR-induced BMAT expansion (Cawthorn 
et al., 2016). Thus, it seems that hypoleptinaemia is not a critical regulator of BMAT 
formation in this context. 
 
As previously reviewed in section 1.2.2.1, BMAT expansion is associated with 
decreased oestrogen and ovariectomy in humans (Wáng et al., 2015) and animals 
(Elbaz, Rivas and Duque, 2009; Lecka-Czernik et al., 2017). Besides oestrogen, other 
sex hormones might also influence BMAT development. Administrated testosterone 
in female rats decreased BMAT (Tamura et al., 2005). Moreover, aged men with low 
testosterone and oestrogen concentrations have increased BMAT volume (Mistry et 
al., 2018). These findings suggest that sex hormones do play a role in regulating 
BMAT, but further research is required to establish the roles of these hormones and 
others such as progesterone in different conditions of altered BMAT. Whether sex 
steroids also influence BMAT expansion during CR or AN also remains to be 
determined. 
 
In addition to the above-mentioned potential regulators, there are many other factors 
that have been researched, including GCs. GCs can increase BMAT, and GC excess 
occurs in many conditions in which BMAT accumulates, including ageing, CR/AN, and 
Cushing’s syndrome (CS). CS can lead to increased visceral adiposity, decreased 
muscle mass and insulin resistance (Lönn, Kvist , Ernest, 1994; Tomlinson et al., 
2002). Since GC therapy (Vande Berg et al., 1999) and increased GCs with CR/AN 
are associated with increased BMAT, one would expect for patients with CS to also 
have increased BMAT due to excess GCs. One earlier study did not find any increase 
in BMAT in CS patients, compared to age-matched controls (Mayo-Smith et al., 1989); 
however, this negative finding may reflect limitations in the techniques available to 
measure BMAT at the time, as the measurements of BMAT were highly variable. 
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Indeed, two very recent publications did find increased BMAT volume in CS patients, 
which was also associated with hypercortisolism (Maurice et al., 2018; Ferraù et al., 
2019), compared to age-matched controls. Thus, along with the coincidence of BMAT 
expansion and GC increases during ageing and CR/AN, these findings in CS patients 
further support an association between increased GCs and BMAT accumulation. CS 
patients in remission have decreased BMAT, similar to age-matched controls (Geer 
et al., 2012; Maurice et al., 2018). Similar results would be expected for patients with 
AN in remission, and by changing the diet of CR mice to AL, although it has yet to be 
confirmed. 
 
For this thesis, I am especially interested in the GC excess that occurs during CR and 
ageing. This is because of the possibility, discussed above in Sections 1.2.2 and 
1.2.3, that BMAT expansion may not only contribute to the beneficial effects of CR, 
but also to bone loss and other detrimental effects of ageing. Therefore, the 
overarching goal of my PhD research has been to determine if GC excess contributes 
to BMAT expansion during CR and ageing. I discuss this possibility further in Section 
1.3.2; however, before doing so I first summarise the properties and functions of GCs 
in normal physiology and disease, focusing on CR and AN, and the regulation of GC 
action by 11-hydroxysteroid dehydrogenase (11-HSD1).  
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Figure 1.5. Distribution, clinical associations and possible causes and functions of BMAT. Schematic representation of the 
distribution of BMAT shown by the human skeleton, adapted from Kricun (1985). BMAT expands in various conditions, such as during 
caloric restriction (CR), anorexia nervosa (AN), ageing, osteoporosis, obesity, oestrogen deficiency and many more. The expansion could 
potentially be caused by glucocorticoids (GCs), ghrelin, preadipocyte factor 1 (Pref-1), fibroblast growth factor 21 (FGF-21), insulin-like 
growth factor 1 (IGF-1), oestrogen deficiency and possibly other hormones. Possible functions of BMAT include endocrine and metabolic 
functions, skeletal regeneration, haematopoietic regulation and tumour progression. 
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1.3. HPA axis and GCs 
 
In response to stress, GCs are synthesised and secreted by the adrenal gland. GCs 
are a class of steroid hormones that are used pharmacologically to treat inflammation; 
however, they can also cause immunosuppression. The release of circulating GCs, 
predominantly cortisol, but also 10% corticosterone in humans and corticosterone in 
rodents is centrally regulated by the hypothalamic-pituitary-adrenal (HPA)-axis. 
Although, most rodents also have cortisol, besides rats and mice because they lack 
adrenal expression of Cyp17a1. With stress or circadian rhythm, corticotropin-
releasing factor (CRF) (Spiess et al., 1981) and arginine vasopressin (AVP) are 
released from the paraventricular nucleus in the hypothalamus. In turn, these 
neuropeptides bind to the CRF and vasopressin receptors (1B) in the anterior 
pituitary, resulting in the release of adrenocorticotropic hormone (ACTH). CRF has 
been revealed to be the main regulator of ACTH release by the anterior pituitary 
(Rivier and Vale, 1983). ACTH then binds to receptors in the adrenal cortex, 
specifically the melanocortin receptor 2 that belongs to the G protein-coupled receptor 
(GPCR) superfamily, which upregulates intracellular cyclic adenosine 
monophosphate (cAMP). As a result, the steroidogenic acute regulatory protein 
(StAR) (Clark et al., 1994) will increase and up-regulate cholesterol transfer within the 
mitochondria (Simpson and Waterman, 1988). Cholesterol is the precursor to 
steroids; therefore, it is vital for GC synthesis and secretion into the circulation (Figure 
1.6).  
 
Treatment with GCs can lead to visceral obesity, osteoporosis, T2D, increased risk of 
cardiovascular disease, hypertension and atherosclerosis (Van Staa et al., 2000; 
Souverein, 2004; de Vries et al., 2007; Amiche et al., 2018). All of these are 
themselves, to some extent, inflammatory conditions. To exert their effects, GCs bind 
to intracellular nuclear hormone receptors, which results in the translocation of the 
receptor and its bound GC to the nucleus. GCs act via two intracellular receptors, 
glucocorticoid (GR) and mineralocorticoid (MR) receptors. The GR is encoded by the 
NR3C1 gene (Nuclear Receptor Subfamily 3 Group C Member 1) while the MR is 
encoded by the NR3C2 gene (Nuclear Receptor Subfamily 3 Group C Member 2). 
Unbound GR resides in the cytoplasm complexed with particular heat shock proteins 
(HSP), notably HSP90 and HSP70, and chaperone complexes such as FK506 binding 
protein 5 (FKBP5) (reviewed in ((Grad and Picard, 2007)). GCs can directly enter cells 
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by diffusing through the membrane and binding to the GR, thereby inducing 
conformational changes in this receptor. These changes allow the GR to dissociate 
from the multi-protein complex and translocate to the nucleus where it can 
transactivate or transrepress gene transcription. Transactivation occurs once the GC-
GR binds to the glucocorticoid response element (GRE) and up-regulates the 
production of regulatory cells with anti-inflammatory properties (e.g. GILZ). 
Transrepression occurs when the GC-GR complex binds to pro-inflammatory factors 
(e.g. NF-kB), reducing their expression. The anti-inflammatory properties of GCs can 
therefore result from both transactivation and transrepression (Coutinho and 











Figure 1.6. Schematic representation of the HPA axis and GC mechanism of 
action. The hypothalamus secretes corticotrophin-releasing factor (CRF) upon 
stress, which stimulates the pituitary gland to secrete adrenocorticotrophic hormone 
(ACTH). The adrenal glands are then influenced by ACTH, resulting in the synthesis 
and secretion of GCs (cortisol in humans, corticosterone in rodents) which can induce 
various metabolic effects. The minus signs (-) represent a negative feedback signal, 
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maintaining homeostasis. GCs can then induce gene expression by three different 
mechanisms: (1) circulating active GCs (cortisol/corticosterone, a-GCs (a: active)) 
(red line with dashes) can enter peripheral tissues and directly bind to the 
glucocorticoid receptor (GR) and transactivate or transrepress gene transcription; (2) 
inactivation of a-GCs by 11-HSD2 in the kidneys, followed by inactive GCs 
(cortisone/11-dehydrocorticosterone, i-GCs (i: inactive)) entering the peripheral tissue 
where it is reactivated by 11-HSD1; and (3) the activation of the GR increases 11-
HSD1 activity, further amplifying intracellular a-GCs. Adapted from (Morgan et al., 




1.3.1. 11-hydroxysteroid dehydrogenase 
 
11-HSDs are enzymes that catalyse the interconversion of inactive cortisone/11-
dehydrocorticosterone (11-DHC) and active cortisol/corticosterone. 11-HSD1 
catalyses the generation of cortisol/corticosterone whereas 11-HSD2 drives this 
reaction in the opposite direction, thereby producing cortisone/11-DHC from the active 
GCs. 
 
11-HSD1 is a NADPH-dependent enzyme, highly expressed in the liver relative to 
other tissues, with lower expression in AT and other tissues. In contrast, 11-HSD2 
is a NAD+-dependent enzyme, highly expressed in mineralocorticoid target tissues 
such as the placenta, kidney, colon, adrenal cortex and ovary (Condon et al., 1997). 
In the tissues in which it is expressed, the main role of 11-HSD2 is to protect the MR 
from excessive activation by GCs, by converting active to inactive GCs (Figure 1.7). 
This way, 11-HSD2 allows for access of aldosterone to the receptor instead (Holmes 
et al., 2006; Chapman, Holmes and Seckl, 2013). While the HPA axis determines 
circulatory GC levels, the intracellular GCs are regulated by the activity of 11-HSD1 
and 11-HSD2. The former can act bi-directionally in vitro, however, in vivo it 
predominantly catalyses intracellular regeneration of active GCs (Lakshmi and 
Monder, 1988) (Figure 1.5). The Hsd11b1 gene has 3 promoters: P1 (Bruley et al., 
2006) in the lung and kidney; P2 (Bruley et al., 2006) in liver, AT and brain; and P3 
(Moisan, Edwards and Seckl, 1992) in the kidney. Mice lacking this enzyme cannot 
convert 11-DHC to corticosterone in vivo, supporting the fact that 11-HSD1 is the 







Figure 1.7. Reaction catalysed by 11β-Hydroxysteroid dehydrogenase type 1 
and 2. 11β-HSD1, primarily a reductase in intact cells and in vivo, catalyses NADPH-
dependent reduction of cortisone in humans and 11-dehydrocorticosterone in rodents 
to active cortisol and corticosterone, respectively. 11β-HSD2, an oxidising enzyme, 
converts the NAD+-dependent inactivation of cortisol and corticosterone to cortisone 
and 11-dehydrocorticosterone, respectively (Griffiths and Wang, 2019). Adapted from 




1.3.1.1. Regulation of 11-HSD1 
 
11-HSD1 regulation is influenced by numerous factors such as metabolic conditions, 
pro-inflammatory cytokines, sex hormones, insulin, thyroid hormone and other 
endocrine mediators. However, the effects of these factors are tissue-specific and 
also vary between species (further reviewed by (Tomlinson et al., 2004)). 11-HSD1 
is also regulated by GCs themselves, both in primary cells in vitro (Jamieson, 1995; 
Whorwood et al., 2001) and in vivo (Hundertmark et al., 1994; Jamieson, Chapman 
and Seckl, 1999; Michailidou, Coll, et al., 2007). Indeed, 11-HSD1 expression in 
mice is up-regulated by GCs in both AT (Michailidou et al., 2007) and in the liver 
(Morgan et al., 2014). HFD-fed mice overexpressing 11-HSD1 in AT are not only 
obese, but they also have increased 11-HSD1 activity in AT (Masuzaki, 2001). 
Whereas in obese rats, 11-HSD1 is unaltered in subcutaneous AT but increased in 
omental AT and decreased in liver, compared to lean rats (Livingstone et al., 2000). 
A different study further confirmed the decrease in 11-HSD1 mRNA in the liver of 
obese mice (Liu et al., 2003). In contrast, a later publication showed an increase in 
11-HSD1 mRNA and activity in obese compared to lean mice (Morton et al., 2005). 
In obese humans compared to lean counterparts, 11-HSD1 activity is increased in 
subcutaneous AT (Rask et al., 2001, 2002; Paulmyer-Lacroix et al., 2002; Wake et 
al., 2003; Desbriere et al., 2006). However, at least one contradictory study suggests 
otherwise (Tomlinson et al., 2002). In contrast, in visceral AT, both increased 
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(Desbriere et al., 2006) and unchanged (Goedecke et al., 2006) expression of 11-
HSD1 mRNA concentration have been reported in obese subjects compared to 
healthy age-matched controls. This contradiction could be due to the fact that in the 
first mentioned study, lean vs obese women were examined (23 – 50 years of age), 
whereas, in the second study, premenopausal women (24 – 53 years of age) were 
examined. Thus, age and obesity may influence the relative expression of 11-HSD1 
in visceral vs subcutaneous AT. In contrast to obesity, only one study has examined 
11-HSD1 activity and mRNA expression during CR (Loerz et al., 2017). This study 
incorporated a porcine and a mouse model and revealed that 11-HSD1 regulation 
following CR and re-feeding is species-dependent (Loerz et al., 2017). Thus, in the 
mouse liver, mRNA was not changed between the AL-and CR-fed mice but it was 
increased in the CR-fed mice following re-feeding. However, protein levels showed 
the opposite results, while 11-HSD1 activity was significantly increased post-CR and 
re-feeding. Moreover, in the porcine model 11-HSD1 was unaltered in liver, AT and 
skeletal muscle following CR and re-feeding (Loerz et al., 2017). These results further 
confirm that regulation of 11-HSD1 is species-dependent. However, for better 
comparison between the two models, mouse AT should have been included.  
 
It is unknown if the effects of obesity and CR on activity and expression of 11-HSD1 
are similar between WAT and BMAT. Given that both of these adipose depots 
increase with obesity and HFD, it is possible that they also share similar responses in 
terms of 11-HSD1 function. However, considering the divergent effects of CR on 
WAT and BMAT, a key question is whether CR elicits differential effects on 11-HSD1 
function, and indeed GC action, in WAT and BMAT. This is important to establish 
considering the insights that may be revealed from better understanding the formation 
and function of BMAT during CR. 
 
1.3.1.2. 11-HSD1 deficiency  
 
Intracellular GCs are not only determined by systemic levels within the plasma, but 
also by intracellular levels that are regenerated from inert-11 keto forms by 11-
HSD1. To further understand the importance of this enzyme in vivo, a 11-HSD1 
knockout mouse model was first created in 1997, with exons 3 and 4 of the Hsd11b1 
gene replaced with a neomycin-resistance cassette (Kotelevtsev et al., 1997). 
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However, this KO model proved to be hypomorphic (partial loss of gene function) and 
continues to express Hsd11b1 in lung and kidney (Yang, 2010). Hereinafter, this KO 
model will be referred to as the ‘hypomorphic’ 11-HSD1 KO. An improved model was 
later created, with Cre-LoxP deletion of exon 3 in a C57BL/6 genetic background, 
completely lacking activity of 11-HSD1 (Vandermosten et al., 2017; Zhang et al., 
2017; Verma et al., 2018). Indeed, these improved 11-HSD1 KO mice did not 
regenerate corticosterone from 11-DHC, and 11-HDS2 was not affected by the 
knock out. This further confirmed 11-HSD1 as the predominant or sole 11-
reductase in the body. Hereinafter, this improved KO model will be referred to as the 
‘null’ 11-HSD1 KO. In addition to the null 11-HSD1 KO model, a third 11-HSD1 
KO model was generated by Semjonous et al., (2011). Compared to the hypomorphic 
and null 11-HSD1 KO model, this model was generated by removing exon 5 with 
LoxP sites (Semjonous et al., 2011). This model will be referred to as the 11-HSD1 
‘exon 5’ KO.   
 
Previously, the hypomorphic 11-HSD1 KO male mice on a MF1/29 background were 
used to investigate HPA axis regulation compared to age-matched controls. 
Overnight, circulatory corticosterone and ACTH concentration were significantly 
increased in the KO mice. Upon stress, corticosterone and ACTH concentrations were 
further increased, with an extended fall in concentration post stress. These 
observations implied that the KOs had increased basal HPA axis activity with reduced 
GC feedback, presumably to make up for the lack of intracellular regeneration of 
corticosterone (Harris et al., 2001). In addition, in a different strain of KOs, C57Bl/6J, 
these results differed. Plasma corticosterone and ACTH concentrations were not 
increased as in the MF1/29 strain. Furthermore, C57Bl/6J 11-HSD1 KOs have an 
increase in plasma corticosterone at only 10 min post restraint, whereas at 45-and 
90-minutes, no genotype differences were present. ACTH concentration was 
increased in both genotypes post 10 minutes of restraint, but returned to baseline 
levels after 45 and 90 minutes, with no genotype differences at any time point (Carter 
et al., 2009).  
 
The hypomorphic KO model was also shown to be protected from obesity, 
hyperglycaemia and dyslipidaemia induced by HFD (Kotelevtsev et al., 1997; Morton 
et al., 2004). However, in the newer, null KO model, this finding was not reproducible 
(K. Chaman, personal communication). In addition, pharmacological inhibition of 11-
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HSD1 in Apolipoprotein E (Apoe) KO mice prevented atherosclerosis progression, as 
well as further improving glucose tolerance and lowered triglycerides and FFA 
(Hermanowski-Vosatka et al., 2005). Furthermore, a different publication also treated 
Apolipoprotein E KO mice with an 11-HSD1 inhibitor, which reduced atherosclerosis 
by 74-76% but without influencing lipids or glucose (Kipari et al., 2013). A double 
knockout of Apolipoprotein E KO and 11-HSD1 KO mice was generated and showed 
a greater reduction in atherosclerosis compared to the inhibition of 11-HSD1 only. 
Transplantation of BM cells from the double knockout to the Apolipoprotein E KO mice 
further reduced atherosclerosis by 51%. These results suggest that 11-HSD1 
inhibitors could have beneficial effects on atherosclerosis, especially via effects on 
BM cells (Kipari et al., 2013). However, the 11-HSD1 KO model used in the 
publication was the original, hypomorphic KO; it remains to be investigated if the 
improved KO model has the same effects. A different study looked at metabolic 
consequences of the lack of 11-HSD1, specifically focusing on lipid and lipoprotein 
profile (Morton et al., 2001). Plasma triglyceride levels were decreased in AL-fed 
hypomorphic 11-HSD1 KO mice compared to WT controls. The KOs also had 
increased HDL cholesterol, with increased liver mRNA and serum concentrations of 
apolipoprotein A1 (protein component of HDL). Moreover, AL-fed KOs had 
significantly increased circulating corticosterone concentration, but with neither 
fasting nor re-feeding, the concentration in the KOs did not vary compared to the WTs, 
suggesting a deficiency in intracellular GCs in times of stress (Morton et al., 2001).  
 
These effects of 11-HSD1 on cardiovascular risk and metabolic function also extend 
to situations of systemic GC excess. Thus, Tomlinson et al., revealed that a 20-year 
old student with CS did not exhibit the classic phenotypes of this syndrome and 
instead had normal adipose distribution, lacked muscle weakness and had ideal blood 
pressure (115/70 to 122/82 mm Hg). In addition, she had mildly increased circulating 
cortisol but highly increased urine cortisol. Furthermore, cortisol to cortisone ratio was 
low, suggesting a partial defect of 11-HSD1 activity (Tomlinson et al., 2002). 
Likewise, a later publication showed similar results from a patient lacking the CS 
phenotype with a defect in 11-HSD1 activity (Arai et al., 2008). These studies 
suggest that deficiency and/or a defect in 11-HSD1 activity could improve the side 
effects of CS. More recently, 11-HSD1 has been revealed to be a regulator of tissue-
specific effects of circulating GC excess in mice (Morgan et al., 2014). Global 11-
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HSD1 exon 5 KO mice were protected from glucose intolerance, hyperinsulinemia, 
hepatic steatosis, adiposity and further symptoms of CS compared to age-matched 
controls. In addition, hepatocyte-specific 11-HSD1 exon 5 KO male mice developed 
a full CS phenotype, but adipocyte-specific KO male mice did not (Morgan et al., 
2014). In humans, 11-HSD1 inhibitor INCB13739 has shown to increase morning 
plasma ACTH and DHEAS levels in T2D patients. Four weeks in the treatment, the 
hormones increase, but they do not exhibit a further increase at week twelve, not even 
with the highest concentration treatment. ACTH and DHEAS concentrations return to 
baseline three weeks post the final treatment. Morning cortisol was unaltered by the 
inhibitor throughout the treatment, suggesting that the increase in ACTH might have 
been a compensatory response. Androstenedione, an androgen steroid hormone 
showed a dose-related increase in morning fasting serum. Testosterone was 
unaltered in male patients, but increased in a dose-related manner in the females 
(Rosenstock et al., 2010). Overall, this treatment improved the patient’s 
hyperglycaemia and it also indicates a functional HPA axis function post treatment. A 
different 11-HSD1 inhibitor, MK-0916, showed similar results in T2D patients with 
increases in androstenedione, DHEA and DHEAS concentrations (Feig et al., 2011). 
However, female patients did not have an increase in testosterone as they did with 
the INCB13739 inhibitor. Testosterone concentrations were not reported for men 
(Feig et al., 2011). Overall, these data from animal and human research further 
support that concept that inhibition of 11-HSD1, systemically or within adipose tissue 
only, may be a potential approach to treat CS and protect against metabolic disease. 
Whether it can also modulate GC action in other conditions of increased GCs, such 
as ageing or CR, remains to be determined. 
 
1.3.1.3. Role of 11-HSD1 in bone cells 
 
The latter point is of interest in the context of bone loss and BMAT expansion. Firstly, 
a short description about bone remodelling. The formation of bone can be regulated 
by two different ways. Firstly, the conversion of MSCs into bone (intramembranous 
ossification) which primarily occurs in the skull. Secondly, endochondral ossification, 
the formation of a cartilage intermediate followed by being converted into bone by 
osteoblasts (further reviewed Berendsen and Olsen, 2015; Katsimbri, 2017; Klar, 
2018). Throughout life, bone is further remodelled and regenerated by the interplay 
of osteoblasts (bone forming cells) and osteoclasts (bone resorption cells). Cortical 
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bone remodelling is more complex than trabecular but it not remodelled as often as 
trabecular. Bone remodelling consists of three stages: resorption, reversal and 
formation. During resorption, osteoclasts produce irregular cavities on the bone 
surface, followed by reversal where the osteoclasts enter apoptosis and mononuclear 
cells emerge on the surface. Thereafter, numerous proteoglycans are deposited on 
the surface, allowing the differentiation and proliferation of osteoblasts. Finally, during 
formation osteoblasts deposit osteoid that is transformed into mineralised bone 
(Berendsen and Olsen, 2015; Katsimbri, 2017; Klar, 2018). Bone metabolism is 
controlled by numerous signalling pathways. FGF, BMP and the Wnt signalling 
pathway are vital for osteoblast differentiation. Transcription factors such as RUNX2 
and osterix are also important for osteoblast differentiation (Javed, Chen and Ghori, 
2010; Lin and Hankenson, 2011). To maintain healthy bone mass and strength, bone 
must be continuously replaced.  
The effects of GCs on bone are well described, both for negative and positive 
outcomes. The negative outcomes include decreased osteoblast differentiation, 
apoptosis of osteoblasts/osteocytes and increased osteoclastic bone resorption, 
resulting into GC-induced osteoporosis (GIO). In contrast, the positive outcome is the 
increased differentiation of osteoblasts, resulting in greater bone formation. This was 
also shown by transgenic 11β-HSD2 mice (Sher et al., 2004). Different strains of mice 
have been shown to be affected differently by excess GCs. GIO was induced in both 
C57Bl/6J and CD1 mice over 56 days, however, the C57Bl/6J mice osteoclast and 
osteoblast were not as responsive to GCs as CD1 mice. Furthermore, C57Bl/6J mice 
were not susceptible to bone changes associated with GIO (Ersek et al., 2016). GIO 
is the consequence of reduced osteoblast differentiation and osteocyte function, and 
increased osteoclast differentiation, resulting in decreased bone mass which further 
increases the risk of fractures. GC administration in mice has shown that GCs directly 
act on osteoclasts by increasing their lifespan, resulting in bone loss (Jia et al., 2006; 
Henneicke et al., 2011; Zhou, Cooper and Seibel, 2013). However, the suppression 
of osteoblasts and osteocytes plays a bigger role in GIO, as shown in both clinical 
and experimental data (O’Brien et al., 2004; Zhou, Cooper and Seibel, 2013). 11-
HSD1 exon 5 KO mice treated with corticosterone for four weeks showed almost a 
complete protection against bone loss compared to WT mice, who had decreased 
bone volume. Compared to the above-mentioned study regarding strain difference, 
this study treated the mice with 100g/ml corticosterone (Fenton et al., 2019). 
Therefore, it is worth acknowledging that the dose, duration and strain are all 
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important factors. Further effects of GCs on bone cells and GIO models are reviewed 
by Wood et al., (2018). Briefly described, most GIO models are in mice as they share 
more than 95% of the human genome and have been identified as appropriate pre-
clinical models of GIO (Wood et al., 2018). Osteoblasts and osteocytes are the main 
bone cells in humans that express 11-HSD1, although osteoclasts can also express 
it (Cooper et al., 2000). Besides increased levels of circulatory GCs, 11-HSD1 
expression and activity has also been reported to be up-regulated in ex vivo cultured 
human osteoblasts with ageing and with GC administration (Cooper et al., 2002) and 
in mouse bones (Weinstein et al., 2010). Bone expression of 11-HSD1 is significantly 
up-regulated in aged (25-31 months old) compared to young (4 months old) male and 
female mice (Weinstein et al., 2010). Moreover, in aged humans (61 – 73 years of 
age) a negative association was indeed revealed between circulatory cortisone 
concentration and serum osteocalcin (Cooper et al., 2005). No correlations were 
found between cortisol and bone markers. However, a different study showed that in 
response to ACTH, a positive association was found between cortisol and the loss of 
mineral density in the spine of men (Reynolds et al., 2005). In women, cortisol was 
associated with increased femoral bone loss rate. As GC concentration and bone 
expression of Hsd11b1 both increase with ageing, it suggests age-induced bone loss 
is associated with increases in GCs.  
Cooper et al., investigated the role of 11-HSD1 activity in predicting GC effects on 
bone. Healthy men on 5 mg prednisolone for seven days showed decreased bone 
formation but unaltered bone resorption markers. The decreased bone formation was 
strongly correlated with increased 11-HSD1 activity, suggesting that the enzyme 
activity could predict susceptibility to GIO (Cooper et al., 2003).   
 
Genome-wide association studies have further implicated 11-HSD1 in age-
associated bone loss (Hwang et al., 2009; Feldman et al., 2012). A polymorphism in 
the HSD11B1 gene is associated with reduced BMD and an increased risk of fractures 
in postmenopausal women (Hwang et al., 2009). A different study examined whether 
HSD11B1 gene polymorphisms could affect bone in healthy and postmenopausal 
osteoporotic women. One of twelve single nucleotide polymorphisms (SNPs) showed 
an association with higher BMD in the spine in both groups. Further in vitro work on 
this SNP showed suppression of 11-HSD1, suggesting a beneficial effect of the SNP 
to reduce the regeneration of GCs and their detrimental effects on bone (Feldman et 
al., 2012).  
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Several 11-HSD1-selective inhibitors have been proposed to protect against GIO, 
with one of them being BVT.2733 (Wu et al., 2013). Overexpression of 11-HSD1 in 
mouse osteoblast precursor cells resulted in increased 11-HSD1 activity and 
decreased osteogenic differentiation. However, the addition of the inhibitor in vitro 
returned the osteogenic genes to normal levels, suggesting bone formation may also 
be restored in the face of GC excess in vivo. 
 
Up until now, several studies have addressed the function of 11-HSD1 in bone 
(Tomlinson et al., 2004; Gathercole et al., 2013; Zhou, Cooper and Seibel, 2013; 
Fenton et al., 2019) but very little is known about its function in the BM and BMAT. 
Gathercole et al., (2013) published a review about translational and therapeutic 
aspects of 11-HSD1 in metabolism, bone, cardiovascular diseases, inflammation, 
ageing and nervous system, and only mentioned BM as one of many stromal cell 
types in which 11-HSD1 expression and activity are increased with inflammation. 
Justesen et al., (2004) investigated BMAT as well as the bone phenotype in the 
hypomorphic 11-HSD1 KO mice. They reported that these KO mice lack BMAT but 
do not exhibit any other obvious bone phenotype. These results could infer that the 
lack of BMAT is not necessary for normal bone development and remodelling. 
However, Coutinho et al., (2012) later demonstrated histologically that the 
hypomorphic KO mice do not lack BMAT (Coutinho et al., 2012).  Subsequently, our 
lab has also shown that, on a normal diet, the null 11-HSD1 KO mice have a normal 
BMAT phenotype; this latter finding is based on osmium tetroxide staining, which, as 
described in the Methods (Section 2.6), allows BMAT quantification in intact whole 
bones, ex vivo, and is emerging as the gold-standard for BMAT quantification. It is 
important to reiterate that the data from Coutinho et al., (2012) and Justesen et al., 
(2004) used the hypomorphic KO model, whereas in our lab, we used the more-robust 
null 11-HSD1 KO model.  
 
Beyond these studies, there is no other direct evidence for a role of 11-HSD1 in 
BMAT. On balance, these data show that lack of 11-HSD1 does not robustly 
influence BMAT development, at least in a normal developmental and physiological 
context. However, a key goal for my thesis was to determine the basis for BMAT 
formation during CR and ageing, which, as discussed below, are conditions often 
characterised by GC excess.  
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1.3.2. Glucocorticoids: Possible mediators of BMAT expansion and bone 
loss during CR and ageing 
 
As briefly mentioned in Section 1.2.4, GCs have been postulated to regulate BMAT 
expansion. In terms of the association between GCs and BMAT, several studies show 
effects of GCs in a therapeutic context. For example, CR has been reported to elevate 
circulating GCs (cortisol in humans, corticosterone in rodents) (Sabatino et al., 1991; 
Patel and Finch, 2002; Chacón et al., 2005; Levay et al., 2010; Pankevich et al., 2010; 
Tomiyama et al., 2010; Cawthorn et al., 2016; Fontana et al., 2016). In addition, 
besides increased GCs and BMAT volume, CR has been well established to slow the 
ageing process and to prolong lifespan. Although increased longevity is a positive 
outcome of CR, negative outcomes of ageing, such as physical, mental and cognitive 
impairment are common (Kehler, 2019). This means poor health with ageing, 
including bone loss, increased BMAT and the risk of fractures, as previously 
discussed in Section 1.2.2.1. Indeed, ageing-related chronic disease is currently a 
major burden on public health worldwide (James et al., 2018). It is therefore important 
to understand the association between bone loss and increased BMAT with ageing, 
and if GC action contributes to these outcomes. Besides CR in animals and humans, 
AN in humans is strongly associated with circulatory (Boyar et al., 1977; Walsh et al., 
1978; Misra et al., 2004; Lawson et al., 2009) and salivary (Putignano et al., 2001; 
Oskis et al., 2012; Paszynska et al., 2016) hypercortisolaemia (Luz Neto et al., 2019). 
Hypothalamic CRF secretion has been reported to decrease with CR (Brady et al., 
1990; Lindblom et al., 2005), whereas ACTH was shown to either be reduced (Chacón 
et al., 2005) or unaltered (Levay et al., 2010) with CR. This could mean that the HPA 
axis responses could also be attenuated. A different study examined the responses 
of CR and stress on the HPA axis in rats, and besides increased circulatory 
corticosterone concentration, no other changes were detected (Kenny et al., 2014). 
This suggests a beneficial effect of CR to retain stress responses.  
 
A study in humans showed similar responses compared to rodents. Obese volunteers 
underwent 30% CR for 12 weeks, and although they lost significant weight, the 
restriction did not influence the HPA axis. For example, basal cortisol and 11-HSD1 
activity were not changed compared to at the end of the 12 weeks (Ho et al., 2007). 
In contrast to CR, obesity has been shown to dysregulate the HPA axis (further 
reviewed in more detail (Seimon et al., 2013)), with increased ACTH and cortisol 
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concentration. However, both short-and long-term food restriction in obese men and 
women has shown either no change (Ho et al., 2007; Tomlinson et al., 2008), 
decrease (Giovannini et al., 1990; Hainer et al., 1992; Vilà et al., 2001; Espelund et 
al., 2005; Pasiakos et al., 2011) or an increase (Johnstone et al., 2004) in cortisol 
concentration. One limitation to the above studies is that they focus on CR as a weight 
loss intervention in obese individuals: although this brings health benefits, it is distinct 
from CR in normal-weight subjects, in which CR is of interest to further improve health 
span. In this regard, one study investigated food restriction in non-obese men and 
women and showed a significant increase in circulatory cortisol concentration 
(Fontana et al., 2016). Moreover, patients with AN do not only exhibit increased 
BMAT, but also hypercortisolaemia (Boyar et al., 1977; Walsh et al., 1978; Misra et 
al., 2004; Lawson et al., 2009). These observations confirm that the BMAT and GC 
relationship extends to conditions of energy deficit in humans, and not just in animal 
models. The obese subjects showed contradicting effects in response to fasting, 
whereas the non-obese and AN subjects showed increased circulating cortisol 
concentrations. These disparate findings might therefore be due to age, sex and body 
mass differences in the individuals studied. 
To summarise, evidence from non-obese subjects, AN patients and CR-fed animals 
presents a similar finding: that GC excess and BMAT accumulation coincide in these 
conditions. Other evidence for this relationship in humans is based on MRI-scanned 
GC-treated pre-menopausal women. The patients presented BMAT expansion, bone 
loss and higher risk of developing osteoporosis, suggesting an association between 
increased BMAT volume and GC exposure (Vande Berg et al., 1999). To add to this 
conclusion, one in vivo study further elucidated these relationships in CR-fed mice 
and rabbits (Cawthorn et al., 2016). Here, circulating corticosterone and BMAT were 
elevated in male and female mice during CR, whereas neither corticosterone, cortisol 
nor BMAT was altered during CR in rabbits. This supports the possibility that GC 
excess is required for BMAT expansion during CR. Further in vitro experiments 
support this association between GCs and BMAT expansion. In vitro treatment of 
human femoral head BM MSCs with dexamethasone increased BM adipogenic 
differentiation as well as enlarging adipocyte size (Kitajima et al., 2007), suggesting 
that GCs do increase BMAd differentiation and lipogenesis. Likewise, 
dexamethasone treatment of rat and mouse BM MSCs resulted in similar findings, 
with an increase in BM adipogenic differentiation and target genes, and reduced bone 
transcription factors (Yin, Li and Wang, 2006; Lin, Dai and Fan, 2010). Progressive 
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changes in BMAds were reported in GIO and osteonecrosis in rabbits. Small-sized 
BMAds were significantly increased in the early stage of the treatment, with the total 
volume increasing later on (Li et al., 2013; Sheng et al., 2013). Overall, the in vivo 
and vitro results show that GCs can directly promote BMAT expansion. The 
hypercortisolaemia that occurs alongside CR-induced BMAT expansion could be 
associated with changes in the HPA axis that have yet to be explored. The previous 
findings of Morgan and colleagues (2014) shows that lack of 11-HSD1 can block the 
effects of GC excess (Morgan et al., 2014), even if it does not prevent BMAT formation 
in normal conditions (Coutinho et al., 2012). Based on the presented evidence, further 
and more in-depth research is necessary to comprehend the regulation behind CR-
induced BMAT expansion. For this reason, my PhD research focused on GCs as 
potential mediators of CR-induced BMAT expansion. My rationale for addressing this 
hypothesis was that, by understanding the formation and function of BMAT during 
CR, we might further understand if/how BMAT contributes to the health benefits of 
CR; we might be able to treat CR-and age-related bone loss by preventing BMAT 
expansion, or by targeting BMAT to improve other adverse conditions such as obesity; 
and, finally, that understanding the association between increased GCs and BMAT 
might aid the development of new treatments for conditions involving bone disease 
and excess GCs, such as CS. 
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1.4. Hypothesis and aims 
 
1.4.1. Hypothesis  
 
Based on the preceding evidence, my hypothesis is: 
 
11-HSD1 contributes to GC excess that mediates BMAT expansion and bone 
loss during CR and ageing. 
 
BMAT and bone morphology have not previously been investigated in null 11-HSD1 
KO mice in conditions of GC excess. Since CR/AN, ageing and GC therapy are 
associated with increased BMAT and circulating GC concentration, and mice deficient 
in 11-HSD1 can resist the consequences of excess GCs, I investigated if null 11-
HSD1 KO mice could resist CR-and age-induced BMAT expansion and bone loss.  
 
My specific hypotheses are as follows: 
 
1. CR contributes to increased GC action within AT and BM 
2. 11-HSD1 KO mice resist CR-induced BMAT expansion  
3. 11-HSD1 KO mice resist CR-induced bone loss  
4. Age-associated GC excess contributes to BMAT expansion and bone loss. 
 
1.4.2. Aims  
 
My PhD research aimed to test the above-mentioned hypotheses, by determining if 
GC excess mediates BMAT expansion and bone loss during CR and ageing. I sought 
to address this aim by using null 11-HSD1 KO and WT male and female mice. My 
rationale for using this model is that these KO mice also resist the effects GC excess 
in the context of exogenous corticosterone administration (Morgan et al., 2014). 
  
My specific aims were as follows:  
 
1. Firstly, to identify if GC action is increased in BM and AT during CR in WT 
mice.  
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2. Secondly, determine if the lack of intracellular regeneration of corticosterone 
(KO of 11-HSD1) prevents BMAT expansion. 
3. Thirdly, to identify if the lack of intracellular regeneration of corticosterone (KO 
of 11-HSD1) prevents bone loss with CR. 
4. Finally, to establish if the lack of intracellular corticosterone regeneration (KO 
of 11-HSD1) prevents bone loss and BMAT expansion with ageing. 
 
To test the hypotheses, quantification of GCs in the circulation and within BM, as well 
as analysis of GC target gene expression in BM and AT, were performed. Moreover, 
BMAT and bone morphology were also analysed in the younger mice undergoing CR 





Chapter 2. Methods  
 




The mice were kept and experimented under humane conditions in accordance to the 
Animal (Scientific Procedures) Act UK 1986, with the 3Rs (replacement, reduction 
and refinement) implemented wherever possible.  
 
Global HSD11β1Del1/Del1 (KO) mice were received by Karen Chapman (University of 
Edinburgh) within the same animal facility, Bioresearch and Veterinary Services 
(BVS), Little France, Edinburgh, UK. The KO mice are carrying a null allele of 
Hsd11b1, generated by Cre-LoxP deletion of exon 3 in a C57BL/6JOlaHsd genetic 
background, completely lacking activity of 11-HSD1 (Vandermosten et al., 2017; 
Zhang et al., 2017; Verma et al., 2018). The KO mice were generated by mating 
heterozygous males and females. The experiment used KO male and female mice 
with age-matched C57BL/6J mice as controls (WT). The mice were housed 
individually or in groups of 2-5 mice per cage and kept under controlled conditions 
(7:30am to 7:30pm light/dark cycle, 21°C) with ad libitum (AL) access to water and 
regular rodent chow (Special Diet Services, UK), unless stated otherwise.  
 
2.1.2. Caloric restriction  
 
At 8 weeks of age, the mice were single-housed and the diet changed from standard 
chow to a low-fat control diet (Research Diets D12450B) to allow them to get used to 
the different food. The mice were weighed daily (Figure 2.1.A) to prevent loss either 
due to stress from being single-housed or due to adaptation to the new food. Daily 
AL-food intake was also recorded (Figure 2.1.B), firstly to ensure the mice were 
eating, and secondly, to identify the average food intake for calculating out the CR 





Figure 2.1. Body mass progression and food intake during the first week of diet 
change. (A) Body mass progression over the first week of single-housing. (B) Daily 
AL food intake during the first week of single-housing. Each point represents the 
weighed food mass eaten per day. 
 
 
Post the first week of single-housing, the mice were randomly assigned to two equally 
sized groups, consisting of both males and females, for the time of one or six weeks. 
One group was assigned to AL food intake (Research Diets D12450B); the other 
group was assigned to a CR diet (Research Diets D10012703) at 70% of the 
previously calculated AL food intake (2.1g). Previous experiments (Devlin et al., 2010; 
Cawthorn et al., 2014), found that 70% of the AL food intake was sufficient to drive 
BMAT expansion and bone loss in mice. Therefore, it was a clear-cut decision to 
choose this method. The CR diet was enriched to prevent deficiency of micronutrients. 
Further details about the caloric information on the diets is described in Table 2.1.  
 
Diet 
Ad libitum control diet 
(D12450B) 
Caloric restriction diet 
(D10012703) 
Food group grams % (kcal) grams % (kcal) 
Protein 19.2 20 18.9 20 
Carbohydrate 67.3 70 66 70 
Fat 4.3 10 4.2 10 
kcal/gram 3.85 3.77 
Table 2.1. Caloric information on ad libitum control and caloric restriction diet.  
 
Throughout the one or six-week period, all mice were monitored and weighed daily 
for the first two weeks (mice on six-week CR) or for the entire one week (mice on one-
week CR) of the CR experiment, ensuring their body weight did not exceed loss of 
30% of their current body weight. Afterwards, the mice were still monitored daily, but 
weekly weighed only. If their body weight did not exceed loss of 30% of their starting 







































body mass in the first two weeks, it meant they were maintaining a suitable body 
weight.  
 
2.1.3. Weakly measurements 
 
Post the weekly body weights, blood glucose was also weekly measured to monitor 
the mice for hypoglycaemia, by a blood glucose meter (OneTouch Verio® meter or 
OneTouch Verio® IQ meter). Blood sampling was weekly collected in the morning, 
approximately 09:00, before feeding the CR mice. Blood was collected from the tail 
vein in Ethylenediaminetetraacetic acid (EDTA)-lined capillary tubes (Sarstedt, 
16.444) and placed on ice until centrifuged down at 2000 rcf for 10 minutes at 4°C. 
Plasma was then collected and stored at -80°C until required.  
 
Body composition was also weekly measured and recorded using time domain 
nuclear magnetic resonance (TD-NMR, Bruker). The TD-NMR measurement 
provided details regarding the mice body fat, lean mass and free fluid. It allows to 
measure body composition without harming the mice, using radio-frequency energy, 
allowing non-destructively analysing the entire sample volume. The mice are inserted 
in plastic tubes that are provided by Bruker, followed by gently pushing the mice at 
the end of the tube with the inserter which will then lock onto the tube to keep the 
mice safely inside. The tube will then be inserted into the TD-NMR machine for 
approximately 20-30 seconds. Once the scanning is complete, the values for body 
fat, lean mass and free fluid are provided as absolute mass. The tube will then be 
removed from the TD-NMR, and opened above the cage to release the mouse.  
 
2.2. Genotyping   
 
Initially, I started performed the genotyping myself. However, to save time, I provided 
these primers and amplicon details to Transnetyx so that subsequent genotyping 
could be done by sending ear clips to them. Genotype was then further confirmed 
after euthanasia by qPCR measurement of Hsd11b1 mRNA in adipose depots (iWAT 
and gWAT, figure 4.8) and the BM (Figure 4.12.A-B). The genotyping protocol is 
described below.  
Primers 
Flox 1F:  CTTGCATGTGTTTGGTGTTGG  
Flox 1R: AATGTTTCCAAATGCATTGTGGG  
DEL 1F: GTGATGTCAGATCTACAGAAGG 
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Two reactions were used due to uncertainty of the results, as sometimes the bands 
were too weak to distinguish between the WT and KO: one using Flox 1F + Flox 1R 
primers, and the second one using DEL 1F + Flox 1R. The cycling conditions are the 
same for each reaction. DNA was extracted from the ear clips by adding them to 75l 
of solution 1 (100ml dH2O, 40μl of 0.5M EDTA, 0.1g NaOH), followed by incubation 
at 95°C for 30 minutes in a thermal cycler. Afterwards, 75l of solution 2 (96ml dH2O, 
4ml 1M TRIS, adjust to pH 5.5) was added to neutralise the solution. Thereafter, it 
was kept on ice or stored at -20°C until use. 
 
PCR reaction mix 
 
Reagents Flox 1F + 1R 
reaction (l) 
DEL 1F + Flox 1R 
reaction (l) 
5xQ solution (Qiagen Taq PCR Core 
Kit, 201225)  
10 10 
10x Buffer (Qiagen Taq PCR Core Kit, 
201225) 
5 5 
dNTP (10mM) (Qiagen Taq PCR Core 
Kit, 201225) 
1 1 
Flox 1F primer (25M) 2 - 
Flox 1R primer (25M) 2 2 
DEL 1F primer (25M) - 2 
Qiagen Taq (Qiagen Taq PCR Core Kit, 
201225) 
0.24 0.24 
H2O (VWR, SH30538.03) 26.8 26.8 
Total Volume 47.04 47.04 
DNA (from the earclip)  3 3 
 
 
PCR cycling conditions 
 
Cycle 1 (1 cycle)  95°C, 10 min 
Cycle 2 (35 cycles) 95°C, 30 sec 
63.2°C, 30 sec 
72°C, 90 sec 
Cycle 3 (1 cycle) 72°C, 10 min 









2.3. Euthanasia and tissue sampling  
 
2.3.1. Young mice on CR 
 
At the end of the CR experiment, the day before termination, a final body composition 
measurement was performed using TD-NMR. The evening prior to termination, the 
mice on the six-week CR experiment were fasted. The AL fed mice had their food 
removed, and were given half a portion of the 70% of food that they were daily 
consuming (1.5 g). The CR fed mice were also given half a portion (1.05 g) of their 
30% CR diet. Thereafter, they were fasted approximately 12 hours before dissections. 
The mice on the one-week CR experiment were not fasted prior to termination. They 
were equally scanned by TD-NMR the day prior to termination, but they were not 
fasted nor re-fed in the evening.  
 
The morning of dissections, between 08:00 – 09:00, blood glucose was measured 
and tail vein blood collected. The mice were then transferred over to the department’s 
ex vivo room, where they were culled between 09:00 – 11:00 by cervical dislocation, 
followed by decapitation to confirm death. Core blood was then collected from the site 
of decapitation and organs were harvested. Half of the tissues of the liver, both 
kidneys’, both adrenal glands and the WAT, such as inguinal WAT (iWAT), gonadal 
WAT (gWAT), mesenteric WAT (mWAT) and BAT, were collected and placed in 
Eppendorf tubes containing 10% formalin (Sigma Life Science, HT501320-9.5L), and 
the other halves of tissues were placed in empty Eppendorf tubes stored on dry ice. 
The spleen and thymus were placed in 1x PBS (Gibco, 14190-094) in preparation for 
flow cytometry analysis. The heart, caudal and lumbar vertebrae were merely 
collected for storage in 10% formalin. One of each of the long bones collected, two 
tibiae, two femurs, two humeri and two forearms, were placed in 10% formalin, and 
the others on dry ice.  
 
2.3.2. Aged mice  
 
At approximately 42-and 70-weeks of age, the WT control and 11-HSD1KO mice 
were the appropriate age for the ageing experiment. Throughout the 42-and 70-
weeks, the mice were seldom handled. When they reached the appropriate age, the 
mice were weighed and also scanned for body composition, specifically for the fat 
mass, by TD-NMR.  
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Prior to dissections, the mice were fasted for one hour. An hour later, blood was 
collected from the tail vein. Thereafter, the mice were transferred over to the ex vivo 
room of the department where they were culled by cervical dislocation, followed by 
decapitation to confirm death. Core blood was then collected from the site of 
decapitation and organs were harvested as previously, apart from the spleen and 
thymus which were collected for formalin only.  
 
2.4. Transcript quantification  
 
2.4.1. Frozen tissue homogenisation using mortar and pestle 
 
The frozen adipose depots were put on dry ice to remain cold. The mortar and pestle 
were also put on dry ice and liquid nitrogen was poured over them to accelerate the 
cooling down process. The frozen AT was put in the mortar and liquid nitrogen was 
poured over the tissue and grounded up using the pestle. Once the tissue was ground 
up, a small amount of liquid nitrogen was added while mixing the tissue with a pre-
chilled spatula towards one side of the mortar. Half of the tissue was then transferred 
using the spatula into a new 1.5 mL tube for RNA isolation, and half was transferred 
to a different 1.5 mL tube for DNA/protein isolation. The top of the tubes were 
punctured to prevent explosion. Once all AT were ground up, RNA was isolated.  
 
2.4.2. RNA isolation of AT and whole bone  
 
1. 600 L of Ribozol (VWR chemicals, N580) was added to each tube with the 
powdered tissue specifically for RNA isolation. It was then mixed using the tip 
of a 21G needle in a 1.5 mL syringe, and then aspirated into the syringe 
gradually to dissolve clumps.  
2. Further 600 L of Ribozol was added and resuspended through the needle 
until a homogenous lysate was produced. Clumps of tissue that did not go 
through the needle were worn down by scraping between the needle tip and 
the side of the tube, or removed. 
3. Once homogenised, the solution was stored at room temperature for 10 
minutes.  
 
4. For AT 
a. Due to AT containing high lipid content, a layer of lipid was formed 
above the homogenate,  
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b. The lipid layer was removed and replaced with the same volume of 
fresh Ribozol.  
 
5. The homogenate was moved to a new tube due to having a punctured lid from 
the grinding stage.  
6. 240 L chloroform (Fisher Scientific, C/4960/17) was then added to the 
homogenate and shaken for 20 seconds, followed by allowing it to rest at room 
temperature for 2-3 minutes.  
7. Thereafter, it was centrifuged in a microfuge at 4C for 15 minutes at 15,000 
rcf, resulting into an upper aqueous phase (clear), a thin interphase (white 
solid) and a lower organic phase (pink).  
8. The upper aqueous phase was transferred to a new 1.5 mL tube containing 
700 L isopropanol (VWR chemicals, 20842.323). The samples were then 
mixed by inverting the tubes 4-5 times, then incubated at room temperature 
for 15 minutes, following centrifugation at 18,000 rcf for 60 minutes at 4ºC.  
9. The supernatant was transferred into a labelled tube, in case sample was lost. 
10. The pellet was then washed with 75% ethanol (VWR chemicals, 20821.330) 
(1.5 mL per sample) and gently vortexed so that the pellet floated up in the 
ethanol, and then centrifuged at 12,000 rcf for 5 minutes at 4C.  
11. The above step (10) was repeated, but the ethanol was discarded in the waste.  
12. After the second centrifugation, the ethanol was removed and the tubes were 
put open on a 55C heating block until leftover ethanol had evaporated.  
13. Thereafter, the pellets were resuspended in 35 L RNase-free water (Omega 
BIO-TEK, PD092) and put on ice while quantifying for RNA by NanoDrop. The 
RNA was then stored in the freezer at -80C until reverse transcription was 
performed. 
 
2.4.3. RNA isolation of BM 
 
1. 0.5 ml and 2 ml Eppendorf tubes were prepared ahead. The 0.5 ml tubes had 
their ends cut off, and the 2 ml tubes contained 100 l Ribozol and were 





2. For isolation from bones stored at -80C 
a. The tibia was quickly removed off the dry ice, and the ends were cut 
off using a razor blade. The tibia was then put back on dry ice in its 
corresponding 0.5 ml tube.  
b. The 0.5 ml tube containing the tibia was then quickly inserted into a 2 
ml tube, and put into the centrifuge to spin down the BM into the 2 ml 
tube.  
c. The BM was centrifuged down into the 2 ml tube at 8000 rcf for 1-2 
minutes. 
 
3. For isolation from freshly dissected bones 
a. Soft tissue was quickly removed off the tibia. The ends of the tibia were 
then cut off using a razor blade.  
b. The tibia was then inserted inside the 0.5 ml tube, followed by inserting 
the 0.5 ml tube in the 2 ml tube that already contained 100 l Ribozol, 
and then put into the centrifuge to spin down the BM into the 2 ml tube.  
c. The BM was centrifuged down at 8000 rcf for 1 minute.  
 
4. 500 L of Ribozol was further added to each tube with the BM. It was then 
mixed using the tip of a 21G needle in a 1.5 mL syringe, and then aspirated 
into the syringe gradually to dissolve clumps.  
5. Once homogenised, the solution was stored at room temperature for 10 
minutes.  
6. Thereafter, the solution was stored in the freezer at -80C until all samples 
were homogenised and ready for the next stage.  
 
7. Once all samples were homogenised, the 2 ml Eppendorf tubes containing 
Ribozol and homogenised BM were taken out and allowed to defrost on ice.  
8. The samples were then vortexed for approximately 10 seconds each.  
9. 120 L chloroform was then added to the homogenate and shaken for 20 
seconds, followed by incubating at room temperature for 2-3 minutes.  
10. Thereafter, it was centrifuged at 4C for 15 minutes at 15,000 rcf.  
11. The upper aqueous phase was transferred to a new 1.5mL tube containing 
200 l 70% ethanol, and vortexed. From this step onwards, the RNeasy Mini 
Kit (QIAGEN, 74106) protocol was followed. 
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12. The entire sample was transferred to a RNeasy Mini spin column in a 2 ml 
collection tube, followed by centrifugation for 20 seconds at 10000 rcf. The 
flow-through was discarded.  
13. 700 l of buffer RW1 was added to the column, and centrifuged as previously 
mentioned. The flow-through was discarded.  
14. 500 l of buffer RPE was added to the column, and centrifuged as before. The 
flow-through was discarded. 
15. Further 500 l of buffer RPE was added to the column, and centrifuged for 2 
minutes at 10000 rcf.  
16. The collection tube was then replaced with a new one, and centrifuged again 
for 1 minute at 10000 rcf to dry the membrane.  
17. The RNeasy spin column was then placed in a new 1.5 ml collection tube, and 
40 l RNase-free water was directly added to the spin column, and left at room 
temperature for 10 minutes. 
18. Thereafter, the tubes were centrifuged for 2 minutes at 10000 crf to elute the 
RNA.  
19. The RNA was then put on ice while quantified and thereafter stored in the 
freezer at -80C.  
 
2.4.3.1. Optimisation of frozen BM isolation  
 
The bones collected from the six-week CR mice were either put in formalin for BMAT 
analysis, or put on dry ice for RNA isolation for a later time. Previously, whole bone 
was crushed for gene expression. However, it was later realised that separating the 
bone from the BM would provide more reliable results in regards to what essentially 
happens in the BM. Since the tibiae were frozen at -80C, a few tests were 
implemented to make sure the BM and bone RNA were not degraded throughout the 
process. A few of those tests incorporated different thawing processes of spare bones 
(on ice, at room temperature, in cold ribozol and in RNA later (Invitrogen, AM7020) 
including trying to speed the process up to avoid RNA degradation. Although the RNA 
isolation was abundant, the RNA was degraded compared to freshly flushed BM RNA 
(Figure 2.2).  
 
RNA later Ice (Invitrogen, AM7030) is similar to RNA later, but allows frozen 
tissue/cells to thaw in the solution without RNA degradation. Whole bones were 
allowed to thaw in the solution, but also bones that had their end cut to allow the 
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solution to enter the BM straightforwardly. This process was performed a few times, 
allowing the bone to thaw in the solution for 5-10 minutes, up to 1 hour. The 
centrifugation of the BM failed when the bones were left in RNA later Ice for longer 
than 10 minutes due to the BM “drying out” and needing to grind it out of the bone 
with a needle after cutting through the bone to open it up. It was therefore concluded 
that RNA later Ice was not adequate. Because of the failed optimisations of obtaining 
undegraded RNA from the frozen bones, the next step taken was to work with the 
degraded RNA. The frozen BM was compared to fresh BM RNA, and the results were 
analysed for comparisons. The BM was isolated from spare frozen and fresh bones 
(from the same mouse, i.e. left and right tibia), and RNA was isolated as previously 
described and reverse transcribed as in the next section (Secton 2.3.4). The following 
housekeeping genes were analysed: 18s, Actb, Gapdh, Ppia and Tbp. Hsd11b1 and 
Fabp4 were used as genes of interest. Average CT values were compared as raw 
data, but also based on standard curve made from the samples. The fresh samples 
gave lower CT values (greater amount of target nucleic acid in the sample) compared 
to the frozen samples that gave approximately 1.5 CT values higher. The frozen 
samples followed a similar pattern to the fresh ones, suggesting that the results would 
be marginally reliable, but showing lower amounts of the target nucleic acids. A few 
examples are shown in Figure 2.3. Based on the comparison to the fresh BM samples, 
it was decided that the frozen BM would be used anyway, but analysed with caution.  
 
 
Figure 2.2. Comparison of fresh vs frozen BM RNA on 1% agarose gel. The BM 
was isolated from spare frozen and fresh bones (from the same mouse, i.e. left and 
right tibia), followed by RNA isolation and reverse transcription. Thereafter, 1% 
agarose gel was prepared to run the samples. The two lines below the fresh BM 
represents the 28/18S intact ribosomal RNA. The RNA below the frozen BM lack the 




Figure 2.3. Comparison between fresh vs frozen Hsd11b1 and Fabp4 mRNA in 
BM. Fresh (light green/red) vs frozen (dark green/red) BM was evaluated by 
quantitative polymerase chain reaction (qPCR) of Hsd11b1 (green) and Fabp4 (red). 
(A) Combination of housekeeping genes Gapdh, Tbp and Actb. (B) Combination of 
housekeeping genes Ppia, Tbp and Actb. (C) Combination of housekeeping genes 
Actb and 18s. The numbers represent the sample numbers, and are matched i.e. 









2.4.4. Reverse transcription  
 
1 g (1000 ng) of total RNA was reverse transcribed to cDNA using random hexamers 
primers. Table 2.2 contains the master mix recipe for reverse transcription of RNA to 
cDNA, with the cycling conditions in Table 2.3.  
 
RT recipe Final concentration # reactions 
 1 
10X RT buffer (Applied 
Biosystems, 4486221) 
1x 5 
MgCl2 (25mM) (Applied 
Biosystems, 4486225) 
5.5mM 11 
dNTPs (10mM; 2.5mM each) 
(Applied Biosystems, 1710366) 
0.5mM each 10 
Random hexamers (100M 
stock; diluted 1:6 to 16.7M) 
(Thermo Scientific, SO142) 
0.83M 2.5 
RNase inhibitor (40U/L) 
(Thermo Scientific, E00381) 
0.8U/L 1 
MultiScribe MMLV reverse 
transcriptase (50I/l) (Thermo 
Scientific, 4311235) 
1.25U/L 1.25  
 31.75L/tube 
RNA-H2O (1g) 1g/18.25L 19.25 
31.75L of the master mix was added to each tube of RNA-H2O. 
Total 50L 
Table 2.2. Master mix recipe for reverse transcription of RNA to cDNA. 
 
 
Step 1 2 3 4 
Temperature 
(C) 
25 37 95 4 
Time 
(minutes) 
10 30 5 Hold 
Table 2.3. Cycling conditions for reverse transcription. 
 
2.4.5. Quantitative polymerase chain reaction 
 
Quantitative polymerase chain reaction (qPCR) was used to detect a variety of gene 
expressions from AT, BM and bones from mice. Transcript expression was analysed 
by qPCR in 10L duplicate reactions using qPCRBIO SyGreen Blue Mix (PCR 
Biosystems, PB20.17-50) and/or qPCRBIO Probe Blue Mix Separate-ROX TaqMan 
(PCR Biosystems, PB20.27-50). The samples were loaded into 384-well plates 
(Sarstedt, 72.1985.202) and run on a Light Cycler 480 (Roche). Transcript expression 
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was calculated based on a cDNA titration loaded on each plate and was shown 
relative to geomean expression of the housekeeping genes (Table 2.4 and 2.5). 
 
2.4.5.1. Primers and probes used 
 
Gene Protein Sequence 











F: AGA CCA GAA ATG CTC CAG GG 






Tbp TATA box-binding protein 
F: ACCTTATGCTCAGGGCTTGG 
R: GCCGTAAGGCATCATTGGAC 













Table 2.4. Sybr Green primer sequence for qPCR. 
 
 
Gene Protein Assay ID 
Fkbp5 FK506 binding protein 5 Mm00487406_m1   
Gapdh Glyceraldehyde 3-Phosphate dehydrogenase Mm99999915_g1 
TSC22D3 
(Gilz) 
TSC22 Domain Family Member 3 
(Glucocorticoid-induced leucine zipper) 
Mm00726417_s1 
Per1 Period Circadian Regulator 1 Mm00501813_m1   
Table 2.5. Taqman probes for qPCR. 
 
2.4.5.2. Cycling conditions  
 
Sybr Green # reactions: x1 (uL) 
2x Sybr Master mix (PCR 
BIOSYSTEMS, PB20.17-50) 
5 




Total 10 (8uL mix + 2uL cDNA) 
Table 2.6. qPCR Master Mix Recipe for SybrGreen primers. 
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Step Temperature C Time # Cycles 








65 to 95 C (increasing 
at 0.06 C/second, 10 
acquisitions per C) 
10 seconds 1 
Cool 37 Hold 1 
Table 2.7. qPCR cycling conditions for SybrGreen primers. 
 
 
Taqman # reactions: x1 (uL) 
2x Taq Master mix (PCR 
Biosystems, PB20.27-50) 
5 




Total 10 (8uL mix + 2uL cDNA) 
Table 2.8. qPCR Master Mix Recipe for Taqman probes. 
 
 
Step Temperature C Time # Cycles 








Cool 37 Hold 1 
Table 2.9. qPCR cycling conditions for Taqman probes.  
 
 
2.5. Corticosterone Enzyme-linked immunosorbent assay 
 
Corticosterone Enzyme-linked immunosorbent assay (ELISA) (Enzo Life Sciences, 
Famingdale, NYADI-901-097) was used to quantify corticosterone concentration in 
weekly plasma from the six-week CR and aged mice. The ELISA was performed 
according to manufacturer’s instructions. The ELISA was a colorimetric competitive 
enzyme immunoassay used to quantify corticosterone levels in the mouse plasma. A 
polyclonal antibody was used to bind corticosterone, in a competitive manner. The 
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first step was to prepare the reagents for the assay following manufacturer’s 
instructions.  
 
1. Assay buffer 15: The assay buffer was prepared by diluting 10mL of the stock 
with 90 mL deionised water.  
2. Corticosterone standard: The 200,000 pg/mL corticosterone standard 
solution was taken out in advance to warm up to room temperature. Five 12 x 
75mm glass tubes were labelled #1 through #5. 1ml of the Assay buffer 15 
was added to tube #1, and 800 L was added into tubes #3 through #5. 
200000 pg/ml corticosterone standard was then serially diluted to 20000, 
4000, 800, 160, 32 and 0 pg/ml. 
3. Wash buffer: 5mL of the stock was diluted with 95mL of deionised water.  
 
Next, plasma was prepared according to the small volume protocol, due to inadequate 
plasma, by mixing 10 l steroid displacement reagent with 10 l plasma, followed by 




1. 100 L of assay buffer 15 was added to the NSB and the B0 wells, meaning 
these well did not contain corticosterone concentration (0 pg/mL Standard).  
2. 100 L of each standards #1 through #5, and 100 L of each sample was 
added to the appropriate well. 
3. Additional 50 L of assay buffer 15 was added to the NSB well.  
4. 50 L of blue Conjugate was added into each well, apart from the total activity 
(TA) and blank well.  
5. 50 L of yellow antibody was added into each well, apart from the blank, TA 
and NSB wells. The plate was then covered with a plate sealer and incubated 
at room temperature on a plate shaker for 2 hours. 
6. Following the 2 hours incubation time, the plate contents were emptied and 
washed by adding 400 L of wash solution to every well. This washing step 
was repeated 2 more times for a total of 3 washes.  
7. Post the final wash, the wells were emptied and firmly tapped on a lint free 
paper towel to remove any leftover wash buffer.  
8. 5 L of blue conjugate was added to the TA well. 
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9. 200 l of para-Nitrophenylphosphate substrate was then added to every well 
and incubated at room temperature for 1h without shaking.  
10. After 1h, 50 L of stop solution was added to every well and the plate was 
read instantly at 405 nm, with correction at 580 nm.   
 
Plasma corticosterone concentration was calculated from interpolation against 
absorbance of the standards and correction for initial dilution. 
 
2.6. Steroid analysis by Liquid chromatography-tandem mass 
spectrometry in murine plasma and bone marrow 
 
Liquid chromatography tandem mass spectrometry (LC-MS/MS) is a sensitive and 
specific analytical tool and methods can be developed to allow for simultaneous 
analysis of more than one compound in a single sample. In recent years LC-MS/MS 
has been adopted for both clinical and pre-clinical studies for accurate quantification 
of steroids in biological samples such as plasma, serum and tissue. The Journal of 
Clinical Endocrinology and Metabolism released a position statement in 2013 
(Handelsman and Wartofsky, 2013) requiring analysis of sex steroid hormones be 
carried out by LC-MS/MS.  
 
When developing a quantitative LC-MS/MS method, to ensure that the data generated 
is accurate and precise, certain bioanalytical guidelines must be followed, such as 
inclusion of analogous or more preferably isotopically labelled internal standard and 
calibration standard curves that are appropriate for the expected concentration ranges 
of the analytes in the samples. The developed method of sample preparation 
chromatographic separation and mass spectral analysis must be assessed for 
accuracy, precision, extraction efficiency and matrix effects before its application to 
biological samples.  
 
2.6.1. Assessment of a Supported Liquid Extraction LC-MS/MS analysis 
of GCs, testosterone and progesterone in mouse samples 
 
In order to assess steroid concentrations in end-point plasma from both male and 
female mice that were on one-and six-week CR, an LC-MS/MS method was required 
for separation and quantitation of the steroid hormones 11-DHC, Corticosterone 
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(CORT), Testosterone (T) and Progesterone (P) to investigate concentrations in WT 
and 11-HSD1 KO mice. The volume of plasma sample available from mice in this 
study was limited (<100 L). Previously published methods required 150 L (Verma 
et al., 2018) using Liquid Liquid Extraction (LLE) to successfully detect 11-DHC in the 
samples. As such, the method required re-evaluating to assess whether the volume 
of mouse plasma available was sufficient to detect steroids in small volumes. 
Experiments were performed to assess a different sample preparation technique 
called Supported Liquid Extraction (SLE), aiming to improve the precision of sample 
preparation while reducing the volume of sample required.  
 
2.6.1.1. Liquid Chromatography tandem Mass Spectrometry settings 
 
An LC-MS/MS method for excellent separation and detection of both GCs and 
androgens had already been developed and applied to human clinical samples 
(Gifford et al., 2019). The suitability of this method was assessed in the context of 
mouse GCs, focussing on 11-DHC, CORT, T and P. Briefly, the LC-MS/MS system 
consisted of a Sciex 6500+ QTrap tandem quadrupole mass spectrometer used in 
Multiple Reaction Monitoring (MRM) mode. Automated injection of samples took place 
using a Shimadzu Nexera uHPLC system. Separation was performed on a 
Phenomenex Kinetex C18 column (150 mm x 3.0 mm, 2.6 µm particle size) fitted with 
a Phenomenex KrudKatcher Ultra In-Line Filter 0.5 µm porosity. The column was 
maintained at a temperature of 40°C. Mobile phase A consisted of formic acid (FA) 
(0.1%) in LC-MS graded water (VWR, 83645.320), and mobile phase B consisted of 
FA (0.1%) in LC-MS graded methanol (VWR, 83638.320). A flow rate of 0.5 mL/min  












Time (min) Composition (%) A Composition (%) B 
Initial 45 55 
4.00 45 55 
10.00 0 100 
12.00 0 100 
12.10 45 55 
16.00 45 55 
Table 2.10. Gradient details for Phenomenex Kinetex C18 (150 x 3.0 mm; 2.6 m) for 
steroid separation.  A- 0.1% FA in water, B- 0.1% FA in methanol (40C, 0.5 mL/min).  
The mass spectrometer was operated in positive ion MRM mode and monitored for 
quantitative and qualitative ions for each steroid of interest plus corresponding internal 
standards (d8B, d4F, (Table 2.11)). Instrument control, data acquisition and integration 
were achieved using Sciex Analyst software running Version 1.6.3. Chromatographic 
separation of the steroids of interest are shown in Table 2.12. 
 





345.1 121.2 3.98 
11-dehydrocorticosterone 
(11-DHC) 2 
345.1 91.2 3.98 
Corticosterone (B) 1 347.1 121.1 5.98 
Corticosterone (B) 2 347.1 90.9 5.98 
d4-Cortisol  1 (d4F 1) 367.3 121.1 5.00 
d4-Cortisol  2 (d4F 2) 367.3 91.1 5.00 
d8-Corticosterone (d8B) 1 369.2 169.0 4.11 
Testosterone 1 289.1 97.0 7.75 
Testosterone 2 289.1 109.2 7.75 
13C3-Testosterone 1 292.2 100.2 7.74 
Progesterone 1 315.1 97.1 8.99 
Progesterone 2 315.1 109.1 9.00 
D9-Progesterone 1 324.1 100.0 9.00 
Table 2.11. Corresponding internal standards and analytes of interest. Positive 
Ion MRM mode, Curtain Gas 40, Collision Gas (medium), Ionspray Voltage 5.5 kV, 
temperature 600C, Ion source gas 1 and 2, 40 and 60 psi.   
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Figure 2.12. Chromatographic separation of the steroids of interest. Extracted 
Ion Chromatogram showing the major steroids (11-DHC, CORT, T and P) and their 
separation on the Kinetex C18 (150 x 3 mm; 2.6 um) column using 0.1% FA in 
water/methanol as a gradient system over 16 minutes at 40C.  
 
 
2.6.1.2. Assessment of SLE as an alternative to LLE for sample 
preparation of mouse plasma for steroid analysis 
 
Materials: SLE array cartridges were from Biotage (SLE400 and SLE200 were 
compared, using an array cartridge vacuum manifold by IST, Sweden). Deep Well 
collection plates were from Waters, UK. Plate seal films were zone-free plate seals 
from Waters. Rimless cultured glass tubes 12mm x 75mm (FisherbrandTM, 11517403) 
were used. Total recovery glass vials from Waters. All solvents used were LC-MS 
grade water and LC-MS grade Methanol from Fisher Scientific, UK  
 
Stock solutions of steroid hormones: All steroid powders were from Steraloids. 1 
mg/mL stock solutions were made up individually in methanol and stored at -20C. 
These 1 mg/mL stocks were diluted in methanol on the day of analysis. Combined 
stock solutions of the analytes were prepared by adding 1 mg/mL 11-DHC (5 L) and 
corticosterone (5 L) up to 1 mL methanol. Further dilutions were prepared to give 
500 ng/mL, 50 ng/mL, 5 ng/mL and 0.5 ng/mL solutions in methanol. 
Stock solutions of internal standards: d8-corticosterone (d8B) and deuterated 
cortisol (d4-F) were prepared in methanol at 1 mg/mL from powders from Steraloids 
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and diluted to give a working internal standard at 250 ng/mL in methanol. 
Calibration standard curves were prepared at the following levels: 0, 0.01, 0.025, 
0.05, 0.1, 0.25, 0.5, 1, 2, 5, 10, 20, 50 ng (from 0.01 – 50 ng) of both Corticosterone 
and 11-DHC. Each standard and sample were enriched with 10 L x 2500 ng/mL of 
d8B and d4F (2.5 ng).  
 
2.6.1.2.1. LLE (Aqueous calibration and plasma) 
 
Calibration standards were prepared using the calibration solutions above. Water (50 
L) was aliquoted into a glass culture tube and the appropriate amount of calibration 
standard was added (e.g. 10 L x 5 ng/mL CORT and 11-DHC to give 0.05 ng 
standard), enriched with d4F and d8B (2.5 ng) and mixed. Chloroform was added 
(500 L), mixed and the top layer was transferred to a clean glass vial, dried down 
under nitrogen, resuspended in 70:30 water/methanol (100 l), transferred to an LC-
MS total recovery vial and analysed by LC-MS/MS. 
A pool of mouse plasma was prepared, mixed thoroughly and an aliquot of 50 L 
plasma was added to a glass culture tube and enriched with d4F and epiB (25 ng). 
500 l chloroform was added, the tube was vortexed and the top layer was transferred 
to a clean glass vial, dried down under nitrogen and resuspended in 70:30 
water/methanol (100 L), transferred to an LC-MS total recovery vial and analysed by 
LC-MS/MS. 
 
2.6.1.2.2. SLE 400 (Aqueous calibration and plasma) 
 
For each aqueous standard, 50 l water was aliquoted into a glass culture tube, and 
the appropriate amount of calibration standard was added (e.g. 10 L x 5 ng/mL 
CORT and 11-DHC to give 0.05 ng standard), and internal standard (d4F and eD8B 
(25 ng)) was added. 150 l water was added to dilute the sample to final volume of 
200 L.  
For each mouse plasma sample, 50 l mouse plasma was aliquoted into a glass 
culture tube and internal standard (d4F and epiB (2.5 ng)) was added. 150 L water 
was added to dilute the sample to final volume of 200 L. 200 l of 0.5 M ammonium 
hydroxide (Fisher Chemical, 10305170) was added to the sample, vortexed and the 
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400 L was transferred to individual SLE400 array cartridges in an IST array holder. 
Standards and samples were left to soak on cartridges for 5 minutes, followed by 
careful vacuuming for approximately 2 seconds to absorb onto the cartridge. Samples 
were left for 5 minutes. 600 l Dichloromethane/isopropanol (95:5) (VWR, 23373.320; 
and VWR, 20880.320) was added to each cartridge, vacuumed through into a 96-well 
deep well collecting plate for 2 minutes. The addition of 600 L elution solvent was 
repeated twice. The eluent was dried down in the 96-well deep well collecting plate, 
under nitrogen and resuspended in 70:30 water/methanol (100 L), the plate sealed, 
placed on plate shaker for 5 minutes at 300 rpm, and transferred to the autosampler 
for analysis by LC-MS/MS. 
 
2.6.1.2.3. SLE 200 (Aqueous calibration and plasma) 
 
For each aqueous standard, 50 l water was aliquoted into a glass culture tube, and 
the appropriate amount of calibration standard was added (e.g. 10 L x 5 ng/mL 
CORT and 11-DHC to give 0.05 ng standard), and internal standard (d4F and epiB 
(25 ng)) was added. 50 L water was added to dilute the sample to final volume of 
100 L. 
For each mouse plasma sample, 50 l mouse plasma was aliquoted into a glass 
culture tube and internal standard (d4F and d8B (2.5 ng)) was added. 50 L water 
was added to dilute the sample to final volume of 100 L. 0.5 M ammonium hydroxide 
(100 L) was added to each sample, vortexed and the 200 L was transferred to 
individual SLE200 array cartridges in an IST array holder. Standards and samples 
were left to soak on cartridges for 5 minutes, followed by careful vacuuming for 
approximately 2 seconds to absorb onto the cartridge. Samples were left for 5 
minutes. Dichloromethane/isopropanol (95:5, 450 L) was added to each cartridge, 
vacuumed through into a 96-well deep well collecting plate for 2 minutes. The addition 
of 450 L elution solvent was repeated twice. The eluent was dried down in the 96-
well deep well collecting plate, under nitrogen and resuspended in 70:30 
water/methanol (100 L), the plate sealed, placed on plate shaker for 5 minutes at 
300 rpm, and transferred to the autosampler for analysis by LC-MS/MS 
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2.6.1.3. Method validation 
 
To validate the SLE LC-MS/MS assay, the recovery, linearity and lower limits 
of detection and quantitation were determined in accordance with the 
European Medicines Agency bioanalytical method validation guidelines 
(European Medicines Agency, 2011) 
 
2.6.1.3.1. Recovery of 11-DHC and corticosterone from water  
 
The absolute recovery was assessed by enriching water with 2.5 ng of 11-DHC and 
CORT, using the SLE method described (Section 2.5.1.1.3/4). Peak areas of CORT 
and 11-DHC in these enriched aqueous samples were compared with those from pure 
water subjected to the extraction procedure and post-spiked with CORT and 11-DHC 
(2.5 ng). 
 
2.6.1.3.2. Recovery of internal standards, d8B and d4F from plasma  
 
Recoveries of d4F and d8B from pooled control murine plasma (150 L) enriched with 
D4F and d8B (2.5 ng) were ascertained using the extraction procedure described in 
section 2.5.1.1.4. The peak areas of d4F and d8B from these ‘pre-spiked’ plasma 
samples were divided by those of plasma that were post-spiked with d4F and d8B 
(2.5 ng) and the percentage recovery of the internal standards from mouse plasma 
was calculated. The pre-spiked values were compared to pure-solutions of d4F and 
d8B (2.5 ng) to calculate the matrix effects on the internal standards. 
 
2.6.1.3.3. Sensitivity and linearity (LOD, LOQ, accuracy and precision) 
 
Six sets of calibration standards (0.01-10 ng) were prepared and extracted by SLE200 
and analysed by LC-MS/MS. The detection and quantitation limits (LOD and LOQ 
respectively) were calculated. Linearity was evaluated in calibration standards 
generated on six different days, assessing peak area ratios of analyte (CORT and 11-





Accuracy and precision were determined by assessing calibration standards, 
following extraction, at the LLOQ and at low, medium and high amounts of 11-DHC 
and CORT (0.01, 2.5, 10 ng) in replicates of six prepared on the same day (intra) and 
of three prepared on different days (inter). The amount of steroid was calculated using 
the calibration curve and accuracy calculated as the relative mean error (RME). 
 
2.6.1.4. Recovery following extraction by LLE, SLE400 and SLE200 of 50 
L murine plasma 
 
LLE using chloroform (10:1) was compared with SLE400 and SLE200 of 50 L mouse 
plasma from a pool of mouse plasma. The calculated amounts were related to the 
corresponding calibration curve. The precision of the calculated amounts in triplicate 
was compared for each steroid, for each method of preparation – LLE, SLE400 and 
SLE200. The variability of the calculated amounts (26 % for CORT and 45 % for 11-
DHC) was much larger in LLE than that seen in the SLE400 extracts (21 % for CORT 
and 13 % for 11-DHC) and yet the variability in calculated amounts (10 % for CORT 
and 2% for 11-DHC) was further improved using the SLE200 (Table 2.5.4.) Therefore, 
SLE200 (Section 2.5.1.2.3) was considered the acceptable and reliable method of 






















LLOD 0.25 0.5 0.1 0.05 0.1 0.05 























Table 2.13. Comparison of %RSD at limit of detection following extraction of 
mouse plasma (50 L) using LLE, SLE400 and SLE200 extraction. LLOD = Lower 
limit of detection. ULOD = Upper limit of detection. %RSD = percentage relative 
standard of deviation ((standard deviation/average) * 100). 11-DHC = 11-
dehydrocorticosterone. Cort = corticosterone. 
 
 
2.6.1.4.1. Sensitivity and linearity 
  
1-week CR: 11-DHC = 0.001 and 5 ng; Corticosterone = 0.0025 and 10 ng; 
Testosterone = 0.001 and 10 ng; Progesterone = 0.0025 and 10 ng.  
6-week CR: 11-DHC = 0.01 and 2 ng; Corticosterone = 0.05 and 20 ng; Testosterone 
= 0.01 and 5 ng. 
Based on regression parameters, d4F was consistently found to be the best internal 
standard for 11-DHC, as they elute close to each other, while d8B was the best 
internal standard for CORT. 
 
2.6.1.4.2. Method Application of SLE200 for murine plasma steroid 
analysis 
 
The plasma from 122 individual mice, were analysed using the validated SLE200 
protocol for mouse plasma, where the range for the steroids are shown below.  
 
1-week CR: 11-DHC = 0.0338 and 76 ng/mL; Corticosterone = 12.3 and 330 ng/mL; 
Testosterone = 0.0227 and 0.31 ng/mL; Progesterone = 0.0478 and 10.56 ng/mL  
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6-week CR: 11-DHC = 1.1 and 60.4 ng/mL; Corticosterone = 44.3 and 364 ng/mL; 
Testosterone = 0.0035 and 8.96 ng/mL 
 
2.6.2. Optimisation of sample preparation of murine BM for LC-MS/MS 
analysis of steroids 
 
LC-MS/MS was performed on femoral BM from both male and female mice that were 
on one-and six-week CR. Analytes of interest; 11-DHC, CORT, T and P were detected 
and quantified. Prior to performing LC-MS/MS on the experimental frozen femoral 
BM, prior steps had to be taken to optimise a protocol for extracting the BM from the 
bone. The sample preparation of the BM was optimised from previous methods 
(Tobiansky et al., 2018), followed by our SLE200+ protocol (2.5.1.2.3) prior to analysis 
by LC-MS/MS. Test BM samples were flushed and used to assess the levels of CORT 
and 11-DHC, T and P in the samples.  
 
2.6.2.1. Optimisation of BM collection from bone 
 
2.6.2.1.1. Assessment of different masses of BM for steroid extraction by 
SLE200 
 
BM samples were prepared from one, two, four or eight tibiae and femurs to determine 
what mass of BM is needed to detect the four steroids of interest using our sensitive 
LC-MS/MS assay previously applied to plasma (50 L). BM collection was carried out 
using the same protocol as Tobiansky et al., (2018) followed by extraction using 
SLE200 and LC-MS/MS analysis. 
 
Bones were transferred from dry ice onto wet ice, and ends were cut off using a razor 
blade. A razor blade was used to remove the base of a 0.5 ml Eppendorf tube. The 
tube was placed inside an intact Eppendorf tube. The bone was added into the double 
layer tube and centrifuged at 8000 rcf for 1 minute. The BM pellet was weighed and 
recorded. 500 l Acetonitrile (VWR, 20060.320) with 0.01% FA (v/v) was added to the 
BM pellet. The BM was homogenised with a metal bead in a bead mill homogeniser 
at 30 Hz for 30 seconds. Samples were incubated for 1h at -20C, centrifuged for 5 
minutes at 16,100 rcf, and the supernatant was transferred to a clean glass vial. A 
further aliquot of acetonitrile (400 L, 0.01% FA, v/v) was added to the pellet, vortexed 
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and centrifuged as before. The supernatant was added to the glass vial containing 
the initial supernatant. The samples were dried down with nitrogen at 40C for 
approximately 30 minutes and resuspended in 200 l water prior to extraction by 
SLE200 (like previously from the plasma, same protocol and same calibration curve, 
Section 2.5.1.2.3), following enrichment with internal standards (2.5 ng). The samples 
were analysed alongside a calibration curve (0.01 -10 ng) also enriched with internal 
standards (2.5 ng). 50 L of BM aliquot used for the extraction.  
CORT and T were quantified in the BM from all samples, but the table below (Table 
2.14) shows data from 1 femur only. However, 11-DHC and P were not detected, but 








T (13C3T) P (d9P) 
LLOD (ng) 0.01 0.01 0.01 0.01 




79% 81% 101% 94% 
Table 2.14. Comparison of recovery of internal standards between analytes 
following extraction of mouse BM. LLOD = Lower limit of detection. ULOD = Upper 
limit of detection. 11-DHC = 11-dehydrocorticosterone. CORT = corticosterone.  
 
 
2.6.2.1.2. Assessment of 0.01% and 0.1% FA in acetonitrile (v/v) on 
steroid recovery from collected BM by SLE400 
 
0.01 % and 0.1 % FA in acetonitrile was compared in BM test samples. The amount 
of the BM aliquot was increased from 50 l to 200 l so that the steroids fell within the 
detection limit of the method. The final change included decreasing the resuspension 
volume to 70 l from 100 l prior to running it on the LC-MS/MS. The method for BM 
collection was increased to 200 l, which resulted in a higher liquid volume and a 
transfer to SLE400 from SLE200.  
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For each mouse sample, 200 l mouse BM was aliquoted into a glass culture tube 
and internal standard (d4F and epiB (2.5 ng)) was added. 200 l of 0.5 M ammonium 
hydroxide was added to the sample, vortexed and the 400 L was transferred to 
individual SLE400 array cartridges in an IST array holder. Standards and samples 
were left to soak on cartridges for 5 minutes, followed by careful vacuuming for 
approximately 2 seconds to absorb onto the cartridge. Samples were left for 5 
minutes. 600 l Dichloromethane/isopropanol (95:5) was added to each cartridge, 
vacuumed through into a 96-well deep well collecting plate for 2 minutes. The addition 
of 600 L elution solvent was repeated twice. The eluent was dried down in the 96-
well deep well collecting plate, under nitrogen and resuspended in 100l 70:30 
water/methanol, the plate sealed, placed on plate shaker for 5 minutes at 300 rpm, 
and transferred to the autosampler for analysis by LC-MS/MS. 
 
The results obtained from the assessment of the percentage of FA in acetonitrile 
showed that 0.1 % was not an improvement on 0.01 % FA solution for extraction. 
Based on the results in table 2.15, it was clear that the % of FA did not impact the 
quantification of the analytes of interest. Therefore, it was decided to continue with 
the original 0.01% solution. Further tests were performed to investigate whether the 
resuspension volume of the BM pellet (400 l vs 200 l) and the incubation 
temperature (-20C vs -80C) could alter the results, but no differences were observed 





Table 2.15.  Comparison between 0.01 % and 0.1 % FA in acetonitrile in mouse femoral BM samples. %RSD = percentage relative standard 
of deviation ((standard deviation/average) * 100). 11-DHC = 11-dehydrocorticosterone. CORT = corticosterone. T = testosterone. P = 
progesterone. 





T ng/mg P ng/mg 
 





T ng/mg P ng/mg 
Male 1 - 0.01% 10222.22 1294.44 1266.667 109.44 
Female 1 - 
0.01% 
2470.00 6266.67 103 3500.00 
Male 2 - 0.01% 13704.55 9068.18 422.7273 <0 
Female 2 - 
0.01% 
337.80 2158.54 <0 6646.34 
Male 3 - 0.01% 881.48 710.37 178.5185 82.22 
Female 3 - 
0.01% 
505.62 2505.62 <0 8786.52 
 
% RSD 80% 126% 92% 20%  % RSD 107% 63% N/A 42% 
 





T ng/mg P ng/mg 
 





T ng/mg P ng/mg 
Male 1 - 0.1% 569.8113208 1971.698 2150.943 364.1509 Female 1 - 0.1% 537.7778 4733.333 104.2222 3400 
Male 2 - 0.1% 2081.447964 1330.317 78.28054 200.4525 Female 2 - 0.1% 590.6977 3465.116 <0 12441.86 
Male 3 - 0.1% 3123.222749 319.4313 90.99526 368.7204 Female 3 - 0.1% 733.3333 12380.95 378.0952 34000 
 
% RSD 67% 69% 154% 31%  % RSD 16% 70% 80% 95% 
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2.6.2.2. Final step: Extension of calibration curve to lower limits for all 
experimental steroids 
 
The final protocol for quantifying 11-DHC, corticosterone, testosterone and 
progesterone from femoral BM is described in Section 2.6.2.1.2. No further changes 
were done to the BM collection. Instead, further lower standards were added to the 
calibration curve to include the lower limits of steroids, and the higher standards of 5, 
10, 20 and 50 ng were excluded. The final calibration curve was the following: 0, 
0.001, 0.0025, 0.005, 0.01, 0.025, 0.05, 0.1, 0.25, 0.5, 1, 2 ng (from 0.001 – 2 ng).  
 
2.6.2.3. Method Application of BM extraction by SLE400 for steroid 
analysis 
 
The BM from 122 individual mice (an aliquot of 200 l femoral BM per sample), were 
analysed using the SLE400 protocol (section 2.6.2.1.2), where the range for all 
steroids for 1-and 6-week CR was 0.001 and 2 ng; comfortably within the validated 
ranges of the assay: 0.001 – 2 ng. Furthermore, additional lower standards were 
added to the protocol as described in Section 2.6.2.2.  
 
2.7. Bone morphology and bone marrow adiposity quantification by CT  
 
2.7.1. Bone preparation 
 
The tibiae of the mice were surgically isolated and all tissue around it removed. To 
obtain the morphology of trabecular and cortical bone, the tibiae were fixed in 10% 
formalin (Sigma, HT501380-9.5L) at 4°C for 7 days until embedded in 1% agarose 
(1g agarose in 100ml deionised water). Six tibiae were arranged in parallel in two 
layers in the 1% agarose (w/v), in a 30-ml universal tube and then mounted in a 
Skyscan 1172 desktop micro CT (CT) (Bruker, Kontich, Belgium).  
 
To further quantify BMAT, following the scanning, the tibiae were removed from the 
1% agarose and transferred to 14% EDTA at 4°C for 2 weeks for decalcification. The 
EDTA solution was replaced every 2 days. Thereafter, the tibiae were washed in 
Sorensen’s Phosphate buffer (81 mM KH2PO4, 19 mM Na2 HPO4 ⋅ 7H2 O, pH 7.4) 
to ensure removal of EDTA.  
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Once decalcified, the tibiae were stained using osmium tetroxide (2% w/v; Agar 
Scientific, UK). Firstly, the osmium tetroxide was diluted 1:1 in 0.1M Sorensen’s 
Phosphate buffer. The tibiae were then stained with the 1% osmium tetroxide solution 
over 48 hours at room temperature. Subsequently, the tibiae were washed and stored 
in Sorensen’s Phosphate buffer at 4°C until embedded in 1% agarose for CT 
scanning to quantify BMAT. 
 
2.7.2. CT scanning for bone and BMAT  
 
The tubes containing the tibiae were then scanned through 360°, using a step of 0.40° 
between exposures. An isotropic voxel resolution of 6 μm and 12 μm was obtained in 
the scans, for fixated unstained bones and decalcified osmium-tetroxide stained 
bones, respectively, using the following settings: 54 source voltage, 185 source 
current with a filter exposure time of 1767ms for fixated unstained bones and 885ms 
for osmium stained bones. To further optimise the scan, a 2-frame averaging for 
fixated unstained bones, and 4-frame averaging for stained bones, was used 
alongside a 0.5mm aluminium filter. For fixated unstained bones, the minimum and 
maximum for CS to image conversion was 0.005 and 0.125, while for osmium stained 
bones it was 0.005 and 0.35. Following scanning, data was reconstructed using 
Skyscan software NRecon v1.7.3.0 (Bruker, Kontich, Belgium). The reconstruction 
thresholding window was accustomed to capture all bones within the image. The ring 
artefact for fixated unstained bones was 5 with the beam hardening set at 40%, while 
for stained bones it was 10 and 40%, respectively. Bone morphology and BMAT were 
quantified using CT Analyser v1.16.4.1 (Bruker, Kontich, Belgium).  
 
2.7.3. Bone morphology analysis  
 
Prior to analysing the tibiae for bone morphology, the 6 parallel tibiae on the dataset 
were separated out and saved each to their own for analysis by CT (computed 
tomography) Analyser. To obtain the trabecular morphology of the tibiae, the 
trabecular bone was analysed by counting the inner trabecular part, starting 16 slices 
away from the growth plate (area of growing tissue at the proximal part of the bone) 
and then again further 167 slices (Figure 2.13). The area in between was contoured 
around the trabecular, marked as the “region of interest” (ROI), excluding any cortical 
bone, with a threshold of 50-255. 3D analysis of the trabecular ROI was then 
performed, with the following settings: Threshold as 50-255; Despeckle, to remove 
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white speckles in 2D less than 4 pixels; 3D analysis with basic and additional values 
added. The threshold of 50-255 refers to the inclusion of the trabecular or cortical 
bone that will be analysed. Any background noise, meaning anything other than bone 
will be excluded. To obtain the cortical morphology, the cortical bone was analysed 
by counting 500 slices away from the growth late, and then again further 83 slices 
(Figure 2.13). The area in between was contoured around the cortical bone – being 
the ROI, with a threshold of 50-255. Thereafter, a similar 3D analysis was performed, 
with the following settings: Threshold as 50-255; Despeckle, to remove white speckles 
in 2D less than 4 pixels; ROI shrink-wrap for 2D space, stretching over holes with a 
diameter in 20 pixels; 3D analysis with basic values added; 2D analysis with all results 
added.  
The medullary cavity was also quantified for presenting the BMAT data proportional 
to the space within the bone cavity. To receive the data for the tibia medullary cavity, 
the fixated unstained bones were divided in two parts; proximal and distal, by using 
CT Analyser.  The proximal region starts at the growth plate of the tibiae, and ends at 
the tibia-fibula-junction. While the distal region starts from the tibia-fibula-junction and 
ends at the bottom of the tibia. Each region was analysed separately. The proximal 
region was analysed by contouring the tibia, excluding the fibula, from the growth 
plate to the tibia-fibula-junction. The distal region was analysed by contouring the 
tibia, including the fibula, from the tibia-fibula-junction to the bottom of the tibia. The 
settings used to obtain the medullary cavity were the following: Threshold as 50-255; 
Despeckle, to remove white speckles in 2D less than 5 pixels; Despeckle, to remove 
black speckles in 2D less than 5 pixels; ROI shrink-wrap for 2D space, stretching over 
holes with a diameter in 16 pixels; 3D analysis with basic values added.  
 
 
Figure 2.13. Analysis of trabecular and cortical bone. Analysis of 167 slices for 
trabecular and 83 slices for cortical bone by CT Analyser. 
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2.7.4. BMAT analysis 
 
To obtain BMAT quantification, the tibiae were divided into two parts: rBMAT 
(proximal) and cBMAT (distal), by using CT Analyser. The rBMAT region starts at the 
growth plate of the tibiae, and ends at the tibia-fibula-junction. While the cBMAT 
region starts from the tibia-fibula-junction and ends at the bottom of the tibia. Each 
region was analysed separately. Starting with rBMAT, the BMAT is distinguished as 
white due to it being stained with osmium-tetroxide and can therefore be contoured 
around, from top to bottom through every slice. Remaining soft tissue can also be 
distinguished as white due to the staining, therefore, only white regions within the 
bone are contoured around, excluding any bits that appear to be outside the cortical 
bone. The threshold for BMAT quantification was set to 70-255 to exclude background 
noise. Thereafter, cBMAT was similarly contoured, from the junction to the end of the 
bone. The settings used to obtain the amount of BMAT present within the bones were 
the following: 3D analysis with basic values added. BMAT volume in the distinct tibial 
regions were quantified and presented proportional to total tibial marrow volume.  
 
2.8. Statistical analysis  
 
Statistical analysis was performed using GraphPad Prism 8 software (GraphPad 
Software). Two-and Three-way ANOVA tests were performed to compare overall 
interaction between two-and three factors, respectively. In addition, multiple 
comparisons by Sidak’s/Tukey’s test were performed to detect specific differences 
between the groups (male/female, AL/CR, WT/KO). Furthermore, non-parametric 
Mann-Whitney U-test was also performed between two groups only that were not 




Chapter 3. Sex-specific effects of caloric restriction on 




3.1. Introduction  
 
CR without malnourishment decreases the risk of ageing-associated diseases and 
can extend lifespan in numerous species, including rodents (Masoro, Yu and 
Bertrand, 1982), rhesus monkeys (Bodkin et al., 2003), yeast (Lin, Defossez and 
Guarente, 2000) and nematodes (Houthoofd et al., 2002). This highlights CR as a 
nutritional strategy to combat chronic disease and promote healthy ageing. However, 
the mechanisms underlying these CR-associated health benefits remain incompletely 
understood.  
 
With CR, decreased body mass, lower blood pressure and cholesterol levels are 
evident (Fontana et al., 2004; Meyer et al., 2006; Devlin et al., 2010; Narita et al., 
2018), and these may contribute to the health benefits of CR. For example, CR 
showed improved results on the major atherosclerosis risk factors that would normally 
increase with age (Fontana et al., 2004). Although decreased blood pressure is not 
always required for certain health benefits (e.g. protection from stroke or neuron loss 
(Speakman and Mitchell, 2011)). CR also decreases adiposity, and this is postulated 
to contribute to the metabolic and lifespan-extending effects of CR (Muzumdar et al., 
2008).  
 
In striking contrast to WAT, recent studies have revealed that CR causes increases 
in BMAT (Devlin et al., 2010, 2016; Devlin, 2011; Cawthorn et al., 2014, 2016; Ghali 
et al., 2016). During CR, BMAT contributes to increased circulating concentrations of 
adiponectin, a hormone that exerts beneficial cardiometabolic and anti-inflammatory 
effects (Cawthorn et al., 2014; Straub and Scherer, 2019). Thus, another possibility 
is that, by producing adiponectin or through other mechanisms, BMAT expansion 
contributes to the health benefits of CR. However, the mechanisms through which CR 
drives BMAT expansion are still incompletely understood. One under-explored 
possibility is that GCs contribute to these effects of CR. Indeed, CR increases activity 
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of the HPA axis, resulting in increased circulating GC concentrations (Stewart et al., 
1988; Cawthorn et al., 2016). GCs are steroid hormones that regulate gene 
expression by activating the GR, which is present in almost all cells (de Guia, Rose 
and Herzig, 2014; Caratti et al., 2015). GCs thereby exert diverse metabolic and 
immunomodulatory effects. Cortisol is the major circulating GC in humans, whereas 
in rodents corticosterone is the predominant circulating GC. The intracellular 
concentrations of these GCs are regulated by the enzymes 11-HSD1 and 11-
HSD2. 11-HSD1 is mainly expressed in the liver and AT, where it acts as a 
reductase, generating corticosterone. In contrast, 11-HSD2 is mostly expressed in 
the kidney and generates 11-DHC from corticosterone. Although GCs are anti-
inflammatory, chronic elevation of GCs causes CS, where visceral obesity, decreased 
muscle mass and insulin resistance are common characteristics (Hauner, Schmid and 
Pfeiffer, 1987; Pantoja, Huff and Yamamoto, 2008). Investigating GCs at a molecular 
level, it has been shown that GCs are required for adipocyte precursor differentiation 
(Hauner, Schmid and Pfeiffer, 1987; Pantoja, Huff and Yamamoto, 2008; Velez-
delValle et al., 2013). Nonetheless, the effects of CR on GCs at a molecular level are 
less well known, especially in adipose depots and the BM. 
 
The above observations demonstrate that GCs can have profound effects on WAT 
biology, often in contrast to those occurring during CR. Whilst CR-induced GCs 
appear to be anti-inflammatory (Klebanov et al., 1995; Allen et al., 2019), GC excess 
promotes visceral adiposity and inflammation. However, most of our knowledge of 
this is based on CS or other states of GC excess, when GCs are compromising 
adipose function. This raises the question of how CR-associated GC excess 
influences WAT function. Previous results from our lab also suggest that GC excess 
may contribute to BMAT expansion during CR. Our previous publication (Cawthorn et 
al., 2016) revealed that CR-induced BMAT expansion is associated with 
hyperglucocorticoidaemia. CR and GC therapy have both shown to increase BMAT 
(Vande Berg et al., 1999; Bredella et al., 2009; Devlin et al., 2010; Ecklund et al., 
2010). However, the relationship between CR, BMAT expansion and GC action within 
BM remains to be addressed. Despite there being an increase in circulatory GCs 
during CR, is the GC action equally increased in different adipose depots and the 
BM? The action of GCs specifically during CR in the BM has not been explored. 
Therefore, in this chapter, 30% CR was implemented in mice to determine if elevated 
corticosterone concentration affects adipose depots and BM, with the aim to 
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determine if GC action is increased during CR in young mice. The hypothesis tested 
was that CR leads to increased GC action within AT and BM. To address this, 
C57BL/6JOlaHsd male and female mice were fed ad libitum (AL) or 70% of ad libitum 
food intake (CR) from 9-10 or 9-15 weeks of age, followed by analysis of 
corticosterone in the circulation and within BM, as well as analysis of GC target gene 
expression in these tissues. 
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3.2. Results  
 
3.2.1. Body mass of young mice decreases with CR  
 
To determine if the CR protocol had functioned as expected, the body weight of the 
mice was measured over the course of the experiment. It was expected for the mice 
on CR diet to have a decrease in body weight compared to the mice on AL diet. Figure 
3.1 shows the body weight progression of both male and female mice measured 
weekly for six weeks. Both male and female mice were randomly assigned to AL or 
CR diet, so both diet groups started at approximately the same body mass. After one 
week of CR both sexes showed a decrease in body mass, whilst the AL mice 
continued to gradually increase body mass at the same rate as observed before 
commencing the diet intervention. The male mice on CR continued to show a 
decrease in body weight until week four post-dietary intervention, where they reached 
maximum loss. Meanwhile, the female mice on CR did not lose additional weight after 
week one. Indeed, three-way ANOVA confirmed a significant interaction between diet 
and sex, such that the magnitude of the CR effect differed between males and 
females. Up until week five the CR mice maintained their lower body mass, but by 
week six they began to regain body weight in comparison to previous weeks. At the 
end of the experiment, the CR mice still showed reduced body weight compared to 







Figure 3.1. Young male and female mice lose body mass with 30% CR diet over 
six weeks. C57BL/6JOlaHsd male (black) and female (red) mice were fed ad libitum 
(AL, closed symbols, solid line) or 70% of ad libitum food intake (CR, open symbols, 
dotted line) for six weeks, from 9 weeks until 15 weeks of age. The mice were weekly 
weighed. Data is mean +/- SEM and were analysed by 3-Way ANOVA with Sidak’s 
multiple comparison test. Within each sex, significant differences between AL and CR 
at each timepoint are indicated by *** (p<0.001). n (AL male) = 7. n (CR male) = 11. 
n (AL female) = 8. n (CR female) = 13.
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3.2.2. CR decreases fat mass in male, but not female mice 
 
As discussed in section 3.1, decreased adipose mass may contribute to the health 
benefits of CR (Muzumdar et al., 2008). Thus, to further characterise the tissue losses 
and understand the association between diet and body mass, body composition was 
measured weekly by TD-NMR throughout the six weeks. TD-NMR uses radio-
frequency energy, which measure identified fat and lean masses based on the 
location of protons in the mice. Figure 3.2 shows fat and lean mass of male and female 
mice, expressed as absolute mass (g) and as a % of total body mass.  
 
Male fat mass showed a significant decrease throughout the six weeks of CR diet, 
both as absolute mass (Figure 3.2.A) and as a % of body mass (Figure 3.2.B). In 
contrast, female fat mass as absolute mass (Figure 3.2.A) showed a small diet effect 
at weeks four and five only. As % of body mass (Figure 3.2.B), female fat mass 
showed no significant diet effect.  
 
The male lean mass as absolute mass (Figure 3.2.C) showed a significant decrease 
during CR, from week two onwards. Nonetheless, as % of body mass (Figure 3.2.D), 
the lean mass was significantly higher in the CR compared to the AL males. In 
females, absolute lean mass (Figure 3.2.C) significantly decreased with CR. 
Meanwhile, as % of body mass (Figure 3.2.D), no diet effects were present.   
 
These results show sex differences in changes in body composition in response to 
CR, suggesting that male mice are mainly losing fat mass but are protecting against 
loss of lean mass, while female mice are not. Instead, female mice are mainly losing 
fat and lean mass in proportion to the decrease in body mass; hence, females’ % fat 





   
Figure 3.2. Body composition determined by TD-NMR in response to CR. Male 
and female mice were fed AL or CR diets from 9-15 weeks of age, as described for 
Figure 3.1 and Methods (2.1.2). Both male and female mice were weekly scanned by 
TD-NMR. Male and female fat mass shown in grams (A) and % of body mass (B). 
Male and female lean mass shown in grams (C) and % of body mass (D). Data is 
mean +/- SEM and were analysed by 3-Way ANOVA with Sidak’s multiple comparison 
test. Numbers of mice per group, and presentation of statistically significant 
differences between groups, are as described for figure 3.1. Within each graph, 
significant differences between AL and CR at each timepoint are indicated by 
asterisks: *: p<0.05. **: p<0.01 ***: p<0.001. 
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3.2.3. White adipose depot masses are decreased in male mice in 
response to CR  
 
To further investigate if specific WAT depots were reflecting the TD-NMR results, after 
euthanising mice the AT were dissected out and weighed to determine diet 
differences. Figure 3.3 shows the absolute and relative masses of WAT depots as 
well as BAT, in both male and female mice subject to CR or AL diets. Inguinal WAT 
(iWAT) is a subcutaneous AT, whereas gonadal WAT (gWAT) and mesenteric WAT 
(mWAT) are visceral AT.  
 
Male mice subject to CR lost absolute mass of iWAT (Figure 3.3.A) and gWAT (Figure 
3.3.C), whereas the masses of these depots were unaltered by CR in females. As % 
of body mass, only gWAT in males showed a significant loss with CR (Figure 3.3.D). 
No mWAT loss was observed in mice subject to CR (Figure 3.3.E, F). This suggests 
that the loss detected in fat mass with TD-NMR could be from the WAT depots. In 
females no diet differences were observed, further confirming the lack of loss of fat 
mass detected by TD-NMR. Overall, these adipose depot masses confirmed the TD-
NMR results, showing that males lost fat mass with CR, especially gWAT and to a 
lesser extent iWAT, whereas females maintained their fat mass. For BAT, a 
thermogenic adipose depot, both absolute (Figure 3.3.G) and relative mass (Figure 
3.3.H) significantly increased with CR across both sexes, although multiple 
comparisons showed that, within each sex, this CR effect reached statistical 
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Figure 3.3. Dissected adipose depots of male and female mice post six weeks 
of CR diet. Male and female mice were fed AL or CR diets from 9-15 weeks of age, 
as described for Figure 3.1 and Methods (2.1.2). iWAT in male and female mice 
shown in grams (A) and as % of body mass (B). gWAT in male and female mice 
shown in grams (C) and as % of body mass (D). mWAT in male and female mice 
shown in grams (E) and as % of body mass (F). BAT in male and female mice shown 
in grams (G) and as % of body mass (H). Data points are presented with median, 
interquartile range and range shown by box and whisker plot. Data was analysed by 
2-Way ANOVA with Sidak’s multiple comparison test. n (AL male) = 7. n (CR male) = 




3.2.4. CR promotes hypercorticosteronaemia and sex-dependent effects 
on adrenal masses  
 
It has previously been shown that circulating GC concentrations increase during CR 
(Sabatino et al., 1991; Chacón et al., 2005; Levay et al., 2010; Pankevich et al., 2010; 
Tomiyama et al., 2010; Cawthorn et al., 2016; Fontana et al., 2016). Therefore, I 
sought to confirm this in my AL and CR mice. Prior to termination, tail and core blood 
was collected for plasma. Adrenal glands were dissected and weighed as indicators 
of increased capacity of corticosterone synthesis.  
 
Figure 3.4 presents plasma corticosterone concentrations throughout the six-week 
CR. ANOVA confirmed that circulating corticosterone concentration was significantly 
increased during CR across both sexes, with multiple comparisons revealing that CR 
males (Figure 3.4 – black dotted lines) had increased corticosterone compared to AL 
males at each week of CR. CR males also had greater corticosterone than CR 
females at week two of CR. Meanwhile, multiple comparisons revealed that female 
mice (Figure 3.4 – red dotted lines) on CR showed a significant increase only at week 
five of CR. Together, these data show that CR increases plasma corticosterone in 
male and female mice and that this effect is greater in males. 
 
At week six, corticosterone concentrations in AL female mice were increased 
compared to the previous week, whereas males and females on CR showed a 
decrease at week six compared to the previous week. As discussed further in the 
discussion (Section 3.3), this variability between weeks 5-6 likely resulted from fasting 
both AL and CR mice for several hours prior to termination. One concern was that 
these changes in plasma corticosterone might extend to altered GC action within WAT 
and BM. If so, such tissue-specific readouts of GC action might not be representative 
of the tissue-level GC effects occurring throughout the remainder of the six-week CR 
regimen. Therefore, to overcome this, a short-term one-week CR experiment was also 
done, similarly to the six-week experiment, but without fasting the mice prior to the 
endpoint. 
 
The short-term one-week CR mice were culled at 10-weeks of age, whereas, the long-
term six-week CR mice were culled at 15-weeks of age. Quantification of 
corticosterone by ELISA was not implemented on the one-week CR mice, as it was 
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already clear from figure 3.4 that corticosterone would increase prior to termination. 
Therefore, subsequent analyses will not only compare between sex and diet, but also 
between the long-term six-week (15-weeks of age) and short-term one-week CR (10-
weeks of age) mice.  
 
Figure 3.5 shows the adrenal gland masses. In the 15-week-old males, CR caused a 
significant increase in absolute mass (Figure 3.5A) and relative mass (Figure 3.5.C) 
of the adrenal glands. Analysis by ANOVA revealed an overall diet effect in the 15-
week-old mice for relative mass of the adrenal glands (Figure 3.5.C). It also revealed 
an overall sex effect, with heavier adrenal glands in the females (Figure 3.5.A, C). In 
the 10-week-old mice, diet differences were not detected (Figure 3.5.B, D) although 
ANOVA revealed an overall sex effect for relative adrenal mass (Figure 3.5.D), with 
females again having a greater % mass than males.  
 
Figure 3.6 displays plasma corticosterone and 11-DHC concentrations as determined 
by LC-MS/MS, as well as the ratio between the two. CR was associated with 
significantly increased plasma corticosterone concentration in the 10-week-old mice 
(Figure 3.6.B), whereas 15-week-old mice lacked diet effects (Figure 3.6.A). No diet 
or sex effects were detected for plasma 11-DHC concentrations in the 15-week-old 
mice (Figure 3.6.C), whereas 10-week-old mice subject to CR showed an increase in 
plasma 11-DHC (Figure 3.6.D). The ratio of 11-DHC to corticosterone was 
significantly decreased in 10-week-old male mice on CR (Figure 3.6.F), whereas no 





Figure 3.4. Circulating corticosterone concentration is increased in mice 
subject to CR. Male and female mice were fed AL or CR diets from 9-15 weeks of 
age, as described for Figure 3.1 and Methods (2.1.2). Throughout the CR experiment, 
blood was sampled and quantified by ELISA as described in Methods (2.4). 
Circulatory corticosterone concentration in male and female mice from weekly 
collected plasma. Data is mean +/- SEM and was analysed by 3-Way ANOVA with 
Tukey’s multiple comparison test. n (AL male) = 7. n (CR male) = 10. n (AL female) = 
6. n (CR female) = 9. * (male): p<0.05. ** (male) ** (female): p<0.01. *** (male): 





























Sex effect: p = 0.04
Interaction: p = 0.0005
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Figure 3.5. Adrenal gland mass is predominantly increased in male mice subject 
to CR. Male and female mice were fed AL or CR diets from 9-15 (left graphs) and 9-
10 (right graphs) weeks of age, as described for Figure 3.1 and Methods (2.1.2). 
Fasting protocol is described in Methods (2.3.1). Post termination, adrenal glands 
were dissected and weighed. 15-and (A) 10- (B) week-old male and female adrenal 
glands shown in grams. 15-and (C) 10- (D) week-old male and female adrenal glands 
shown % of body mass. Data points are presented with median, interquartile range 
and range shown by box and whisker plot, and were analysed by 2-Way ANOVA with 
Sidak’s multiple comparison test. 15-week-old mice: n (AL male) = 7. n (CR male) = 
10. n (AL female) = 7/8. n (CR female) = 9. 10-week-old mice: n (AL male) = 8. n (CR 
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Figure 3.6. End-point GCs are increased in mice subject to CR. Male and female 
mice were fed AL or CR diets from 9-15 (left graphs) and 9-10 (right graphs) weeks 
of age, as described for Figure 3.1 and Methods (2.1.2). Fasting protocol is described 
in Methods (2.3.1). Prior to termination, end-point blood was sampled and quantified 
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Diet effect: p = 0.15
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concentration in 15-and (A) 10- (B) week-old mice. Circulatory 11-DHC concentration 
in 15-and (C) 10- (D) week-old mice. Ratio of circulatory corticosterone to 11-DHC in 
15-and (E) 10- (F) week-old mice. Data points are presented with median, interquartile 
range and range shown by box and whisker plot, and were analysed by 2-Way 
ANOVA with Sidak’s multiple comparison test. 15-week-old mice: n (AL male) = 7. n 
(CR male) = 10. n (AL female) = 7. n (CR female) = 9. 10-week-old mice: n (AL male) 
= 8. n (CR male) = 8. n (AL female) = 5. n (CR female) = 6. *: p<0.05. ***: p<0.001.  
 







3.2.5. GC regeneration in the BM is modulated by CR 
 
Due to the differences observed between the circulatory GCs in 15-week-old vs 10-
week-old mice, I next sought to determine if CR exerted similar effects on GC 
concentrations within the BM. Indeed, no previous studies have addressed the impact 
of CR on BM GC concentrations, underscoring the rationale for this experiment. Post-
termination, femurs were collected and stored at -80ºC until LC-MS/MS quantification 
of GCs within the femoral BM.  
 
Figure 3.7 shows the results obtained from LC-MS/MS for corticosterone, the active 
GC, and for 11-DHC, the inactive GC, as well as the ratio between the two. 
Corticosterone (Figure 3.7.A) and 11-DHC (Figure 3.7.C) concentration in 15-week-
old mice lacked diet differences. However, in the 10-week-old mice, both 
corticosterone (Figure 3.7.B) and 11-DHC (Figure 3.7.D) were increased with CR. 
The ratio of 11-DHC to corticosterone lacked diet differences in the 15-week-old mice 
(Figure 3.7.E), although an overall sex effect was detected by ANOVA, with higher 
expression in the female mice. For the 10-week-old mice ANOVA revealed that CR 
significantly decreased the ratio across both sexes of mice (Figure 3.7.F). Multiple 
comparisons further confirmed that CR significantly decreased the ratio in females, 


















Figure 3.7. BM GCs are increased in mice subject to CR. Male and female mice 
were fed AL or CR diets from 9-15 (left graphs) and 9-10 (right graphs) weeks of age, 
as described for Figure 3.1 and in Methods (2.1.2). Fasting protocol is described in 
Methods (2.3.1). Post termination, femurs were collected and the femoral BM was 
quantified for 11-DHC and corticosterone by LC-MS/MS as described in methods 
(2.5.2). BM corticosterone concentration in 15- and (A) 10- (B) week-old mice. BM 
11-DHC concentration in 15- and (C) 10- (D) week-old mice. Ratio of corticosterone 
to 11-DHC in 15- and (E) 10- (F) week-old mice. Data points are presented with 
median, interquartile range and range shown by box and whisker plot, and were 
analysed by 2-Way ANOVA with Sidak’s multiple comparison test. 15-week-old mice: 
n (AL male) = 7. n (CR male) = 10. n (AL female) = 8. n (CR female) = 9. 10-week-
old mice: n (AL male) = 8. n (CR male) = 8. n (AL female) = 5. n (CR female) = 6. *: 
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3.2.6. CR is associated with increased GC target gene expression in the 
BM 
 
As mentioned previously, corticosterone concentration assessed by ELISA in plasma 
showed increased levels with CR (Figure 3.4). Likewise, the 10-week-old mice cohort 
showed increased corticosterone in the circulation and the BM. Therefore, to further 
compare how CR modulates peripheral tissues, and if tissue-specific GC action 
differed between the 15-week-old vs 10-week-old mice, expression of GC target 
genes were examined in the BM of both cohorts. 
  
Figure 3.8. shows expression of Hsd11b1, a GC target gene in the BM of 15-and 10-
week-old mice. Hsd11b1 expression was increased with CR in the 15-week-old mice 
(Figure 3.8.A), whereas in the 10-week-old mice, no diet differences were detected 
(Figure 3.8.B).  
 
Figure 3.9 shows additional GC target genes, Fkbp5, Gilz and Per in the BM of 15-
and 10-week-old mice. Fkbp5 expression was upregulated with CR in the BM of the 
10-week-old mice (Figure 3.9.B), but not in the 15-week-old mice (Figure 3.9.A). Gilz 
(Figure 3.10.C) and Per1 (Figure 3.10.E) expression was unaltered with CR in the 15-













Figure 3.8. Hsd11b1 expression is increased post six-weeks but not one-week 
of CR in the BM. Male and female mice were fed AL or CR diets from 9-15 (left 
graphs) and 9-10 (right graphs) weeks of age, as described for Figure 3.1 and 
Methods (2.1.2). Fasting protocol is described in Methods (2.3.1). Post termination, 
the tibiae were collected and snap-frozen on dry ice. The tibia BM was then 
centrifuged down as described in Methods (2.3.3), followed by RNA extraction and 
reverse transcription to cDNA. qPCR was performed to quantify expression of 
Hsd11b1 in the BM. Genes were normalised to geomean of the following 
housekeeping genes: Ppia, Tbp and Actb, and presented as relative to the WT AL 
average of male and female mice together. Hsd11b1 expression of BM in 15- (A) and 
10- (B) week-old mice. Data points are presented with median, interquartile range and 
range shown by box and whisker plot, and were analysed by 2-Way ANOVA with 
Sidak’s multiple comparison test. 15-week-old mice: n (AL male) = 7. n (CR male) = 
10. n (AL female) = 8. n (CR female) = 9. 10-week-old mice: n (AL male) = 8. n (CR 
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Figure 3.9. GC target genes, Fkbp5, Gilz and Per1, are increased with CR in BM. 
Male and female mice were fed AL or CR diets from 9-15 (left graphs) and 9-10 (right 
graphs) weeks of age, as described for Figure 3.1 and Methods (2.1.2). Fasting 
protocol is described in Methods (2.3.1). Post termination, the tibiae were collected 
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extraction and reverse transcription to cDNA. qPCR was performed to quantify 
expression of Fkbp5, Gilz and Per1 in the BM. Genes were normalised to geomean 
of the following housekeeping genes: Ppia, Tbp and Actb, and presented as relative 
to the WT AL average of male and female mice together. Fkbp5 expression of BM in 
15- (A) and 10- (B) week-old mice. Gilz expression of BM in 15- (C) and 10- (D) week-
old mice. Per1 expression of BM in 15- (E) and 10- (F) week-old mice. Data points 
are presented with median, interquartile range and range shown by box and whisker 
plot, and were analysed by 2-Way ANOVA with Sidak’s multiple comparison test. 15-
week-old mice: n (AL male) = 7. n (CR male) = 10. n (AL female) = 8. n (CR female) 
= 9. 10-week-old mice: n (AL male) = 8. n (CR male) = 8. n (AL female) = 5. n (CR 




3.2.7. CR alters expression of GC target genes in WAT   
 
As shown in sections 3.2.2 and 3.2.3, male mice subject to CR had significantly 
decreased fat mass whereas female mice resisted this effect of CR. More specifically, 
CR significantly decreased the masses of iWAT and gWAT in male mice only (Figure 
3.3). Moreover, plasma corticosterone concentrations were significantly increased 
throughout CR in males, but less so in the females (Figure 3.4). Therefore, one 
possibility is that sex differences in GC excess contribute to the sex differences in 
adipose mass during CR, perhaps through molecular mechanisms induced by GCs. 
To further address this, transcript markers were used to assess the effects of CR on 
expression of GC target genes in adipose depots.   
 
Figure 3.10 shows expression of the GC target genes Hsd11b1, Gilz, Per1 and Fkbp5 
in iWAT and gWAT of both CR cohorts. Hsd11b1 was significantly increased in 15-
week-old male mice subject to CR (Figure 3.10.A), with females showing a similar but 
non-significant trend; however, ANOVA detected overall diet effects across both 
sexes. In the 10-week-old mice, no diet differences were detected with CR (Figure 
3.10.B). Overall sex effects by ANOVA was detected in both cohorts, with females 
having lower Hsd11b1 expression than males. Gilz expression was upregulated in 
iWAT of 15-week-old male mice subject to CR (Figure 3.10.C), and in iWAT of 10-
week-old females subject to CR (Figure 3.10.D). Overall diet effects by ANOVA were 
detected in all groups, apart from gWAT of 15-week-old mice. Per1 expression was 
significantly increased in 10-week-old iWAT females and gWAT males, with CR 
(Figure 3.10.F) Overall diet effects by ANOVA for Per1 expression were detected in 
iWAT of both cohorts, and gWAT of the 10-week-old mice. The overall diet effects for 
iWAT of the 15-week-old cohort reflected a decrease with CR in males only, whereas 
in the 10-week-old cohort, it revealed the opposite. Fkbp5 expression was significantly 
decreased in iWAT of 15-week-old male mice subject to CR (Figure 3.10.G). 
However, in the 10-week-old males, an overall diet effect by ANOVA suggested an 
increase in Fkbp5 expression (Figure 3.10.H). gWAT in the 10-week-old mice on CR 
showed increased Fkbp5 expression (Figure 3.10.H), but no diet differences were 
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Figure 3.10. Effects of CR on GC target genes in WAT. Male and female mice were 
fed AL or CR diets from 9-15 (left graphs) and 9-10 (right graphs) weeks of age, as 
described for Figure 3.1 and Methods (2.1.2). Fasting protocol is described in 
Methods (2.3.1). Post termination, iWAT and gWAT depots were dissected and snap-
frozen on dry ice. The depots were homogenised in liquid nitrogen, followed by RNA 
extraction and reverse transcription to cDNA. qPCR was performed to quantify 
expression of Hsd11b1, Gilz, Per1 and Fkbp5. Genes were normalised to geomean 
of the following housekeeping genes: Ppia, Tbp and Hprt, and presented as relative 
to the WT AL average of male and female mice together. Hsd11b1 expression of 
iWAT and gWAT in 15- (A) and 10- (B) week-old mice. Gilz expression of iWAT and 
gWAT in 15- (C) and 10- (D) week-old mice. Per1 expression of iWAT and gWAT in 
15- (E) and 10- (F) week-old mice. Fkbp5 expression of iWAT and gWAT in 15- (G) 
and 10- (H) week-old mice. Data points are presented with median, interquartile range 
and range shown by box and whisker plot, and were analysed by 2-Way ANOVA with 
Sidak’s multiple comparison test. 15-week-old mice: n (AL male) = 7. n (CR male) = 
10. n (AL female) = 8. n (CR female) = 9. 10-week-old mice: n (AL male) = 8. n (CR 










3.3.1. Sexual dimorphism in body composition 
 
A surprising observation from the quantification of body composition was that female 
mice did not lose fat mass during CR. Further analysis of the adipose depots 
confirmed the lack of loss in fat mass in female mice. This suggests that female mice 
are resistant to fat mass loss, most likely due to adiposity being fundamental for 
reproductivity, for example the release of leptin from WAT. Leptin is essential for 
maintaining pregnancy, as it is increased throughout pregnancy, and only declines 
postpartum (Hardie et al., 1997; Schubring et al., 1998). Furthermore, leptin-deficient 
females are infertile (Ahima et al., 1997; Chehab, 1997; Ewart-Toland et al., 1999), 
and the fall in leptin is why females can become amenorrhoeic if they become too thin 
as in AN or in female athletes. However, during CR, leptin is decreased (Cawthorn et 
al., 2016) in male mice only, suggesting that female mice on CR maintain their leptin 
and fat mass for possible reproduction. Moreover, mild 5% CR has shown to induce 
fat accumulation in female mice (Li et al., 2010). Porter et al., investigated mild (5%) 
to moderate (29%) CR in male and female rats and found that females preserved 
adipose fat cells, but the fat cell volume was shrunken (Porter et al., 2004). 
Meanwhile, male rats showed the opposite results. Although a stricter CR diet was 
implemented in my mice, it is confirming the lack of loss in fat mass in female mice 
(Li et al., 2010). Previous research has compared gluteal vs abdominal adipocytes 
and found that both noradrenaline-and catecholamine-induced lipolysis is greater in 
abdominal than gluteal, and more so in women than men (Wahrenberg, Lönnqvist 
and Arner, 1989; White and Tchoukalova, 2014). This further highlights the resistance 
of gluteal fat loss in women. However, a limitation of my study is that adipocyte size 
was not quantified and can therefore not be commented on for the sex difference.  
 
It is also common in humans for women to have higher adiposity relative to men. The 
adipose distribution varies between men and women, with men having more visceral 
adipose, whereas women have more gluteal adiposity (Machann et al., 2005; Camhi 
et al., 2011). It has also been shown that although women can lose fat mass to a 
similar extent as men while subject to 25% CR for six months, they lose significantly 
less visceral adiposity compared to men (Redman et al., 2007). It is however 
important to notice that the study was performed on obese, but healthy volunteers. 
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Moreover, the starting points between men and women did vary as the men were 
heavier and fatter at baseline. Meanwhile, a 20% CR study was performed on non-
obese healthy men and women, where body weight and composition were 
significantly lost with CR, but no sex differences were investigated (Racette et al., 
2006). Furthermore, previous publication reported that GCs are dependent on insulin 
and adrenalin to induce lipolysis in subcutaneous AT; visceral AT resisted the lipolytic 
effects (Stimson et al., 2017). These findings could point towards the characteristics 
of central adipose accumulation with chronic GC excess. The males in this study lost 
subcutaneous and visceral adiposity, suggesting that insulin and/or adrenaline could 
have been involved with CR, or other factors that are yet to be revealed. In addition, 
correlation data between plasma corticosterone and absolute fat mass was negatively 
associated, although not significant (data not shown). However, the females which 
resisted the loss of fat could have potentially also resisted the insulin and/or 
adrenaline, or their insulin and/or adrenalin levels could have been significantly lower 
to have had an impact.  
 
In the present study, CR mice were given their food portion approximately at 9:00. 
From approximately 10:00 until 9:00 the following day, the mice underwent short-term 
fasting between daily feeds, which could have increased the males’ metabolism to 
burn fat mass, while female mice resisted lipolysis (Mauriège et al., 1999). Another 
reason the female mice are resisting fat loss could be due to being fed more food per 
body mass. The CR food mass was decided on how much the mice ate daily during 
their first single-housed week, and that was averaged at the end of the week, for male 
and female mice together, suggesting the female mice might receive less than 30% 
CR. To test this out, we investigated the association between their food intake and 
changes in fat mass (data not shown), and no associations were evident enough that 
the feeding affected the fat mass. However, to understand this further, data from all 
animal studies could be collected to look separately in AL-and CR-fed males and 
females. 
 
These data show that sexual dimorphism, especially during CR, ought to be 
considered when researching AT. By doing so, better diagnosis and treatments will 
become available for various adiposity conditions, where sex-specific treatments 
might be required.  
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3.3.2. Diet effects – to fast or not to fast  
 
Excluding possible sex differences, a diverse reason for not observing any diet 
differences between GC target genes and BM corticosterone concentration, in the 15-
week-old six-week CR cohort, could be due to the previously mentioned fasting of the 
AL mice and re-feeding of the CR mice prior to termination. If the mice were culled 
without fasting, the AL mice would be culled in a fed state, whereas the CR mice 
would be in a fasted state. The aim with six-weeks of CR was to look at the effects of 
GC action in the WAT and more specifically in the BM as this is when it has been 
previously been reported that BMAT expands (Devlin et al., 2010). Six-weeks of CR 
would therefore be described as long-term CR, rather than short-term fasting. Thus, 
the aim with the fasting prior to termination was to investigate long-term CR, rather 
than short-term fasting, hence it was required that both groups were fasted. This way, 
any dissimilarities observed would not be subjective by their variation in the short-
term feeding prior to termination. A similar approach has been advocated in other 
recent large-scale CR studies in mice (Mitchell et al., 2015). Based on the fasting of 
the AL mice, and refeeding of the CR mice, it is possible that the fasting might have 
affected the corticosterone synthesis in the AL mice, intensifying their stress levels 
above their natural concentration as they are not used to short-term fasting. Another 
option to consider would be the re-feeding of the CR mice at the same time that the 
AL mice had their food removed. Once the AL mice had their food removed, they 
received half a portion of AL food of what they would normally eat each day (1.5 g), 
and the CR mice received half a portion (1.05 g) of their daily CR diet ration (2.1 g). 
By refeeding the CR mice, their GC levels compared to previously in AT and BM could 
have decreased. Their circulatory corticosterone concentration at week six were 
decreased in comparison to previous week, suggesting that their tissue-specific levels 
could equally be affected. Based on the uncertainty of these results, I considered it 
was imperative to assess my fasting hypothesis. The six-week study showed that 
corticosterone concentration was increased by one-week of CR, therefore a one-week 
cohort was used to assess the fasting hypothesis as this would be sufficient for CR to 
increase plasma corticosterone. Based on the lack of diet differences, it was 
concluded that pursuing the short-term one-week CR cohort was imperative to 
address my hypothesis regarding effects of CR on GC action within BM and WAT. 
 
Pursuing the short-term one-week CR cohort, and comparing these data to the six-
week cohort, provided further insight into the relationship between CR duration, 
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circulating corticosterone, and tissue-specific GC effects. The GC target genes of the 
15-week-old mice were significantly decreased (possibly due to re-feeding) in 
comparison to the 10-week-old mice. These results indicate that the long-term effects 
of CR are masked by the refeeding of the mice, rather than the overnight fasting. 
However, the age of the mice could have also impacted these results. Therefore, to 
overcome this, an aged-match cohort for six-week CR would have to be conducted, 
without fasting prior to termination, to compare to my current six-week CR cohort. 
 
3.3.3. Causes and consequences of GC excess during CR 
 
3.3.3.1. CR increases circulating and tissue-specific GCs  
 
Previous study have shown that plasma corticosterone is increased after six weeks 
of CR (Cawthorn et al., 2016). My results extend this previous study by showing that 
the increase begins after only one week of CR; persist throughout CR; and are greater 
in males than in females. Moreover, in the 10-week-old cohort, mass spectrometry 
confirmed that the CR effects are more significant in males than females, for 
circulatory corticosterone (Figure 3.6). Previously, decreased leptin was shown to 
contribute to hypercorticosteronaemia during fasting (Ahima et al., 1996; Perry et al., 
2014). Based on my results, it could be that females have blunted increases in 
circulating corticosterone because they did not have decreased leptin (or fat mass) 
as much as males. In addition to circulatory levels, tissue-specific GC concentrations 
were also analysed. GCs were increased with CR in the BM, although, the CR effects 
did not vary between males and females for corticosterone concentration (Figure 3.7). 
Since GC regeneration in tissue is regulated by 11-HSD1, it suggests that circulatory 
concentrations do not affect tissue-specific GCs, but instead, they are indeed 
regulated by 11-HSD1.  
 
The conversion of corticosterone to 11-DHC is catalysed by the enzyme 11-HSD2. 
My results showed a decrease in the plasma ratio of 11-DHC to corticosterone in the 
10-week-old males only on CR (Figure 3.6.F). Although, in the BM, Anova showed an 
overall decrease in both sexes (Figure 3.7.F). The 15-week-old mice lacked diet 
differences in both the plasma and BM, probably due to the fasting/re-feeding blunting 
the end results. These results could potentially suggest that 11-HSD1 activity is 
decreased with CR in the BM in both males and females, and in the circulation in 
males only. However, these results could also be due to plentiful conversion of 
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corticosterone to 11-DHC by 11-HSD2 with CR, hence 11-DHC regeneration is 
magnified. Furthermore, these results are different from a 11-HSD1 activity 
measurement, as LC-MS/MS and mRNA results are not functional and whilst these 
might give an idea of activity, they are not informative of activity in a controlled way. 
Therefore, it cannot be concluded that 11-HSD1 activity is necessarily lower, nor not 
important with CR. However, in the circulation, female mice lacked diet differences, 
suggesting that 11-HSD1 activity was unaltered by the diet. Multiple comparison by 
ANOVA lacked diet differences in 11-DHC, suggesting that there was less 11-DHC to 
be converted by 11-HSD1 into corticosterone, and the increased corticosterone was 
due to increased activity in the HPA-axis. So far, this ratio has not been investigated 
in the BM, neither in the circulation during CR or AN. However, the effect of circulatory 
GC excess has been investigated in CS patients. It was shown that the cortisone to 
cortisol ratio in plasma was significantly higher in patients compared to healthy adults. 
Circulatory cortisol concentrations were similar increased in CS patients. The 
hypercortisolism in the patients suggest a possible underperforming 11-HSD2, or an 
overperforming 11-HSD1 (Dötsch et al., 2001). Although my own study induces an 
increase in circulatory corticosterone, the end effects of the ratio are not comparable 
to the results from the study using CS patients, as the conditions are massively 
different, and are also in different organisms.  
 
With CR, Hsd11b1 expression was up-regulated in both adipose depots and BM of 
the 15-week-old mice. These results suggest an increase in GC action in AT and BM. 
No previous research has yet identified a target gene that is increased with CR in the 
BM specifically, but these results are suggesting that Hsd11b1 could be one. In the 
BM of 10-week-old mice, Hsd11b1 expression was not upregulated. A possible 
reason behind this could be due to the lack of BMAT expansion during one-week CR 
(R. Sulston, unpublished data). Time course CR studies in the Cawthorn group have 
revealed that BMAT significantly expands past four-weeks of CR, with stronger 
differences at six-weeks of CR, similarly with Hsd11b1 expression in whole bone (data 
not shown). This suggests that Hsd11b1 could be a marker of increased adiposity in 
the BM. A previous publication showed that in vitro adipocyte differentiation increases 
with time during adipogenesis (Cheung et al., 2007), further supporting the notion that 
Hsd11b1 expression would increase during CR as BMAT equally increases. Thus, 
the lack of BMAT expansion with one-week CR could therefore explain the lack of diet 
differences in Hsd11b1 expression. Further investigating the role of this gene in the 
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BM, especially during CR when BMAT is expanded, may offer an opportunity to better 
understand the relationship between GCs and BMAT during CR. 
 
3.3.3.2. Consequences of GC excess during CR   
 
Other GC target genes, such as, Gilz, Fkbp5 and Per1, were also examined in 
adipose depots and BM. Fkbp5 is a co-chaperone of heat shock protein 90 (hsp90) 
regulating GR sensitivity (Binder, 2009). Beyond the GR, Fkbp5 can also bind to the 
AR, PR and MR. Furthermore, this gene has also been shown to interact with 
immunoregulatory pathways that are important for oncogenesis (further reviewed 
Zannas et al., 2016). Since Fkbp5 expression has previously been observed to 
increase due to GCs in AT (Pereira et al., 2014), it was hypothesised that this target 
gene would also be increased in WAT with CR.  My results showed varied results 
between the depots, the two cohorts and sexes (Figure 3.9.A-B, 3.10.G-H), 
suggesting that the CR effects can be diet, age-and/or sex-dependent. Similar results 
were found for Gilz (Figure 3.9/3.10 C-D), a GC target gene that is upregulated with 
GC treatment (D’Adamio et al., 1997; Cheng et al., 2013; Bruscoli et al., 2015), has 
anti-inflammatory properties (Mittelstadt and Ashwell, 2001; Berrebi et al., 2003) and 
is highly expressed in human adipocytes treated with dexamethasone (Lee et al., 
2011). Gilz is also downregulated in dendritic cells in respiratory allergic patients, but 
quickly upregulated post GC treatment. This further confirms its function as an anti-
inflammatory gene (Ronchetti, Migliorati and Riccardi, 2015). A third GC target gene 
was also investigated; Per1, and similar findings were found as above (Figure 
3.9/3.10 E/F). PER1 is an important circadian regulatory of cells (So et al., 2009; 
Reddy et al., 2012) and it also plays a role in cancers as the knockout of Per1 in cells 
enhances tumour formation (Zhao et al., 2016). Overall, the fasting effects seems to 
have affected the results in the 15-week-old mice, blunting the end-results. A 
conclusion of the target gene analysis is that CR generally is increasing the 
expression of the genes, but this seems to be influenced by the short-term fasting/re-
feeding as not all genes show increases with CR. This underscores the importance 
of analysing multiple genes, and not just one, in both cohorts, to draw reliable 
conclusions about GC action in these tissues. Another factor influencing the GC target 
genes during CR could be androgens. It has recently been discovered that androgen 
receptor signalling can influence GC turnover in WAT (Spaanderman et al., 2019). 
Based on these results, it would be possible that the results of the GC target gene in 
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my study could be influenced by androgens/AR. This could also alter the GC turnover 
of circulatory and tissue-specific levels during CR.  
 
Increased GCs can alter adipocyte differentiation and lipolysis, causing an increase 
in circulating FAs (Karatsoreos et al., 2010; Cassano et al., 2012; Geer, Islam and 
Buettner, 2014). GCs can also act differently on specific adipose depots. For example, 
in the presence of insulin, GCs can cause a depot-specific increase in activation of 
cortisone in omental AT, contributing to visceral adiposity (Lee et al., 2008). Moreover, 
although chronic GC excess in CS is associated with increased adiposity, it is also 
associated with increased lipolysis. In male mice  (Karatsoreos et al., 2010; Cassano 
et al., 2012) and rats (Wu et al., 2018), corticosterone administration causes weight 
gain and increased adiposity, but females were not included in these studies. In 
Cushing’s disease, no differences between men and females have been observed 
with regard to cortisol concentration, although independently of sex, the patients do 
have increased cortisol. However, it is difficult to compare the effects of GC excess 
resulting from CR with that which results from exogenously administered 
corticosterone. Indeed, I found that plasma corticosterone concentrations in CR reach 
around 100-300 ng/mL, whereas concentrations of ~600 ng/mL occur when 
corticosterone is orally administered (Morgan et al., 2014). Such high levels is likely 
to increase visceral adiposity and elevate corticosterone, but suppress the HPA axis 
(as observed with decreased adrenal gland masses) (Anagnostis et al., 2009; Arnaldi 
et al., 2012). Meanwhile, with CR, a mild elevation of corticosterone is observed, 
alongside decreased adiposity and improved insulin sensitivity (Fontana et al., 2004).  
 
In my study, we observed male mice losing fat mass (mostly gWAT) and having 
increased corticosterone concentration. In contrast, female mice did not lose fat mass, 
and they had less corticosterone concentration raise. These results suggest that GC 
are promoting lipolysis in male, but not in female gWAT. However, the females had 
increased effects of CR on Gilz and Fkbp5 expression with CR in gWAT (Figure 3.10), 
suggesting that they might not resist the effects of GCs in gWAT after all (although 
they often have lower expression than males). To further confirm these results, 
lipolysis target genes could be investigated such as HSL, ATGL, LXR- and LXR-, 
or direct measurement of released lipolytic products from adipocytes in cultured 
media, or measurement of FA and glycerol in plasma with a lipolysis detection kit.   
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As 11-HSD1 regulates the intracellular regeneration of corticosterone, it has been 
deemed important in the initiation of metabolic disorders. However, during CR, an 
increase in the expression of this enzyme suggests an increase in GC action, which 
is associated with anti-inflammatory properties. Although, selective overexpression of 
this enzyme is associated with visceral obesity, insulin-resistant diabetes and 
dyslipidemia (Masuzaki, 2001) and hepatic overexpression induces steatosis and 
insulin resistance without obesity (Paterson et al., 2004). Conversely, the 
hypomorphic 11-HSD1 KO mice have been reported to be resistant to these effects 
(Masuzaki, 2001; Morton et al., 2004; Park et al., 2014).  
 
One study comparing WT vs 11-HSD1 exon 5 KO mice revealed that the KOs are 
protected from certain effects of circulatory GC excess resulting from administration 
of corticosterone in the drinking water (Morgan et al., 2014). Although the GC 
concentration was much higher than during CR, potentially seen as non-beneficial as 
with CR, the results suggests that 11-HSD1 is a determinant of the consequences 
of GC excess and that knocking it out will improve metabolic abnormalities (Morgan 
et al., 2014). Since the 11-HSD1 KO mice can resist these effects, would they also 
be able to resist CR-associated decreases in body mass and fat mass? What about 
BMAT expansion that comes with CR? Formerly, Justesen et al., showed that the 
hypomorphic 11-HSD1 KO mice completely lack BMAT in the tibia. Meanwhile, 
Couthino et al., revealed the opposite, as did we in our lab (Chapter 4). Admittedly, 
no research on BMAT has been performed on null 11-HSD1 KO mice during CR. As 
CR is known to increase BMAT, it is undefined whether 11-HSD1 KO mice would 
resist this expansion, or not.  
 
3.3.4. Future directions 
 
This Chapter revealed that male mice lose fat mass with CR, whereas female mice 
do not. So far, the reason and the mechanism behind this is still unknown, but it is 
currently under further investigation in the lab. Future work regarding the sex 
differences could include ovariectomy studies to test the hypothesis that female sex 
hormones contribute to these sex differences, and that the ovariectomised mice would 
lose fat mass. Orchidectomy would also be an option, to further investigate the 
relationship between androgens and BMAT during CR. Alternatively, removal of fat 
pads around the ovaries and testis could be performed, and then subjecting the mice 
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to CR. A recent publication investigated the removal of fat pads around the ovaries 
and demonstrated that the fat pads are important for mouse reproduction (Wang et 
al., 2017). In male mice, the fat pad surrounding the testis support spermatogenesis 
(Chu et al., 2010). Although, a more direct and robust approach would still be the 
removal of the reproductive organs. It would be intriguing to have examined the bones 
from these mice, especially to quantify BMAT. The removal of the fat pads around the 
ovaries or ovariectomy results in reduced oestrogen secretion, therefore, it would be 
hypothesised that they would have increased BMAT. In contrast, increased 
testosterone has been shown to be associated with decreased BMAT in both men 
and women (Tamura et al., 2005; Mistry et al., 2018). Anorexic men were shown to 
have decreased testosterone over time (Wabitsch et al., 2001). It would therefore be 
intriguing to further investigate the role of androgens in BMAT expansion during CR.   
 
To overcome the fasting/re-feeding issue that we came across, an aged-matched 
cohort would have to be conducted for six-week CR. That way, the 15-week-old mice 
that were fasted/re-fed could be directly compared to the same aged mice that did not 
undergo fasting/re-feeding.  
 
Further work regarding the endocrine effects of CR would include adrenalectomy, of 
both male and female mice to further investigate the effects of GCs during CR. By 
removing the adrenal glands, the synthesis of corticosterone would stop and 
circulatory concentration would drop. This would allow one to examine circulatory vs 
tissue-specific GC concentrations in both sexes during CR. Subsequently, measuring 
11-HSD1 activity during CR would be advantageous. Although we know that 
Hsd11b1 expression is increased with CR, we do not know how its activity compares 
to that in AL-fed controls, and especially in the BM. To determine 11-HSD1 
reductase and dehydrogenase activity, BM cells from mice subject to CR could be 
cultured, with the addition of 3H-substrate to the medium, to calculate conversation of 
substrate (11-DHC) to product (corticosterone). Dehydrogenase activity would also 
be measured to detect if the reverse conversation would occur in the BM. Although, 
since 11-HSD2 is predominantly present in the kidneys, placenta and salivary 
glands, the dehydrogenase activity would not be expected to show. Alternatively, 11-
HSD1 activity can be measured from freshly isolated whole bone/bone only/BM only 
by incubating the tissue with a specific amount of 11-DHC for 3h. Thereafter, the 
steroids in the media can be extracted and corticosterone concentration can be 
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measured by ELISA (Hardy et al., 2016). In addition, 90% of corticosterone is bound 
to binding globulins and 10% is free only, whereas, 11-DHC has greater free levels. 
Therefore, measuring binding globulins would be useful to determine the amount of 
corticosterone bound, and this can be done by ELISA. Another option, which I 
implemented in the following Chapters, is to stop the intracellular regeneration of 
corticosterone by knocking out the enzyme 11-HSD1 globally. As previously 
mentioned, an unexpected response to CR is BMAT expansion. By knocking out 11-
HSD1, I further investigated circulatory and tissue-specific endocrine effects as well 




Chapter 4. 11-HSD1 KO male mice resist bone 
marrow adiposity expansion during caloric restriction, 
but female mice do not 
 
 
4.1. Introduction  
 
Unlike WAT, BMAT increases in diverse clinical conditions, including following CR in 
animals, and AN in humans, osteoporosis and excess GC treatment. The causes and 
consequences of this expansion remain unknown. CR-induced BMAT expansion may 
contribute to other adaptations to CR, including metabolic adaptations, bone loss and 
immunological changes. As previously mentioned (Chapter 3.1), during CR, BMAT 
contributes to increased circulating concentrations of adiponectin (Cawthorn et al., 
2014; Straub and Scherer, 2019), which might contribute to the health benefits of CR. 
Therefore, it is important to elucidate the mechanisms responsible for CR-induced 
BMAT expansion.  
 
Previous data showed that during CR, when BMAT is significantly increased in 
comparison to control-fed mice, circulatory corticosterone concentration is also 
increased (Cawthorn et al., 2016). Nonetheless, neither moderate (30%) nor 
excessive (40-50%) CR in rabbits is associated with increases in BMAT nor are 
circulating GCs altered during CR in rabbits. These data support the possibility that 
GC excess is required for CR-associated BMAT expansion (Cawthorn et al., 2016). 
In addition to CR, GC administration also increases BMAT in animals and humans 
(Vande Berg et al., 1999; Devlin et al., 2010; Georgiou, Hui and Xian, 2012; Li et al., 
2013). GCs are not only elevated during CR in animals, but also in AN patients (Boyar 
et al., 1977; Walsh et al., 1978; Misra et al., 2004; Lawson et al., 2009), when BMAT 
also increases (Bredella et al., 2009, 2014; Ecklund et al., 2010).  
 
The elevated BMAT in AN is inversely correlated to BMD (Bredella et al., 2009, 2014). 
Young girls with AN have a greater risk of developing osteoporosis by exhibiting 
premature transformation of haematopoietic to adipose cells in the marrow (Ecklund 
et al., 2010). Similarly, CR in animal models is associated with decreases in whole-
body BMD (Berrigan et al., 2005) and loss of cortical bone (Hamrick et al., 2008). 
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Therefore, one possibility is that the expansion of BMAT during CR might be mediated 
by GC excess. Many effects of endogenous GC excess are mediated by 11-HSD1, 
which catalyses intracellular regeneration of active GCs. The importance of 11-
HSD1 in regulating metabolic phenotypes has been highlighted in various tissues. For 
example, transgenic animal models overexpressing 11-HSD1 in AT develop obesity, 
insulin resistance, dyslipidaemia and hypertension (Masuzaki, 2001; Masuzaki et al., 
2003). Conversely, hypomorphic 11-HSD1 KO mice have the opposite phenotype, 
with lower plasma TG levels, improved insulin sensitivity and reduced visceral 
adiposity upon HFD (Morton et al., 2001, 2004). Furthermore, the bone morphology 
of the hypomorphic 11-HSD1 KO mice did not differ compared to the WTs (Justesen 
et al., 2004). It has previously been demonstrated that the conversion of 11-DHC into 
corticosterone in mice, by 11-HSD1, is a significant determinant of the effects of 
exogenous GC excess in mice (Morgan et al., 2014). When 11-HSD1 was deleted, 
the global and fat-specific KO had much greater resistance to the GC effects than the 
liver-specific KO (Paterson et al., 2004; Lavery et al., 2012; Harno et al., 2013; Morgan 
et al., 2014).  However, it is worth noting that the global 11-HSD1 exon 5 KO model 
used by Morgan et al., (2014) and the null 11-HSD1 KO which were created at 
Edinburgh University are full KOs compared to the model used by Justesen et al. 
Overall, based on this research, is it possible that my null 11-HSD1 KO mice will also 
resist BMAT expansion during CR?  
 
Chapter 3 reported that Hsd11b1 expression is up-regulated in the BM after six-weeks 
of CR, but not after one-week. This coincides with the expansion of BMAT at six-
weeks of CR, but not after only one-week of CR. Formerly, Justesen et al., (2004) 
examined bones of hypomorphic 11-HSD1 KO mice under normal conditions, and 
revealed that the mice were lacking BMAT in their tibia. However, a more-recent study 
showed that the same line of hypomorphic 11-HSD1 KO mice do have BMAT 
present in their tibiae, at least when examined 3 weeks after initiation of joint 
inflammation (Coutinho et al., 2012). Preliminary studies from our lab, completed prior 
to the start of my PhD studies, also indicate that BMAT is present in our full 11-HSD1 
KO mice (K. Suchacki, unpublished data).  
 
Based on the evidence presented in Chapter 3, along with previous findings (Morgan 
et al., 2014), my hypothesis is that 11-HSD1 contributes to GC action within the BM 
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and thereby mediates BMAT expansion during CR. To determine if inhibiting 
intracellular regeneration of corticosterone globally is sufficient to prevent or attenuate 
BMAT expansion during CR, C57BL/6JOlaHsd control (WT) and 11-HSD1 KO male 
and female mice were subject to CR for six weeks. Data for WT males and females, 
which were littermates of 11-HSD1 KO mice, are shown in Chapter 3. To minimise 
animal use, the same WT data and cohorts are included in this Chapter, in which they 
are compared to data from their 11-HSD1 KO littermates. Note that the WT and 11-





4.2 Results  
 
4.2.1. CR causes weight loss in WT and 11-HSD1 KO mice  
 
Genotypes of mice were confirmed post-weaning by analysis of genomic DNA 
isolated from ear clips, as described in the Methods (2.1). To determine if CR affected 
body mass similarly in WT and KO, I measured body masses of the WT and KO mice 
over the course of the experiment. It was expected that mice on the CR diet would 
have a decrease in body mass compared to mice on the AL diet. Figure 1 shows the 
body mass progression of both WT (black lines) and KO (red lines) in male (Figure 
4.1.A) and female (Figure 4.1.B) mice, measured weekly for six weeks. Males and 
females of both genotypes were randomly assigned to AL or CR diet, so both diet 
groups started at approximately the same body mass; an exception was for the AL-
fed KO males, which had a higher body mass than AL-fed WT males even at week 0 
of the experiment. However, KO males have been noticed to often be heavier than 
WTs (K. Chapman, personal communication). Although, it could also be a random 
sampling effect because similar KO effects were not observed in subsequent cohorts 
of mice (Chapter 6). Nevertheless, together these data show that, as expected, CR 






Figure 4.1. WT and 11-HSD1 KO male and female mice lose body weight with 
30% CR diet over six weeks. C57BL/6JOlaHsd (WT, black) and 11-HSD1 KO (KO, 
red) male (A) and female (B) mice were fed ad libitum (AL, closed symbols, solid line) 
or 70% of ad libitum food intake (CR, open symbols, dotted line) for six weeks, from 
9 weeks until 15 weeks of age. The evening prior to dissections, all mice were 
fasted/re-fed. The AL fed mice had their food removed and were given half a portion 
of the 70% of food that they were daily consuming (1.5g). The CR fed mice were also 
given half a portion (1.05g) of their 30% CR diet. The mice were weekly weighed. 
Data are mean +/- SEM and were analysed by 3-Way ANOVA with Sidak’s multiple 
comparison test. n (WT AL male) = 7. n (WT CR male) = 11. n (KO AL male) = 8. n 
(KO CR male) = 8. n (WT AL female) = 8. n (WT CR female) = 13. n (KO AL female) 
= 5. n (KO CR female) = 8. ***: p<0.001. 
 
 













Genotype effect: p = <0.0001
Diet effect: p = <0.0001
Interaction: p = 0.0005
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Genotype effect: p = 0.24
Diet effect: p = <0.0001
Interaction: p = 0.34
B
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4.2.2. 11-HSD1 deficiency does not protect male mice against fat loss 
during CR 
 
To further characterise the tissue losses and understand the association between the 
diet, genotype and body weight, body composition was measured weekly by TD-NMR 
throughout the six-week study.  
 
Figure 4.2 presents fat and lean mass of WT and KO male and female mice, 
expressed as absolute mass (g) and as a % of total body mass (%). Male mice subject 
to CR showed significant fat mass loss as absolute mass (Figure 4.2.A) and as % of 
body mass (Figure 4.2.C). ANOVA confirmed a significant genotype and diet effect, 
as well as an interaction between the two for both absolute and % fat mass. A 
genotype difference in absolute fat mass (Figure 4.2.A) between the WT and KO male 
mice was also observed from week three to the final week, and only at week four as 
% of total body mass. This shows that the KO males had more fat, which this differs 
to previous data reporting that the hypomorphic KOs resist obesity on HFD (Morton 
et al., 2004). The male mice on CR continued to show a decrease in fat mass until 
week two post-dietary intervention, where they reached maximum loss. Thereafter, 
from weeks four to six, fat mass began to increase in the CR males of each genotype. 
ANOVA for the female fat mass as absolute mass (Figure 4.2.B) and as % of body 
mass (Figure 4.2.D) revealed significant diet effects. Compared to WT AL-fed 
females, WT CR-fed females showed significantly decreased absolute fat mass at 
weeks four and five post-dietary intervention only (Figure 4.2.B). 
 
A significant diet effect was revealed by ANOVA for the lean mass of both males 
(Figure 4.2.E, G) and females (Figure 4.2.F, H). In addition, a significant genotype 
effect for lean mass was present in males only. The absolute lean mass was 
significantly decreased in male (Figure 4.2.E) and female (Figure 4.2.F) mice subject 
to CR, regardless of genotype. In contrast, relative lean mass was increased in CR-
fed vs AL-fed males (Figure 4.2.G) and only differed between WT AL-fed and CR-fed 
females at week five (Figure 4.2.H). This suggests that the female body mass losses 
observed in figure 4.1.B are due predominantly do decreases in lean mass, rather 
than fat mass. Whereas, in males, the decreased body mass is disproportionately due 
to loss of fat mass whilst lean mass is relatively protected. 
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The genotype differences observed in body composition in response to CR suggest 
that 11-HSD1 deficiency does not protect male mice from losing fat mass, and 
instead may enhance the loss of fat mass during CR, as the difference between AL 
and CR is greater than for the WT males. Moreover, 11-HSD1 does not protect 
females from maintaining their fat mass, as there are no significant genotype effects 

































































Male fat mass (%)
Genotype effect: p<0.0001
Diet effect: p<0.0001

























*** *** *** *** ***
*
*** *** *** *** ***
Male lean mass (g)
Genotype effect: p<0.0001
Diet effect: p<0.0001
Interaction: p = 0.007
E

































Male lean mass (%)
Genotype effect: p = 0.0001
Diet effect: p<0.0001
Interaction: p = 0.08
G







Female fat mass (g)
Genotype effect: p = 0.7
Diet effect: p<0.0001












Female fat mass (%)
Genotype effect: p = 0.5
Diet effect: p = 0.007
Interaction: p = 0.3
D









****** ****** ****** ***
*** ******
Female lean mass (g)
Genotype effect: p = 0.14
Diet effect: p<0.0001
Interaction: p = 0.007
F








Female lean mass (%)
Genotype effect: p = 0.9
Diet effect: p = 0.02
Interaction: p = 0.034
H
 118 
Figure 4.2. Body composition determined by TD-NMR revealed significant fat 
mass differences between WT and 11-HSD1 KO male mice, whereas, female 
mice resisted fat mass loss. WT and 11-HSD1 KO male and female mice were fed 
AL or CR diets and fasted/re-fed as described for Figure 4.2 and in Methods (2.1.2). 
All mice were weekly scanned by TD-NMR. Fat mass in male (A) and female (B) mice 
shown in grams. Fat mass in male (C) and female (D) mice shown as % of body mass. 
Lean mass in male (E) and female (F) mice shown in grams. Lean mass in male (G) 
and female (H) mice shown as % of body mass. Data is mean +/- SEM and were 
analysed by 3-Way ANOVA with Sidak’s multiple comparison test. n (WT AL male) = 
7. n (WT CR male) = 11. n (KO AL male) = 8. n (KO CR male) = 8. n (WT AL female) 
= 8. n (WT CR female) = 13. n (KO AL female) = 5. n (KO CR female) = 8. * (black): 
diet effect in WT mice. * (red): diet effect in KO mice. # (black): genotype effect in AL 
















4.2.3. Male mice on CR are susceptible to WAT loss, whereas females are 
not 
 
In Chapter 3, I showed that the sex differences in fat loss during CR predominantly 
reflect changes in gonadal WAT and that WAT Hsd11b1 expression is greater in 
males than in females (Figure 3.10 A-B). Thus, given the ability of 11-HSD1 to 
influence visceral adiposity (Masuzaki, 2001; Desbriere et al., 2006; Michailidou, 
Jensen, et al., 2007; Veilleux et al., 2010; Mlinar et al., 2011; Wamil et al., 2011) and 
the differences observed in total fat mass (Figure 4.2), I next investigated if 11-HSD1 
KO influences the effects of CR on specific adipose depots. To do so, at necropsy the 
adipose depots were sampled and weighed to determine diet and genotype 
differences. Figure 4.3 shows the absolute mass and % of body mass of iWAT, gWAT 
and mWAT in CR-and AL-fed WT and KO mice.  
 
The subcutaneous iWAT decreased with CR as absolute mass (Figure 4.3.A) and as 
% of body mass (Figure 4.3.D) in male mice only. Similar sex-specific decreases were 
also observed for the visceral depots, gWAT (Figure 4.3.B, E) and mWAT (Figure 
4.3.C, F), although for the latter ANOVA detected an overall diet effect only for 
absolute mWAT mass (Figure 4.3.C). No WAT loss was observed during CR in the 
female mice, and no diet or genotype differences were detected in BAT for either sex 
(Figure 4.4). This indicates that the loss detected in fat mass with TD-NMR is primarily 
from the WAT depots.  
 
Overall, these data confirm the TD-NMR results that only male mice lose fat mass 
with CR and further show that decreased gWAT and iWAT are the main contributors 
to this effect. Moreover, they show that deficiency of 11-HSD1 does not protect 
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Figure 4.3. 11-HSD1 deficiency does not affect WAT mass in female mice and 
does not protect male mice from adipose loss with CR. WT and 11-HSD1 KO 
male and female mice were fed AL or CR diets and fasted/re-fed as described for 
Figure 4.2 and in Methods (2.1.2). At necropsy, WAT (iWAT, gWAT and mWAT) 
depots were harvested and weighed. iWAT (A), gWAT (B) and mWAT (C) in male 
and female mice in grams. iWAT (D), gWAT (E) and mWAT (F) in male and female 
mice as % of body mass. Data points are presented with median, interquartile range 
and range shown by box and whisker plot, and were analysed by 2-Way ANOVA with 
Sidak’s multiple comparison test. n (WT AL male) = 7. n (WT CR male) = 11. n (KO 
AL male) = 8. n (KO CR male) = 8. n (WT AL female) = 7. n (WT CR female) = 13. n 









Figure 4.4. Neither CR nor 11-HSD1 deficiency affects BAT mass. WT and 11-
HSD1 KO male and female mice were fed AL or CR diets and fasted/re-fed as 
described for Figure 4.2 and in Methods (2.12). At necropsy, BAT was harvested and 
weighed. BAT in male and female mice in grams (A) and as % of body mass (B). Data 
points are presented with median, interquartile range and range shown by box and 
whisker plot, and were analysed by 3-Way ANOVA with Sidak’s multiple comparison 
test. n (WT AL male) = 7. n (WT CR male) = 11. n (KO AL male) = 8. n (KO CR male) 
= 8. n (WT AL female) = 7. n (WT CR female) = 13. n (KO AL female) = 6. n (KO CR 
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4.2.4. 11-HSD1 KO does not affect CR-induced 
hypercorticosteronaemia but increases adrenal mass in males 
 
 
As shown in Chapter 3 and in previous studies, CR increases circulating GC 
concentrations and adrenal gland mass. However, 11-HSD1 KO mice have been 
shown to resist the effects of exogenous corticosterone administration even though 
circulating plasma corticosterone concentrations and adrenal mass did not differ to 
those in WT mice (Morgan et al., 2014). Thus, to determine if 11-HSD1 KO alters 
the effects of CR on circulatory corticosterone concentration or adrenal mass, I next 
measured circulating corticosterone and adrenal gland masses in my cohorts of AL- 
and CR-fed WT and KO mice. Tail and core blood were collected for plasma. Adrenal 
glands were dissected and weighed as indicators of increased capacity for 
corticosterone synthesis.  
 
Figure 4.5 shows corticosterone quantification by ELISA in male (Figure 4.5.A) and 
female (Figure 4.5.B) mice in plasma collected throughout the six weeks of CR. 
Significant diet effects were detected by 3-Way ANOVA for both sexes, with the mice 
subject to CR having increased circulatory corticosterone concentrations in 
comparison to mice on AL diet. No significant genotype differences were detected. 
 
AL-fed females and AL-fed KO males showed increased circulating corticosterone 
concentration at week six, whereas CR-fed mice also showed a decrease at week six 
compared to previous weeks. One possibility is that these changes at week six reflect 
a technical issue relating to the sampling method: for previous weeks (0-5), blood was 
sampled approximately at 9am, prior to feeding the CR mice, whereas the 
measurement at week six was made prior to termination, following overnight fasting 
of the mice. As discussed in Chapter 3, the AL and CR mice were fed a set ration of 
food at approximately 18:00 on the evening prior to termination, to ensure that both 
groups were fasted for similar durations prior to cull. The rationale for this is that I was 
interested in assessing the effects of long-term CR, rather than short-term fasting 
effects. However, one concern is that this endpoint feeding/fasting regimen might alter 
GC action in a way that is not representative of the remainder of the CR protocol, 
thereby confounding downstream tissue-specific analyses of GC action. Therefore, to 
overcome this, I performed a short-term one-week CR experiment in which mice were 
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not fasted prior to necropsy. Thus, my subsequent analyses compared not only 
effects of sex, diet and genotype, but also compared the long-term six-week (15-
weeks of age at necropsy, labelled as ‘Chronic CR’ in figures) and short-term one-
week CR (10-weeks of age at necropsy, labelled as ‘Acute CR’ in figures) mice. One-
week CR was used because, as shown in Figure 4.5, this is sufficient to induce 
hypercorticosteronaemia. 
 
Figure 4.6 displays the adrenal gland masses. Six-weeks of CR significantly 
increased absolute and % adrenal gland mass in males but not in females (Figure 
4.6.A, C), whereas no diet effects were detected in the 10-week-old mice (Figure 
4.6.B, D). Consistent with previous findings (Bielohuby et al., 2007), sex differences 
in adrenal mass were also apparent, with females having greater absolute and % 
mass than males at 15 weeks, and greater % adrenal mass in the 10-week cohort 
(Figure 4.6.A-D). 
 
I further investigated the effects on corticosterone and 11-DHC by LC-MS/MS, 
because some journals will not accept ELISAs for steroid hormones because they are 
not specific enough. Furthermore, LC-MS/MS provides more precise readouts and 
can quantify several steroids at once. Figure 4.7. shows plasma corticosterone and 
11-DHC as quantified by LC-MS/MS for both cohorts. In the 15-week-old mice, no 
diet or genotype effects were detected for corticosterone concentration (Figure 4.7.A). 
In contrast, in the 10-week-old mice corticosterone concentration (Figure 4.7.B) was 
significantly increased with CR in all groups except the KO males, in which there was 
only a trend for an increase. In the 15-week mice, ANOVA revealed significant 
genotype effects for 11-DHC in both sexes (Figure 4.7.C). Diet effects occurred in 
males only, with a significant increase detected in the CR-fed KO males compared to 
the AL-fed males (Figure 4.7.C). Moreover, in the 10-week-old cohort, ANOVA 
revealed that CR significantly increased 11-DHC in females and tended to increase 
11-DHC in males (P = 0.08). Multiple comparisons for the 10-week cohort showed 
that 11-DHC was significantly increased in KO females on CR (Figure 4.7.D), perhaps 
resulting from increased regeneration via 11-HSD2 or impaired conversion to 
corticosterone. To gauge the conversion of 11-DHC to corticosterone, the ratio of 
CORT to 11-DHC was calculated. As expected, ANOVA showed significant genotype 
effects in both cohorts, with the KO ratio being markedly reduced compared to that in 
WT mice (Figure 4.7. E, F), which would be consistent with lower 11-HSD1 activity. 
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These results show a significant increase in circulatory corticosterone concentration 
throughout CR, but with the 10-week-old CR-fed KO males resisting the increase. 
This suggests that the fasting/re-feeding prior to termination might have affected the 
end-results of the 15-week-old mice, and that the KO males may have some 
resistance to CR-induced hypercorticosteronaemia. Based on previous research, 
revealing that 11-HSD1 is a regulator of tissue-specific effects of circulating GC 
excess (Morgan et al., 2014), the next step was to investigate Hsd11b1 expression in 





Figure 4.5. Circulating corticosterone concentration was increased in WT and 
11-HSD1 KO mice throughout the six weeks of CR. WT and 11-HSD1 KO male 
and female mice were fed AL or CR diets and fasted/re-fed as described for Figure 
4.2 and in Methods. Throughout the six weeks, blood was sampled from the tail vein 
and quantified by ELISA as described in Methods (2.4). Circulatory corticosterone 
concentration in male (A) and female (B) mice from weekly collected plasma, by 
ELISA. Data is mean +/- SEM and analysed by 3-Way ANOVA with Tukey’s multiple 
comparisons test. n (WT AL male) = 7. n (WT CR male) = 10. n (KO AL male) = 5. n 
(KO CR male) = 6. n (WT AL female) = 7. n (WT CR female) = 7. n (KO AL female) = 
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Figure 4.6. CR and 11-HSD1 KO influence adrenal gland mass in a sex- and 
duration-dependent manner. WT and 11-HSD1 KO male and female mice were 
fed AL or CR diets as described for Figure 4.2 and Methods (2.1.2), and fasted/re-fed 
as described in Methods (2.3.1). At necropsy, adrenal glands were dissected and 
weighed. Male and female adrenal glands shown in grams (A). Male and female 
adrenal glands shown as % of body mass (B). Data points are presented with median, 
interquartile range and range shown by box and whisker plot, and were analysed by 
2-Way ANOVA with Sidak’s multiple comparisons test. 15-week-old mice: n (WT AL 
male) = 7. n (WT CR male) = 11. n (KO AL male) = 8. n (KO CR male) = 8. n (WT AL 
female) = 7. n (WT CR female) = 13. n (KO AL female) = 6. n (KO CR female) = 8. 
10-week-old mice: n (AL male) = 8. n (CR male) = 8. n (KO AL male) = 5. n (KO CR 
male) = 5. n (AL female) = 5. n (CR female) = 6. n (KO AL female) = 8. n (KO CR 
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Figure 4.7. Circulatory GC regeneration is altered in 10-week-old mice subject 
to CR. WT and 11-HSD1 KO male and female mice were fed AL or CR diets as 
described for Figure 4.2 and Methods (2.12), and fasted/re-fed as described in 
Methods (2.3.1). Prior to termination, end-point blood was sampled and quantified by 
LC-MS/MS as described in Methods (2.5.1). Circulating corticosterone concentration 
in 15-and (A) 10-week-old mice (B). Circulating 11-DHC concentration in 15-and (C) 
10-week-old mice (D). Circulating ratio of corticosterone to 11-DHC ratio in 15-and 
(E) 10-week-old mice (F). Data points are presented with median, interquartile range 
and range shown by box and whisker plot, and were analysed by 2-Way ANOVA with 
Sidak’s multiple comparison test. 15-week-old mice: n (WT AL male) = 7. n (WT CR 
male) = 10. n (KO AL male) = 8. n (KO CR male) = 8. n (WT AL female) = 7. n (WT 
CR female) = 13. n (KO AL female) = 6. n (KO CR female) = 8. 10-week-old mice: n 
(WT AL male) = 8. n (WT CR male) = 8. n (KO AL male) = 5. n (KO CR male) = 5. n 
(WT AL female) = 5. n (WT CR female) = 6. n (KO AL female) = 8. n (KO CR female) 
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4.2.5. CR is associated with increased Hsd11b1 expression in WAT  
 
The above findings confirm that CR increases plasma corticosterone regardless of 
genotype. However, 10-week-old CR-fed KO males resisted this increase, suggesting 
that other depots might also resist it. Previous data show that, compared to WT 
controls, 11-HSD1 KO mice resist the effects of administrated corticosterone on 
WAT (Morgan et al., 2014). Therefore, to determine if the KOs also resist these effects 
during CR, I next analysed the expression of GC target genes in iWAT and gWAT. I 
began by analysing expression of Hsd11b1.  
 
As shown for iWAT (Figure 4.8.A) and gWAT (Figure 4.8.B), in the 15-week-old mice 
Hsd11b1 expression was significantly increased with CR, whereas in the 10-week-
old mice, Hsd11b1 expression was upregulated with CR in the iWAT of WT females 
only (Figure 4.8.A). Hsd11b1 mRNA was undetectable in the KOs, confirming the 
genotype of these mice.  
 
These results suggest an increase in GC action in adipose depots with CR, 
particularly for longer-term CR. Therefore, additional GC target genes were next 
examined to investigate if this effect in WT mice extends to other transcriptional 








Figure 4.8. Long-term CR increases Hsd11b1 expression in WAT. WT and 11-
HSD1 KO male and female mice were fed AL or CR diets as described for Figure 4.2 
and Methods (2.1.2), and fasted/re-fed as described in Methods (2.3.1). At necropsy, 
iWAT and gWAT depots were removed and snap-frozen on dry ice, followed by 
cryopulverisation in liquid nitrogen. RNA extraction and reverse transcription to cDNA 
was then performed on all tissues. qPCR was performed to quantify expression of 
Hsd11b1. Hsd11b1 was normalised to the geometric mean of the following 
housekeeping genes: Ppia, Tbp and Hprt, and presented as relative to the WT AL 
average of male and female mice together. Hsd11b1 expression in iWAT of 15-and 
10-week-old mice, respectively (A). Hsd11b1 expression in gWAT of 15-and 10-week-
old mice, respectively (B). Data points are presented with median, interquartile range 
and range shown by box and whisker plot, and were analysed by Mann-Whitney 
and/or Welch’s test as appropriate. Fasted mice: n (WT AL male) = 7. n (WT CR male) 
= 10. n (KO AL male) = 5. n (KO CR male) = 7. n (WT AL female) = 7. n (WT CR 
female) = 9. n (KO AL female) = 4. n (KO CR female) = 5. Non-fasted mice: n (AL 
male) = 8. n (CR male) = 8. n (KO AL male) = 5. n (KO CR male) = 5. n (AL female) 
= 5. n (CR female) = 6. n (KO AL female) = 8. n (KO CR female) = 9. *: p<0.05. ***: 
p<0.001. 
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4.2.6. GC target gene expression in WAT of mice subject to CR 
 
Figure 4.9 shows the expression of the GC target genes Fkbp5, Gilz and Per1 in iWAT 
of 15-and 10-week-old mice. In the 15-week-old mice, ANOVA revealed a diet effect 
across both genotypes for Fkbp5 expression in females, with the KO females on CR 
having decreased Fkbp5 expression compared to the AL-fed females (Figure 4.9.A). 
Whereas, in the 10-week-old mice an overall diet effect was detected by ANOVA for 
males and females, with the CR mice having increased expression (Figure 4.9.B). 
Furthermore, a near-significant genotype effect was detected in females (p=0.0507), 
with the WT females on CR diet showing a higher expression of Fkbp5 than the KO 
females on CR. Gilz expression was significantly increased in 15-week-old male mice 
subject to CR, and ANOVA revealed a similar diet effect in the females (Figure 4.9.C); 
this was unaffected by 11-HSD1 KO. In the 10-week-old mice, ANOVA revealed that 
CR significantly increased Gilz mRNA across both genotypes of females, with a trend 
for this in male mice (Figure 4.9.D). CR significantly increased Gilz mRNA in WT 
females only (Figure 4.9.D). Per1 mRNA was unaltered by diet or genotype in the 15-
week-old mice (Figure 4.9.E). ANOVA showed a near-significant diet effect (p=0.056) 
for 10-week-old males, but a significant increase in Per1 expression for WT males on 
CR (Figure 4.9.F). For the females, ANOVA revealed a diet and genotype effect, with 
an increased expression of Per1 in the CR-fed WT females and a trend for this in KO 
females; however, Per1 expression tended to be lower in iWAT of KO females 
compared to their WT counterparts (Figure 4.9.F). 
 
Figure 4.10. shows the gene expression levels of Fkbp5, Gilz and Per1 mRNA in 
gWAT of 15- and 10-week-old mice. ANOVA showed a significant diet effect for the 
15-week-old females, with a decreased expression of Fkbp5 in the CR-fed KO 
females compared to the AL-fed females (Figure 4.10.A). In the 10-week-old females, 
an overall diet effect on Fkbp5 was detected by ANOVA, with multiple comparison 
showing a significant increase in Fkbp5 in the CR-fed WT females (Figure 4.10.B). 
ANOVA revealed significant diet effects for Gilz mRNA in 15-and 10-week-old 
females, but in opposite directions: decreased expression in 15-week-old KO females 
on CR, but increased in the 10-week old WT females on CR with a similar trend for 
the KO females (Figure 4.10.C-D). Figure 4.10.E shows Per1 expression in 15-week-
old mice, with an overall diet effect in the males only, pointing towards a decrease in 
expression with CR. Whereas, the ANOVA for the female mice shows an interaction 
between diet and genotype effect, with the CR-fed WTs increasing, and the CR-fed 
KOs decreasing Per1 mRNA. In the 10-week-old mice, ANOVA showed a significant 
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diet effect for the Per1 expression in males, with the CR-fed males having higher 
expression of Per1. Whereas, the CR-fed females show a similar but non-significant 
trend to increase Per1 mRNA. (Figure 4.10.F).  
 
These data reveal that both CR and 11-HSD1 KO can influence GC target gene 
expression in WAT; however, these effects are complex, differing depending on the 
target gene analysed, the WAT depot assessed, the sex of the mice, and the CR 
regimen used. Importantly, in most cases there was no interaction between diet and 
genotype, indicating that 11-HSD1 KO did not influence the effect of CR on these 
target genes. Thus, unlike in response to orally administered corticosterone, 11-





Figure 4.9. GC target gene expression in iWAT of 15-and 10-week-old mice on 
CR. WT and 11-HSD1 KO male and female mice were fed AL or CR diets as 
described for Figure 4.2 and Methods (2.1.2), and fasted/re-fed as described in 
Methods (2.3.1). qPCR was performed to quantify expression of Fkbp5, Gilz and Per1 
in iWAT. Genes were normalised to the geometric mean of the following 
housekeeping genes: Ppia, Tbp and Hprt, and presented as relative to the WT AL 
average of male and female mice together. Fkbp5 expression in 15-and (A) 10-week-
old (B) mice. Gilz expression in 15-and (C) 10-week-old (D) mice. Per1 expression in 
15-and (E) 10-week-old (F) mice. Data points are presented with median, interquartile 
range and range shown by box and whisker plot and were analysed by 2-Way ANOVA 
with Sidak’s multiple comparison test. Numbers of mice per group, and presentation 
of statistically significant differences between groups, are as described for figure 4.9. 
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Figure 4.10. GC target gene expression in gWAT of 15-and 1-week-old mice on 
CR. WT and 11-HSD1 KO male and female mice were fed AL or CR diets as 
described for Figure 4.2 and Methods (2.1.2), and fasted/re-fed as described in 
Methods (2.3.1). Expression of Fkbp5, Gilz and Per1 was determined in gWAT of WT 
and KO mice, as described for Figure 4.10. Fkbp5 expression in 15-and (A) 10-week-
old (B) mice. Gilz expression in 15-and (C) 10-week-old (D) mice. Per1 expression in 
15-and (E) 10-week-old (F) mice. Data points are presented with median, interquartile 
range and range shown by box and whisker plot and were analysed by 2-Way ANOVA 
with Sidak’s multiple comparison test. Numbers of mice per group, and presen tation 




















Fkbp5 in gWAT of 15-week-old mice
Diet effect: p = 0.6
Genotype effect: p = 0.07
Interaction: p = 0.5
Diet effect: p = 0.02
Genotype effect: p = 0.08 





















Gilz in gWAT of 15-week-old mice
Diet effect: p = 0.5
Genotype effect: p = 0.2
Interaction: p = 0.16
Diet effect: p = 0.0006
Genotype effect: p = 0.24 



















Per1 in gWAT of 15-week-old mice
Diet effect: p = 0.048
Genotype effect: p = 0.6
Interaction: p = 0.9
Diet effect: p = 0.2
Genotype effect: p = 0.09







Diet effect: p = 0.1
Genotype effect: p = 0.3
Interaction: p = 0.3
Diet effect: p = 0.002
Genotype effect: p = 0.5















Diet effect: p = 0.44
Genotype effect: p = 0.3
Interaction: p = 0.76
Diet effect: p = 0.001
Genotype effect: p = 0.5
Interaction: p = 0.5








Diet effect: p = 0.0008
Genotype effect: p = 0.09
Interaction: p>0.9
Diet effect: p = 0.06
Genotype effect: p = 0.96
Interaction: p>0.9




4.2.7. CR modulates BM GC regeneration 
 
A key goal of the experiments in this chapter was to determine if 11-HSD1 KO mice 
resist BMAT expansion during CR. Thus, despite the lack of genotype difference in 
circulating corticosterone concentration throughout CR and the complex results in 
WAT with the GC target genes, the 10-week-old CR-fed KO males did resist the 
increases in circulating corticosterone (Figure 4.7.B). Therefore, I next assessed the 
effects of CR and 11-HSD1 KO on tissue GC concentrations and target gene 
expression within the BM. I began by using LC-MS/MS to measure corticosterone and 
11-DHC concentrations. 
 
Figure 4.11. shows concentrations of corticosterone, 11-DHC, and the CORT-to-11-
DHC ratio in the BM of 15-and 10-week-old mice. An overall genotype effect was 
detected by ANOVA for 15- and 10-week-old females, with KOs having lower 
corticosterone concentration than WTs (Figure 4.11.A-B). The 15-week-old mice 
lacked diet differences, but ANOVA revealed significant diet differences for the 10-
week-old mice. 10-week-old females and WT males on CR had significantly increased 
BM corticosterone concentration compared to AL-fed mice (Figure 4.11.B). This 
pattern is similar to that for circulating corticosterone concentrations (Figure 4.7.A-B). 
The 15-and 10-week old males showed genotype effects detected by ANOVA for 11-
DHC concentration in the BM, whereas the females did not show this (Figure 4.11.C-
D). The 15-week-old mice also failed to show diet effects (Figure 4.11.C), but the 10-
week-old mice displayed significant diet effects, with the females and WT males on 
CR showing increased 11-DHC concentration compared to the KO males (Figure 
4.11.D). For each cohort, further genotype differences were revealed by ANOVA for 
the ratio of CORT-to-11-DHC (Figure 4.11.E-F), with a lower ratio in the KOs 
indicating the expected decreases in corticosterone regeneration. In addition, this 
ratio was decreased with CR in 10-week-old WT males and females (Figure 4.11.F).  
Of importance for my hypothesis, male 11-HSD1 KO mice resisted increased BM 
corticosterone concentrations during CR (Figure 4.11.B), raising the possibility that 
these male mice also resist other GC-mediated effects of CR within the BM.  
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Figure 4.11. BM GC concentration is upregulated with CR. WT and 11-HSD1 KO 
male and female mice were fed AL or CR diets as described for Figure 4.2 and 
Methods (2.1.2), and fasted/re-fed as described in Methods (2.3.1). Post termination, 
femurs were collected and the femoral BM was quantified for 11-DHC and 
corticosterone by LC-MS/MS, as described in Methods (2.5.2). BM corticosterone 
concentration in 15-and (A) 10-week-old (B) mice. BM 11-DHC concentration in 15-
and (C) 10-week-old (D) mice. BM corticosterone to 11-DHC ratio in 15-and (E) 10-
week-old (F) mice. Data points are presented with median, interquartile range and 
range shown by box and whisker plot, and were analysed by 2-Way ANOVA with 
Sidak’s multiple comparison test. 15-week-old mice: n (WT AL male) = 7. n (WT CR 
male) = 11. n (KO AL male) = 7/8. n (KO CR male) = 8. n (WT AL female) = 7. n (WT 
CR female) = 13. n (KO AL female) = 6. n (KO CR female) = 8. 10-week-old mice: n 
(AL male) = 8. n (CR male) = 8. n (KO AL male) = 5. n (KO CR male) = 5. n (AL 












BM [corticosterone] in 15-week-old mice
Diet effect: p = 0.2
Genotype effect: p = 0.7
Interaction: p = 0.4
Diet effect: p = 0.6
Genotype effect: p = 0.01 









BM [corticosterone] in 10-week-old mice
Diet effect: p = 0.009
Genotype effect: p = 0.2
Interaction: p = 0.6
Diet effect: p = 0.001
Genotype effect: p = 0.03
















BM [11-DHC] in 15-week-old mice
Diet effect: p = 0.9
Genotype effect: p = 0.01
Interaction: p = 0.8
Diet effect: p = 0.9
Genotype effect: p = 0.2 







BM [11-DHC] in 10-week-old mice
Diet effect: p = 0.045
Genotype effect: p = 0.02
Interaction: p = 0.3
Diet effect: p = 0.0007
Genotype effect: p = 0.6 















Ratio of BM CORT to 11-DHC in 15-week-old mice
Diet effect: p = 0.1
Genotype effect: p<0.0001 
Interaction: p = 0.3
Diet effect: p = 0.8
Genotype effect: p<0.0001 








Diet effect: p = 0.3
Genotype effect: p = 0.006
Interaction: p = 0.06
Diet effect: p = 0.01
Genotype effect: p<0.0001 
Interaction: p = 0.0008
***
*
Ratio of BM CORT to 11-DHC in 10-week-old mice
F
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4.2.8. CR is associated with increased expression of GC target genes in 
the BM 
 
I next investigated if the KO mice also resisted an increase in GC action within the 
BM by examining the expression of GC target genes.  
 
Figure 4.12 shows expression of the GC target genes Hsd11b1, Fkbp5, Gilz and Per1 
in BM of 15-and 10-week-old mice. Hsd11b1 was significantly increased with CR in 
15-week-old WT mice (Figure 4.12.A) but not in 10-week-old WT mice (Figure 4.12.B) 
and, as expected, was undetectable in KO mice. ANOVA detected no diet or genotype 
effects for Fkbp5 in males but revealed a diet effect for Fkbp5 in 15-week-old females, 
with a decrease in CR-fed KO females (Figure 4.12.C). Overall diet effects were also 
detected in the 10-week-old mice (Figure 4.12.D), with increased Fkbp5 for males and 
WT females on CR. Gilz expression was downregulated with CR in the 15-week-old 
KO females (Figure 4.12.E). However, in the 10-week-old mice, Gilz expression was 
increased with CR both across and within each genotype (Figure 4.12.F). Per1 
expression was unaltered by diet or genotype in the 15-week-old mice (Figure 
4.12.G), but in the 10-week-old mice ANOVA showed significant diet effects (Figure 
4.12.H). Multiple comparisons showed a significant increase in the 10-week-old 
females and WT males. Moreover, a significant genotype effect was present for Per1 
in the 10-week males, with KO mice having significantly lower expression than their 
WT counterparts (Figure 4.12.H). The 10-week data suggest that CR increases GC 
action within the BM and that 11-HSD1 KO mice generally do not resist this. The 15-
week data does not show these diet differences, suggesting the fasting prior to 
necropsy has altered GC target gene expression so that this does not reflect the 
effects of GC excess experienced throughout most of the duration of CR. Accordingly, 
the gene expression patterns observed in the 10-week cohorts might more accurately 
reflect the effects of CR on GC action within the BM, and the ability of 11-HDS1 KO 
mice to resist these effects. However, it is also possible that expression of these 
transcripts does not fully reflect the consequences of long-term 
hypercorticosteronaemia during CR. Therefore, I next analysed BMAT to determine 
the effects of 11-HSD1 KO on CR-induced BMAT expansion.   
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Figure 4.12. CR increases GC target gene expression in the BM. WT and 11-
HSD1 KO male and female mice were fed AL or CR diets as described for Figure 4.2 














































Fkbp5 in BM of 15-week-old mice
Diet effect: p>0.9
Genotype effect: p = 0.8
Interaction: p = 0.035
Diet effect: p = 0.0024
Genotype effect: p = 0.8 


















Gilz in BM of 15-week-old mice
Diet effect: p = 0.2
Genotype effect: p = 0.6
Interaction: p = 0.16
Diet effect: p = 0.66
Genotype effect: p = 0.2 




















Per1 in BM of 15-week-old mice
Diet effect: p = 0.4
Genotype effect: p = 0.2
Interaction: p = 0.4
Diet effect: p = 0.3
Genotype effect: p = 0.8






















Genotype effect: p = 0.4
Interaction: p = 0.9
Diet effect: p = 0.0006
Genotype effect: p = 0.13
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Diet effect: p = 0.0004
Genotype effect: p = 0.65
Interaction: p = 0.99
Diet effect: p<0.0001
Genotype effect: p = 0.3
Interaction: p = 0.55











Diet effect: p = 0.005
Genotype effect: p = 0.02
Interaction: p = 0.6
Diet effect: p<0.0001
Genotype effect: p = 0.3
Interaction: p = 0.1





termination, the tibiae of the mice were collected and proceeded with as described in 
Methods. qPCR was performed to quantify expression of Hsd11b1, Fkbp5, Gilz and 
Per1 in BM. Genes were normalised to the geometric mean of the following 
housekeeping genes: Ppia, Tbp and Actb, and presented as relative to the WT AL 
average of male and female mice together. Hsd11b1 expression in 15-and (A) 10-
week-old (B) mice. Fkbp5 expression in 15-and (C) 10-week-old (D) mice. Gilz 
expression in 15-and (E) 10-week-old (F) mice. Per1 expression in 15-and (G) 10-
week-old (H) mice. Data points are presented with median, interquartile range and 
range shown by box and whisker plot, and were analysed by 2-Way ANOVA with 
Sidak’s multiple comparison test (C-H), or by Mann-Whitney and/or Welch’s test as 
appropriate (A-B). Numbers of mice per group, and presentation of statistically 
significant differences between groups, are as described for figure 4.12. **: p<0.01. 
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4.2.9. Male 11-HSD1 KO mice, but not female, resist CR-induced BMAT 
expansion 
 
CR has previously been shown to induce BMAT expansion in animals (Devlin et al., 
2010, 2016; Cawthorn et al., 2016). As previously shown, circulatory (Figure 4.7.B) 
and BM (Figure 4.11.B) corticosterone concentration was increased with CR in all 
groups but the KO males. However, the results from the GC target genes (Figure 
4.12) suggest that CR increases GC action within the BM and that 11-HSD1 KO 
mice generally do not resist this; hence, it is unclear if the KO mice would resist other 
effects of CR within the BM. Therefore, I next analysed BMAT to investigate if the 
KOs resisted CR-induced BMAT expansion.  
 
Figure 4.13 shows a respective osmium-stained tibia from each group, highlighting 
the proximal and distal parts of the bone that were analysed. Figure 4.14 shows the 
analysed BMAT in the tibiae of male and female mice, both in the proximal and distal 
regions of the bone, as well as total BMAT. Figure 4.14.A and B represent the 
proximal BMAT of male and female mice. For both sexes, ANOVA detected a 
significant diet effect (Figure 4.14.A-B), whereas a genotype effect was detected in 
males only (Figure 4.14.A). Multiple comparison showed significant increases in 
BMAT in the females (Figure 4.14.B) and WT males with CR but, notably, the KO 
males on CR resisted this expansion (Figure 4.14.A). For the distal BMAT, ANOVA 
detected similar diet effects for both sexes (Figure 4.14.C-D) but indicated no 
genotype effects. Multiple comparison showed identical increases with CR in distal as 
for proximal BMAT. Total BMAT also showed similar results (Figure 4.14.E-F), with 
ANOVA detecting a genotype effect in males only (Figure 4.14.E).  
 
These results show that the KO male mice resist CR-induced BMAT expansion, 
whereas the KO females do not. These results are reminiscent of the BM 
corticosterone concentration (Figure 4.11.B), suggesting that the lack of CR-induced 
BMAT expansion in KO males might be due to the lack of increased BM corticosterone 








Figure 4.13. 11-HSD1 KO males, but not females, are protected from BMAT 
expansion during CR. Young C57BL/6JOlaHsd (WT) and 11-HSD1 KO (KO) male 
and female mice were fed ad libitum (AL) or 70% of ad libitum food intake (CR) for six 
weeks, from 9 weeks until 15 weeks of age. Post termination, bones were decalcified 
and stained with osmium tetroxide staining for 48 hours, and thereafter washed for 24 
hours in Sorensen’s buffer. Tibiae were scanned by uCT, and the images were 
visualised using CTvox (Bruker) software. (A) Male tibia bones representing one bone 




Figure 4.14. 11-HSD1 KO males, but not females, are protected from BMAT 
expansion during CR. WT and 11-HSD1 KO male and female mice were fed AL or 





















Proximal BMAT in male tibia
Diet effect: p = <0.0001
Genotype effect: p = 0.03





















Distal BMAT in male tibia
Diet effect: p = 0.0014
Genotype effect: p = 0.4






















Total BMAT in male tibia
Diet effect: p = <0.0001
Genotype effect: p = 0.02










Proximal BMAT in female tibia
Diet effect: p = <0.0001
Genotype effect: p = 0.6









Distal BMAT in female tibia
Diet effect: p = <0.0001
Genotype effect: p = 0.7









Total BMAT in female tibia
Diet effect: p = <0.0001
Genotype effect: p = 0.5






described in Methods (2.3.1). Post termination, bones were decalcified and stained 
with osmium tetroxide staining for 48 hours, and thereafter washed for 24 hours in 
Sorensen’s buffer. Tibiae were then scanned at 12m by CT and analysed by CTan 
for BMAT as % of total medullary cavity. Proximal BMAT in male (A) and female (B) 
tibiae. Distal BMAT in male (C) and female (D) tibiae. Total BMAT in male (E) and 
female (F) tibiae. Data points are presented with median, interquartile range and 
range shown by box and whisker plot, and were analysed by 2-Way ANOVA with 
Sidak’s multiple comparison test. n (WT AL male) = 13. n (WT CR male) = 11. n (KO 
AL male) = 8. n (KO CR male) = 7. n (WT AL female) = 13. n (WT CR female) = 14. 





4.2.10. CR is associated with decreased testosterone concentration in 
males, but increased in females  
 
The BMAT (Figure 4.14) and BM corticosterone concentration (Figure 4.11.B) results 
suggest that there is an association between BMAT and corticosterone in males only. 
However, RNA data (Figure 4.12) are not consistent with this, with evidence of higher 
GC action within the BM during CR than AL in both males and females regardless of 
genotype. Therefore, I next investigated additional mechanisms that might explain the 
resistance of KO males to CR-induced BMAT expansion. Androgens have been 
shown to modulate BMAT formation (Tamura et al., 2005), with age-induced BMAT 
expansion in old men being associated with decreased testosterone concentration 
(Mistry et al., 2018). Furthermore, healthy lean men on CR have reduced testosterone  
concentrations (Cangemi et al., 2010). Therefore, I measured testosterone 
concentrations in the circulation and BM to test if this is associated with the differences 
in BMAT expansion across the groups.  
 
Figure 4.15. shows circulatory and BM testosterone concentration in the 15- and 10-
week-old mice. 15-week-old males showed neither diet nor genotype differences, 
although a trend for decreased testosterone with CR was apparent (Figure 4.15.A). 
In addition, only two females on CR had detectable testosterone concentration. 
Conversely, the 10-week-old males showed an overall diet effect by ANOVA, with 
lower testosterone concentration in the CR-fed KOs (Figure 4.15.B). Similar results 
were found for the BM testosterone, with the 15-week-old mice lacking diet 
differences (Figure 4.15.C), and the 10-week-old mice showing lower testosterone 
concentrations with CR, particularly in the KO mice. Testosterone was present at 
measurable levels in the BM of some of the CR-fed females from the 15- and 10-week 
groups, suggesting that CR might increase testosterone in female mice. The ability to 
detect these low levels was facilitated by use of a more-sensitive calibration curve 
optimised for the BM. Based on these results, a clear difference between the long-
term six-week CR vs short-term one-week CR cohorts was apparent, as previously 
mentioned regarding the fasting regimen. The KO males showed decreased 
testosterone concentration post-CR and, if anything, this effect was greater than in 
the WT males. Therefore, the resistance of male KO mice to CR-induced BMAT 
expansion is not explained by a failure to decrease testosterone during CR. 
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Figure 4.15. Testosterone is decreased in males; but increased in females on 
CR. WT and 11-HSD1 KO male and female mice were fed AL or CR diets as 
described for Figure 4.2 and Methods (2.1.2), and fasted/re-fed as described in 
Methods (2.3.1). Post termination, femurs were collected and the femoral BM was 
quantified for testosterone by LC-MS/MS, as described in methods (2.5.2). Circulatory 
testosterone in 15-and (A) 10-week-old (B) mice. BM testosterone in 15-and (C) 10-
week-old (D) mice. Data points are presented with median, interquartile range and 
range shown by box and whisker plot, and were analysed by 2-Way ANOVA with 
Sidak’s multiple comparison test. Numbers of mice per group, and presentation of 
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4.2.11. 11-HSD1 KO male mice have increased progesterone 
concentration within BM and plasma  
 
As previously mentioned, it is unclear whether 11-HSD1 KO mice resist GC action 
within the BM during CR as, although the 10-week-old CR-fed KO males resisted CR-
induced BMAT expansion and increases in BM corticosterone concentration, my 
qPCR data (Figure 4.12.D, F, H) suggest increased GC action in all genotypes. The 
testosterone results suggest that the resistance to BMAT expansion in the KO males 
is not a result of a failure to decrease circulating or BM testosterone during CR. 
Therefore, I next explored if other steroid hormones might be influencing BMAT 
expansion. One well-established inhibitor of BMAT accumulation is oestradiol; hence, 
I hypothesised that the KO males might resist CR-induced BMAT accumulation owing 
to increases in oestradiol, and that BMAT expansion in females might be driven 
primarily by decreased oestradiol during CR. However, due to difficulties of analysing 
oestradiol in small amounts of plasma and BM, it was unfortunately not quantified. 
However, during the LC-MS/MS analysis, I was able to also analyse other steroid 
hormones, one of which was progesterone. Since the progesterone receptor has 
similar targets to the oestrogen receptor, one possibility is that progesterone may also 
modulate BMAT formation. Figure 4.16 shows the progesterone concentration in the 
BM of 15-and 10-week-old mice, and in the circulation of 10-week-old mice only. 
ANOVA revealed a significant genotype effect in each cohort for the males only 
(Figure 4.16.A-B), with the KOs having increased progesterone concentration 
compared to the WTs, regardless of diet. No differences were observed in the BM for 
the females. Circulatory progesterone was examined in 10-week-old mice only 
(Figure 4.16.C). ANOVA showed significant genotype as well as diet effects in the 
males only. CR-fed WT males also had increased progesterone concentration 
compared to AL-fed WT males. These results show that 11-HSD1 KO increases 
progesterone in male, but not female mice. Moreover, given the ability of sex steroids 
to modulate BM adiposity, this difference might contribute to the resistance of the KO 
males to CR-induced BMAT expansion. 
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Figure 4.16. Circulatory and BM progesterone was increased in 11-HSD1 KO 
male mice. WT and 11-HSD1 KO male and female mice were fed AL or CR diets 
as described for Figure 4.2 and Methods (2.1.2), and fasted/re-fed as described in 
Methods (2.3.1). Post termination, femurs were collected and the femoral BM was 
quantified for progesterone by LC-MS/MS, as described in methods (2.5.2). (A) BM 
progesterone concentration in 15-week-old mice. (B) BM progesterone concentration 
in 10-week-old mice. (C) Circulatory progesterone concentration in 15-week-old mice. 
Data points are presented with median, interquartile range and range shown by box 
and whisker plot, and were analysed by 2-Way ANOVA with Sidak’s multiple 
comparison test. 15-week-old mice: n (WT AL male) = 7. n (WT CR male) = 10. n (KO 
AL male) = 5. n (KO CR male) = 7. n (WT AL female) = 7. n (WT CR female) = 9. n 
(KO AL female) = 4. n (KO CR female) = 5. 10-week-old mice: n (AL male) = 8. n (CR 
male) = 8. n (KO AL male) = 5. n (KO CR male) = 5. n (AL female) = 5. n (CR female) 
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Chronic CR
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4.3. Discussion  
 
4.3.1. AT effects in response to CR in 11-HSD1 KO mice  
 
In this chapter, I found that the KO males lose fat mass to a similar degree as their 
litter-matched controls. Previous research has shown that the hypomorphic 11-
HSD1 KO mice resist diet-induced obesity (Morton et al., 2004) and further side 
effects of GC excess (Morgan et al., 2014), suggesting that the lack of this enzyme 
can prevent obesity and associated metabolic dysregulation. However, my results 
show that these 11-HSD1 KOs do not resist the effects of CR such as decreased 
adiposity, increased GC concentration and BMAT expansion (besides the KO males). 
This could be due to the genotype differences between the hypomorphic and null 
KOs. The hypomorphic KO model might also exert other effects on peripheral tissues 
that the null KO model does not, allowing the tissues to resist diet-induced obesity. 
Furthermore, on CR, the 11-HSD1 male KOs drop to a similar level as the WTs, 
suggesting that the lack of 11-HSD1 might enhance CR-associated fat loss in males 
only. This could be a result of 11-HSD1 deficiency, or it could be a technical artefact 
as future cohorts did not show the same tendency regarding the body and fat mass 
of the AL-fed males. Interestingly, two cohorts of older 11-HSD1 KO mice show 
opposite results regarding the fat mass, but this is further discussed in Chapter 6. 
Another reason why the KOs might be fatter could be due to the role of GCs in 
lipolysis. Dexamethasone increases lipolysis, FFA and glycerol in primary rat 
adipocytes in a dose-and time-dependent manner (Xu et al., 2009). This would 
suggest that the AL-fed 11-HSD1 KO males might have less corticosterone 
concentration allowing to resist lipolysis, but we know based on the circulatory 
corticosterone ELISA results (Figure 4.5.A) that there were no genotype differences. 
No genotype differences were found in BM of the 15-nor 10-week-old AL-fed KOs 
either, although, this might differ in WAT. Therefore, to further understand the 
genotype difference regarding fat mass in the males, one could quantify GC 
concentration in WAT. If WAT corticosterone concentration would be less than 
circulatory, or less than the WTs, it could explain the genotype difference.  
 
In Chapter 3, I found that WT female mice on 30% CR maintained their fat mass, 
compared to male mice, who lost theirs. In this chapter, I revealed similar results with 
regards to the fat mass of 11-HSD1 KO females subject to CR, as shown in Chapter 
 148 
3. A possible reason for this could be to maintain a healthy reproductive system, as 
discussed in more depth in section 3.3.1. Compared to studies including male mice, 
fewer studies include female mice, especially in experiments where 11-HSD1 KO 
mice are used; this is the case both for the hypomorphic and null 11-HSD1 KO 
models from Edinburgh University, and the 11-HSD1 exon 5 KO from Birmingham 
University (Kotelevtsev et al., 1997; Morgan et al., 2014; Larner et al., 2016; Johnson 
et al., 2017; Verma et al., 2018). This is most likely due to the common perception, 
often erroneous, that the oestrous cycle of female mice confounds the end results. In 
addition, due to most studies from Edinburgh involving the hypomorphic 11-HSD1 
KO model, very few are done on the more recent null KO model, and only one 
(Vandermosten et al., 2017) out of four (Johnson et al., 2017; Zhang et al., 2017; 
Verma et al., 2018) involves female mice. Therefore, the lack of previous studies in 
female null 11-HSD1 KO mice makes it challenging to compare to other research 
and potential mechanisms. Similarly, additional KO models with regards to GC 
excess, such as global and/or adipose-specific GR KO mouse, have not yet been 
investigated during CR. This identifies a gap in the literature, and investigating it 
further would help to elucidate the function of GCs during CR.  
 
4.3.2. Effects of metabolic hormones on CR-induced BMAT expansion 
 
The main finding of this chapter was that 11-HSD1 KO males resisted CR-induced 
BMAT expansion, whereas the KO females did not. Furthermore, the KO males had 
significantly increased circulatory and BM progesterone concentration regardless of 
diet compared to the females and WT males. The results indicate that intracellular 
regeneration of corticosterone by 11-HSD1 is not necessary for BMAT expansion 
with CR in females, but it is in males. Instead, progesterone could be associated with 
the resistance of BMAT expansion during CR in the KO males. However, although 
there is this association between increased progesterone and unaltered BMAT 
volume, it does not mean that GCs are not involved in mediating BMAT expansion 
with CR in males. Although progesterone might play a role in BMAT expansion, it 
cannot be determined without further in vitro experiments (as I have mentioned in the 
next section, 4.3.3). Progesterone may be a marker of change in CR, but it might not 
necessarily indicate that it causes any changes.  
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The KO model that I used intervened with the intracellular regeneration of GCs by 
11-HSD1 only, but the adrenal glands were still releasing circulatory GCs that could 
have impacted the end-results; hence, the 11-HSD1 KOs are not GC insufficient. 
Because of this, it is possible that the KO males are more resistant to circulatory GCs 
within the BM, even though they generally did not resist up-regulation of the GC target 
genes (Figure 4.12), compared to KO females. However, the GC target genes alone 
is not enough to infer GC function. Therefore, directly quantifying 11-HSD1 activity 
in BM and potentially AT would be beneficial to my current results. In addition, the 
resistance of GCs within the BM was further confirmed by LC-MS/MS results, which 
showed increased corticosterone in females and WT males, but not KO males (Figure 
4.11.B). Another reason for the CR-induced BMAT expansion could be due to 
decreased GR affinity in the bone/BM, protecting the tissue from GC excess. This has 
been reported in AN and CS patients with high GC concentrations (Invitti et al., 1999). 
Since the 11-HSD1 KO females did not resist the effects of CR, GC excess might 
not be the main driver of CR-induced BMAT expansion in females; something else 
could be influencing this, with or without GCs, suggesting novel sex differences with 
regards to GC excess and BMAT expansion. This suggests that a different KO model 
could be used to better test if GCs can contribute to BMAT expansion in females. 
Considering that progesterone is the precursor to testosterone and oestradiol, it could 
be hypothesised that the KO males resisted BMAT expansion due to their high 
progesterone concentration. Given that the oestrogen receptor and progesterone 
receptor have overlapping transcriptional targets (Tamm et al., 2009), it is possible 
that progesterone could inhibit BMAT, just like oestradiol (Griffith et al., 2012; 
Limonard et al., 2015). Alternatively, the increased progesterone in the KO males may 
result in increased oestradiol concentrations, thereby suppressing BMAT expansion. 
This suggests that progesterone and/or oestradiol could play a role alongside GCs in 
CR-induced BMAT expansion. One way to test this would be by directly measuring 
oestradiol in the circulation and BM, alongside aromatase, the enzyme that converts 
androgens into oestrogens. Further evidence demonstrates relationships between 
GCs and progesterone. For example, a previous publication revealed that progestin 
(a synthetic form of progesterone) can bind to the GR and induce anti-GC effects in 
adipocyte precursor cells in rats (Xu, Hoebeke and Björntorp, 1990). Similarly, 
progesterone has been shown to supress gene expression in myometrial cells via the 
GR rather than the PR, but it acts on both nuclear receptors to increase expression 
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(Lei et al., 2012). These results suggest that CR-induced BMAT expansion and GC 
target genes could be driven not only by GCs, but also by progesterone/PR.  
 
Besides CR, another model of GC excess is CS. CS patients have increased 
circulating GCs as well as increased BMAT (Maurice et al., 2018). However, patients 
in remission that lack GC excess have decreased BMAT (Geer et al., 2012). This 
further supports my hypothesis that GC excess does impact BMAT formation, 
dependently or independently of other mechanisms/hormones. One way to test this 
would be to examine a different KO model that prohibits complete GC action and 
subject these KOs to CR. A robust model would be a GR KO in osteoblasts, as it has 
previously been proven that GCs cannot induce bone loss in the absence of GR 
expression in osteoblasts (Rauch et al., 2010). This suggests that the GR KO in 
osteoblasts resists the action of GCs in bone. Whether these GR KOs in osteoblasts 
would resist CR-induced BMAT expansion has not been tested. However, since the 
GR KOs resist bone loss upon GC treatment, and that BMAds derive from the same 
precursor as osteoblasts (Liu et al., 2013; Chen et al., 2014), it is possible that they 
would also resist BMAT expansion. Other models of GC excess have shown that GCs 
can act in sexually dimorphic manner (Duma et al., 2010; Quinn and Cidlowski, 2016; 
Spaanderman et al., 2019). For example, GC administration in rats showed opposite 
gene expression in males vs females, and 84 additional GC-responsive genes were 
detected in males, suggesting that the anti-inflammatory effects of GC are more 
effective in males compared to females (Duma et al., 2010). A recent finding revealed 
different patterns of GC-androgen crosstalk in various metabolic tissues, for example, 
the androgen receptor (AR) inducing GR signalling in WAT and BAT (Spaanderman 
et al., 2019). Previous research has highlighted the importance and sensitivity of sex 
hormones between visceral and subcutaneous adipose depots (Rodriguez-Cuenca 
et al., 2005). Investigating this further and including BMAT as another depot, and 
subjecting mice to CR or GC treatment, could give us more information about the 
endocrine functions of CR on BMAT expansion. Since these studies are not focused 
on CR/fasting, it is possible that the results could be influenced by the interplay of 
several receptors and/or hormones in the bone and/or BM. Due to the lack of research 




It is also worth noticing that effects of increased GCs resulting from CR with that which 
results from exogenously administered corticosterone differ as previously discussed 
(Section 3.3.3.2). Moreover, unlike in response to orally administered corticosterone 
(Morgan et al., 2014), the null 11-HSD1 KO mice do not robustly resist tissue-specific 
effects of GC excess during CR. The reason behind this could be that the two ways 
of increasing GCs are different (CR vs excessive GC administration) with distinctive 
end-results for each model; exogenous corticosterone promoting visceral adiposity, 
and CR decreasing it. Other differences between my results and Morgans (Morgan et 
al., 2014) includes hypercorticosteroneaemia. Morgan et al., showed much higher 
concentrations compared to my results. Furthermore, I showed enlarged adrenal 
glands, whereas, the Morgan study showed HPA axis suppression and atrophied 
adrenal glands (Morgan et al., 2014). This further proves that the end-results between 
the two models differ. A limitation to my study is that I did not measure corticosterone 
concentration throughout the day, only prior to feeding. Therefore, although the CR-
fed mice have increased GCs, these concentrations might be altered following 
feeding. In addition, the conversion of corticosterone to 11-DHC is catalysed by the 
enzyme 11-HSD2, and back into corticosterone intracellularly by 11-HSD1. My 
results showed an overall genotype decrease in corticosterone-to-11-DHC ratio in the 
15- and 10-week-old KO mice, in the BM and circulation. These results are evidently 
due to the lack of 11-HSD1. It further suggests either less corticosterone synthesised 
by the adrenals, or plentiful conversion of corticosterone to 11-DHC by 11-HSD2. 
Since the 11-HSD1 KO mice cannot convert 11-DHC back into corticosterone, it is 
possible that the adrenals compensate by over-producing corticosterone, which 
further activates 11-HSD2 into converting corticosterone to 11-DHC. One way to test 
this would be to measure the expression and/or activity of 11-HSD2 within the 
kidneys. 
 
4.3.3. Future directions 
 
To summarise, this Chapter revealed that 11-HSD1 KO male mice resist CR-induced 
BMAT expansion, whereas the KO females did not. Unexpectedly, the KO males also 
had increased progesterone concentration compared to females and WT males. To 
investigate the progesterone hypothesis, different experiments could be conducted to 
reveal whether progesterone impacts BMAT expansion during CR. Firstly, oral 
progesterone in the drinking water can be administered to KO male mice on CR to 
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determine if it stops BMAT expansion. In addition, although the CR-fed WT males had 
increased progesterone concentration, it would be intriguing to further administer 
them progesterone to test if this would influence BMAT formation with CR.  
 
Secondly, PR antagonists (e.g. Mifepristone (Chabbert-Buffet et al., 2005)) could be 
administered to KO male mice on CR to determine if this allows BMAT to expand. 
These experiments would investigate whether progesterone has an impact on CR-
induced BMAT expansion. Alternatively, WT and KO female mice can be 
administered progesterone in the drinking water to see if it would influence BMAT 
expansion, even when on a normal AL diet. In addition, the expression of the 
receptors for progesterone and GCs could be quantified, as well as circulating and 
BM oestradiol concentrations. To further understand the role of GCs on BMAT 
expansion during CR, it is also possible to investigate the function of progesterone, 
testosterone, leptin, adiponectin and other hormones in vitro. By investigating these 
hormones in addition to GCs, it might give us more insight into the mechanism that 
regulates BMAT expansion during basal conditions but also CR. This would be done 
by challenging WT and KO mice with CR, and after 6 weeks of CR, flush out the tibial 
BM and examine the proliferation and differentiation of cells into adipocytes and 
osteoblasts. One can also challenge the differentiated cells with the various hormones 
like progesterone and examine any genotype and/or diet differences. It would also be 
possible to do an identical experiment with the remaining flushed out bone, and 
compare between the BM and bone cells. The BM cells can further be divided into 
MSCs and haematopoietic cells by magnetic cell sorting using negative selection of 
CD45, CD31 and Ter119 cells to obtain BM-MSCs. The positive haematopoietic cells 
can also be examined for comparison and to determine the effects of these hormones 
on the haematopoietic environment (Tencerova et al., 2018).  
 
In Section 3.3.4 I mentioned several future experiments to further address the role of 
GCs, and 11-HSD1, in the effects of CR. For example, during CR it would be 
informative to measure 11-HSD1 activity in the BM and in other tissues of interest, 
to determine if this contributes to increased GC action. Another experiment to further 
investigate the role of GCs in CR, including the sex differences, would be to perform 
adrenalectomy. This would completely stop the synthesis of GCs and also of other 
steroid hormones that are synthesised by the adrenals, such as mineralocorticoids 
(e.g. aldosterone) and androgens (e.g. testosterone). Furthermore, ovariectomy can 
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also be performed on female mice, to determine how big of an impact sex hormones 
have on BMAT expansion during CR. To further apprehend any associations between 
the sex hormones (progesterone, testosterone), one can also look at the correlations 
between the hormones (circulatory and BM) and lean/fat mass as well as BMAT.  
 
The long-term six-week vs short-term one-week CR, further discussed in Section 
3.3.2, exhibited different results. Therefore, to draw firmer conclusions regarding the 
effects of CR on GC target genes, an aged-matched cohort of six-week CR, without 
the fasting/re-feeding prior to termination, would have to performed. However, since 
we know that GCs are increased within a week of CR, and that BMAT does not 
increase until four weeks of CR (Cawthorn lab, unpublished data), a short-term one-
week CR cohort could be done with fasting/re-feeding prior to termination to 
compared to my current one-week CR mice that were not fasted.  
 
Beyond BMAT expansion, another effect of CR and GC excess is bone loss. Several 
studies have demonstrated that BMAT expansion leads to bone loss (Shen et al., 
2007, 2012; Rharass and Lucas, 2018). Therefore, in the next chapter I present my 
investigation into the effects of CR and lack of intracellular regeneration of GCs on 
bone morphology in WT and 11-HSD1 KO mice.  
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Chapter 5. 11-HSD1 KO protects against caloric 




5.1. Introduction  
 
The studies in chapter 4 revealed that 11-HSD1 KO males resist the effects of CR-
induced BMAT expansion, whereas females do not. The effects of CR on bone mass 
have been well examined in rodents (Berrigan et al., 2005; Speakman and Mitchell, 
2011), in which CR induces the loss of cortical bone, but maintenance or increased 
trabecular bone (Hamrick et al., 2008). In contrast, a different publication showed no 
tibial bone loss after 4 weeks of graded CR (Mitchell et al., 2015). This suggests that 
the CR protocol can have different end-results on bone morphology.  
 
Increased BMAT often coincides with bone loss, for example in CR, AN, ageing, 
osteoporosis, GC therapy and oestrogen deficiency. This supports the hypothesis that 
BMAT expansion might contribute to bone loss during CR and in other conditions. 
Furthermore, BMAT expansion has also been associated with weakened bone 
(Schellinger et al., 2001). Patients with AN, have also been diagnosed with bone loss, 
and consequently higher osteoporosis risk (Schellinger et al., 2004; Legroux-Gérot et 
al., 2007; Di Iorgi et al., 2008; Bredella et al., 2009; Ecklund et al., 2010; Veldhuis-
Vlug and Rosen, 2017, 2018; Muruganandan, Govindarajan and Sinal, 2018). 
Impaired bone strength at the distal tibia was also discovered in young adults with AN 
and increased BMAT, once again pointing towards the negative association between 
bone strength and BMAT (Singhal et al., 2018). Furthermore, GCs can also promote 
bone loss, as well as increased BMAT (Vande Berg et al., 1999). In addition, 
circulatory cortisol concentration in patients with AN is associated decreased bone 
formation (Misra et al., 2004; Lawson et al., 2009). These findings confirm that 
CR/AN, GC excess and BMAT expansion are typically each associated with bone 
loss. However, whether GCs promote bone loss in CR, and the involvement of BMAT 
expansion in this response, remains to be addressed. Nevertheless, one study of 
male mice shows that a lack of BMAT does not necessarily protect against bone loss 
 155 
(Keune et al., 2017), while a study in rabbits found that CR-associated bone loss 
occurred without increasing BMAT (Cawthorn et al., 2016). 
 
Based on my findings in chapter 4, one approach to address this possibility would be 
through analysing if 11-HSD1 KO influences CR-induced bone loss. 11-HSD1 
activity in bone was shown to predict the impact of GCs on bone by predicting reduced 
bone formation markers (Cooper et al., 2003). Furthermore, treatment of primary 
human osteoblastic cells with cortisol or dexamethasone significantly increased 11-
HSD1 activity (Cooper et al., 2002). This suggests that 11-HSD1 activity could be 
an important mediator for predicting GIO, and that it can influence GC action in bone. 
Past publication investigated the bone phenotype in hypomorphic 11-HSD1 KO mice 
during normal conditions and showed that there were no differences between WT and 
KOs (Justesen et al., 2004). However, these mice were not examined under other 
conditions similar to CR and/or fasting, and also are not a full 11-HSD1 KO; thus, 
whether complete lack of 11-HSD1 prevents bone loss in CR remains unknown. 
Moreover, total 11-HSD1 KO can prevent BMAT expansion in males (Chapter 4), 
confirming that 11-HSD1 can impact at least some skeletal effects of CR. More 
recently, 11-HSD1 exon 5 KO male mice treated with corticosterone showed almost 
a complete protection against bone loss compared to WT mice, who had decreased 
bone volume. However, this study did not include female mice (Fenton et al., 2019). 
Therefore, based on my results from previous Chapter, and this current finding 
(Fenton et al., 2019), my hypothesis is that male 11-HSD1 KO mice, but not females, 
will resist the effects of CR-induced bone loss. To address this, I studied the effects 
of CR on bone microarchitecture in AL-and CR-fed WT and 11-HSD1 KO male and 
female mice. Trabecular and cortical bone parameters were analysed to determine 






5.2. Results  
 
 
5.2.1. Trabecular bone is maintained with CR in males but increased in 
females 
 
To test if deficiency of 11-HSD1 prevents CR-induced bone loss, I first used µCT to 
measure trabecular and cortical microarchitecture in the tibiae of WT and KO mice 
after six weeks of AL or CR diet. 
 
Figure 5.1 shows representative cross sections of the proximal tibial metaphysis 
(Figure 5.1.A) and graphs of key trabecular parameters (Figure 5.1.B-E), as 
recommended in previous guidelines (Bouxsein et al., 2010). ANOVA showed a 
significant effect of CR in trabecular bone volume (BV/TV) in females, but not males, 
and this was unaffected by genotype (Figure 5.1.B). A similar diet effect was observed 
for trabecular number by ANOVA, with significant increases in CR-fed WT and KO 
females (Figure 5.1.D). However, no significant differences were detected for the 






Figure 5.1. Female mice on CR have increased trabecular mass. 
C57BL/6JOlaHsd (WT, black) and 11-HSD1 KO (KO, red) male and female mice 
were fed ad libitum (AL, closed symbols, solid line) or 70% of ad libitum food intake 
(CR, open symbols, dotted line) for six weeks, from 9 weeks until 15 weeks of age. 
The evening prior to dissections, all mice were fasted/re-fed as described in Methods 
(2.3.1). The AL fed mice had their food removed, and were given half a portion of the 
70% of food that they were daily consuming (1.5g). The CR fed mice were also given 
half a portion (1.05g) of their 30% CR diet. Post termination, bones were fixated in 
10% formaldehyde for seven days. Tibiae were then embedded in layers in 1% 
agarose in a universal tube, followed by being scanned at 6m by uCT and analysed 
by CTan. (A) Representative 2D images of CT horizontal trabecular bone section, 
with the white being the trabecular bone. (B) Bone volume fraction (%) (BV/TV). (C) 
Trabecular thickness (mm) (Tb.Th). (D) Trabecular number (1/mm) (Tb.N). (E) 
Trabecular separation (mm) (Tr.S). Data points are presented with median, 
interquartile range and range shown by box and whisker plot, and were analysed by 
2-Way ANOVA with Sidak’s multiple comparison test. n (WT AL male) = 7. n (WT CR 
male) = 11. n (KO AL male) = 8. n (KO CR male) = 8. n (WT AL female) = 8. n (WT 
CR female) = 13. n (KO AL female) = 5. n (KO CR female) = 8. *: p<0.05.  
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5.2.2. CR-fed female mice have decreased cortical bone compared to 
males 
 
Previous studies have shown that, in mice, CR causes loss of cortical bone but not 
trabecular bone (Hamrick et al., 2008). Therefore, I next analysed tibial cortical bone 
parameters. Representative images of the cortical bone from each group are shown 
in figure 5.2.A, while the key variables to report when describing cortical bone 
morphology, as recommended in previous guidelines (Bouxsein et al., 2010), are 
shown in Figure 5.2.B-E.  
 
ANOVA showed an overall genotype effect for cortical bone area (Ct.Ar) in males 
(Figure 5.2.B), with the KOs having increased bone area compared to the WTs. 
Furthermore, ANOVA also showed a genotype effect between the CR-fed males, with 
the KO males having an increase in cortical bone area compared to the WTs, although 
insignificantly (p=0.0629). This suggests a potential resistance to bone loss. In 
contrast, the females genotype did not influence Ct.Ar but an overall diet effect was 
detected, with the CR-fed females having significantly lower Ct.Ar than the AL-fed 
females. In addition, ANOVA detected that CR significantly decreased cortical area 
fraction in females (5.2.D), with multiple comparisons further showing a significant 
difference between the AL- and CR-fed WT females. However, no significant effects 
of diet or genotype were detected for cortical area fraction in males (Figure 5.2.D), or 






Figure 5.2. Cortical bone area is maintained with CR in 11-HSD1 KO males. WT 
and 11-HSD1 KO male and female mice were fed AL or CR diets and fasted/re-fed 
as described for Figure 5.1 and in Methods (2.3.1). Tibiae were scanned by CT as 
described in Figure 5.1 and in Methods (2.7). (A) Representative 2D images of CT 
horizontal cortical bone section, with the white being the cortical bone. (B) Cortical 
bone area (mm2) (Ct.Ar). (C) Total cross‐sectional area inside the periosteal envelope 
(mm2) (Tt.Ar). (D) Cortical area fraction (%) (Ct.Ar/Tt.Ar) (E) Average cortical 
thickness (mm) (Ct.Th). Data points are presented with median, interquartile range 
and range shown by box and whisker plot, and were analysed by 2-Way ANOVA with 
Sidak’s multiple comparison test. Numbers of mice per group, and presentation of 
statistically significant differences between groups, are as described for figure 5.1. *: 
p<0.05. **: p<0.01.  
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5.2.3. CR is associated with decreased tibial Bglap expression 
 
The bone morphology results revealed that, during CR, trabecular bone was 
maintained or increased. However, while cortical bone was lost in CR-fed females 
and WT males, 11-HSD1 KO males resist it (Figure 5.2.B). Since the p value 
between CR-fed WT and KO males was just below significant (p=0.0629), I next 
wanted to further examine bone remodelling at a molecular level. To do so I used 
qPCR to examine the transcript level of Bglap (osteocalcin), which is used as a 
molecular marker of bone formation (Ducy et al., 1996; Zoch, Clemens and Riddle, 
2016) in tibial bone. 
 
As shown in Figure 5.5, an overall diet effect was detected by ANOVA for both males 
and females, with decreased Bglap expression for the CR-fed mice. Multiple 
comparison was further used to assess diet effects within each genotype (and vice 
versa), confirming that CR significantly decreased Bglap expression in WT males and 
KO females. In addition, a diet x genotype interaction was detected for the females, 
revealing that the effect of CR was greater in the KO than in WT females. However, 
no genotype difference was detected by ANOVA for the males, suggesting that the 














Figure 5.3. Bone formation marker, Bglap, is decreased with CR. WT and 11-
HSD1 KO male and female mice were fed AL or CR diets and fasted/re-fed as 
described for Figure 5.1 and in Methods (2.3.1). Post termination, the tibiae were 
snap-frozen on dry ice, followed by BM isolation, RNA extraction and reverse 
transcription to cDNA. qPCR was performed to quantify expression of Bglap. Bglap 
was normalised to geomean of the following housekeeping genes: Ppia, Tbp and 
Actb, and presented as relative to the WT AL average of male and female mice 
together. Data points are presented with median, interquartile range and range shown 
by box and whisker plot, and were analysed by 2-Way ANOVA with Sidak’s multiple 
comparison test. Data points are presented with median, interquartile range and 
range shown by box and whisker plot, and were analysed by 2-Way ANOVA with 
Sidak’s multiple comparison test. n (WT AL male) = 7. n (WT CR male) = 11. n (KO 
AL male) = 8. n (KO CR male) = 8. n (WT AL female) = 8. n (WT CR female) = 13. n 
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Diet effect: p = 0.0045
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Diet effect: p = 0.0001
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Interaction: p = 0.0056
*
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5.2.4. CR and 11-HSD1 deficiency are not associated with changes in 
tibial GC action  
 
In chapters 3 and 4 I found that both circulatory and BM corticosterone concentrations 
are increased during CR. Therefore, I next addressed if CR alters GC action within 
the bone tissue, after removal of the BM. Due to time constraints I could not measure 
GC concentrations within these bone samples. Instead, GC target genes were 
examined to determine the effects of CR and 11-HSD1 KO on GC action within bone. 
I first analysed Hsd11b1 expression as this was found to be a possible marker of 
increased GC action in WAT and BM. Nonetheless, no diet differences were detected 
between the WT mice, while expression in the KOs was non-detectable, as predicted 
(Figure 5.4).  
 
To further investigate if GC action in bone is altered with CR, additional GC targets 
were examined. Figure 5.5 shows the expression of Fkbp5 (Figure 5.5.A), Gilz (Figure 
5.5.B) and Per (Figure 5.5.C). ANVOA detected an overall tendency for CR to 
decrease Fkbp5 in females (p=0.053) and to increase Per1 in males (p=0.055). 
However, no significant diet or genotype differences were detected by ANOVA for any 
of the genes, indicating that neither CR nor 11-HSD1 KO exerts robust effects on 















Figure 5.4. Tibial Hsd11b1 expression is not increased with CR. WT and 11-
HSD1 KO male and female mice were fed AL or CR diets and fasted/re-fed as 
described for Figure 5.1 and in Methods. Post termination, the tibiae were snap-frozen 
on dry ice, followed by BM isolation, RNA extraction and reverse transcription to 
cDNA. qPCR was performed to quantify expression of Hsd11b1. Hsd11b1 was 
normalised to geomean of the following housekeeping genes: Ppia, Tbp and Actb, 
and presented as relative to the WT AL average of male and female mice together. 
Data points are presented with median, interquartile range and range shown by box 
and whisker plot, and were analysed by Mann-Whitney (males) and Welch’s (females) 
test. Numbers of mice per group, and presentation of statistically significant 






























Figure 5.5. Tibial GC target genes are not modified with CR. WT and 11-HSD1 
KO male and female mice were fed AL or CR diets and fasted/re-fed as described for 
Figure 5.1 and in Methods. Post termination, the tibiae were snap-frozen on dry ice, 
followed by BM isolation, RNA extraction and reverse transcription to cDNA. qPCR 
was performed to quantify expression of Fkbp5, Gilz and Per1. The genes were 
normalised to geomean of the following housekeeping genes: Ppia, Tbp and Actb, 
and presented as relative to the WT AL average of male and female mice together. 
Fkbp5 (A), Gilz (B) and Per1 (C) expression. Data points are presented with median, 
interquartile range and range shown by box and whisker plot, and were analysed by 
2-Way ANOVA with Sidak’s multiple comparison test. Numbers of mice per group, 
and presentation of statistically significant differences between groups, are as 
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5.3.1. Effects of CR and 11-HSD1 on bone  
 
The effects of CR on decrease bone mass have previously been demonstrated in 
animals (Baek et al., 2008; Hamrick et al., 2008; Devlin et al., 2010; Speakman and 
Mitchell, 2011; Behrendt et al., 2016; Cawthorn et al., 2016). In addition, one of the 
publications showed maintenance of trabecular, but loss of cortical bone mass with 
CR (Hamrick et al., 2008), similarly to my results in this chapter. However, a different 
publication showed no bone loss with CR in mice (Mitchell et al., 2015). Moreover, 
decreased bone mass without BMAT expansion was found in rabbits on CR  
(Cawthorn et al., 2016). The variety in the end-results from these studies could be 
due to duration and percentage of CR, as well as the species. Overall, it suggests 
that CR can have diverse effects on bone morphology, where BMAT expansion is not 
always increased. However, my findings in this chapter, where the CR-fed KO males 
resisted BMAT expansion and minor cortical bone loss, it suggests that bone loss 
might be necessary for BMAT expansion, or vice versa. Nevertheless, that is not 
always the case as bone loss and BMAT expansion do not always coincide, as 
previously published; bone loss without changes in BMAT volume (Gokalp et al., 
2011; Devlin and Rosen, 2015; Cawthorn et al., 2016; Keune et al., 2017) and/or 
altered BMAT without bone loss or with increased bone mass (Schellinger et al., 2004; 
Doucette et al., 2015; Iwaniec et al., 2016; Sheu et al., 2017; Yu et al., 2017). 
However, for my findings, GC excess might be necessary for the CR-induced BMAT 
expansion and bone loss. As presented in previous chapter, BM corticosterone 
concentration in the CR-fed KO males was not increased as in the WTs (Figure 
4.11.B). The females and WT males all had increased corticosterone concentration 
in the BM and circulation, as well as increased BMAT and bone loss. This suggests 
that an increase in BM corticosterone concentration is necessary for BMAT expansion 
and more bone loss with CR. It also suggests that the KO males are resistant to 
circulatory GCs, whereas, the KO females are not. Instead, other hormones could be 
involved in the regulation of BMAT expansion and bone loss with CR in females, as 
previously discussed in Chapter 4, section 4.3. One of those hormones could be 
oestrogen (already discussed in Chapter 3 and 4) and/or leptin. Leptin decreases with 
CR (Devlin et al., 2010; Cawthorn et al., 2016), suggesting that hypoleptinemia could 
be involved in the formation of BMAT and bone loss. However, treating CR-fed mice 
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with leptin did not improve bone formation, but it did blunt BMAT expansion (Devlin et 
al., 2016). Leptin concentration was not measured in my study; however, it would be 
informative to measure it and test if the circulatory concentration varies between the 
genotypes on CR. I would expect all CR-fed mice to have decreased concentrations, 
however, the concentration of leptin in the KO males might not be decreased. Since 
leptin treatment blunts BMAT expansion (Devlin et al., 2016), perhaps it also protects 
against bone loss, or at least reduces the effect of CR in the KO males. However, the 
effect of leptin on bone have been contradicting. Some publications found that leptin 
deficient mice had increased bone mass (Amling, Takeda and Karsenty, 2000; Ducy 
et al., 2000; Karsenty, 2001), whilst others found decreased bone mass (Lorentzon, 
Alehagen and Boquist, 1986; Steppan et al., 2000) compared to controls. A different 
publication found that the effect of leptin differs throughout the skeleton, with 
decreased cortical thickness and trabecular volume in the femur, but increased 
density and trabecular bone volume in the lumbar spine (Hamrick et al., 2004). 
Overall, this is a complex topic that needs further researching. Furthermore, when 
quantifying for bone morphology, it would be informative to also measure BMAT 
volume, as bone loss/formation does not always coincide with BMAT expansion as 
previously mentioned.  
 
In addition, Bglap expression was decreased with CR in WT males and KO females, 
whereas no diet differences were detected for KO males and WT females. 
Osteocalcin is restricted to the osteoblast lineage (Lian et al., 1998), therefore, the 
Bglap expression in Figure 5.3 might just hint towards a decrease in osteoblast 
differentiation rather than absolute bone loss. Furthermore, GCs can also inhibit 
osteocalcin in osteoblasts, which might enhance GIO (Leclerc et al., 2005; Rauch et 
al., 2010). However, other genes associated with bone formation would be informative 
to include, such as collagen type 1 (Col1a1) and Runt-related transcription factor 2 
(Runx2) and additional in vitro experiments. Interestingly, trabecular bone was not 
only maintained, but trabecular bone volume (Figure 5.1.B) and number (Figure 
5.1.D) were significantly increased in females only. Trabecular bone volume and 
number were increased in the females, but no changes were detected for trabecular 
spacing. This might be offset by trends towards a decrease in trabecular thickness. 
However, more numbers might be needed to actually determine if there is a 
significance or not. In addition, the time frame for measuring bone morphology at 6 
weeks of CR might not be enough to induce more significant bone loss as the levels 
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of GCs are not as excessive as when orally administrating it (Morgan et al., 2014; 
Fenton et al., 2019). In comparison to my results, Hamrick et al., found increased 
vertebral trabecular bone volume, albeit in male mice (Hamrick et al., 2008). The CR 
experimental method did however differ between the studies. I performed 30% CR for 
six weeks, whereas Hamrick performed CR for a total of ten weeks, with increased 
restriction starting on 10% and ending on 40%. Overall, my results show a similarity 
to previous findings by Hamrick et al., and since 11-HSD1 KO mice have not been 
put on CR until now, it indicates that the KO males might resist CR effects. This 
possibility is also consistent with the key finding from Chapter 4, that the KO males 
resist CR-induced BMAT expansion. However, to be more certain regarding the 
resistance effects of 11-HSD1 KO males during CR, it would be informative to add 
more numbers to the groups, and potentially testing a more extreme CR, for example 
longer duration and/or greater percentage decrease in food intake. Altogether, these 
findings suggest that 11-HSD1 activity does regulate BMAT and possibly bone 
formation with CR. 
 
In contrast to the bone analysis and Bglap expression, my results show that CR does 
not significantly affect expression of GC target genes in bone. Here, it is once again 
worth highlighting that these 15-week-old mice were fasted/re-fed prior to termination, 
which might have blunted the end-term results of CR on gene expression. Indeed, 
this effect was evident for transcript expression within the BM (Figure 4.12). To 
overcome this, it would be interesting to analyse the bones from the short-term CR 
and AL mice, which did not undergo the fasting/re-feeding regimen prior to the 
endpoint. In addition, to further understand how GCs in bone are affected by CR in 
WT and KO mice, measuring GC concentrations by LC-MS/MS would be beneficial. 
This would give us a broader idea on how bone-specific GC concentration correlates 
with BM and plasma GC concentration.  
 
The skeletal effects of CR in humans are also becoming better understood. Although 
CR can promote healthy ageing, it was revealed that it comes at a cost of bone loss 
in sites of where osteoporotic fractures are commonly found (Villareal et al., 2016). 
This was investigated in a two-year clinical trial, where the effects of CR on bone in 
non-obese young adults were examined. On the other hand, to prevent bone loss at 
sites of osteoporotic fractures, it was shown that exercise-induced weight loss is a 
better option than CR as it preserves BMD (Villareal et al., 2006). This suggests that 
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eating a healthy diet, in addition to exercise, might be a better option to evade the 
side-effects of CR on bone. My CR mice, regardless of genotype, were more active 
than the AL-fed mice. However, it is yet to be researched if 11-HSD1 KO mice 
maintain bone mass if put on daily exercise instead of CR. Although the bone loss 
was not major, based on the previous mentioned publication showing that exercise is 
better to maintain bone, it would be expected for these KOs to maintain bone mass. 
Moreover, examining how adipocyte and osteocyte differentiation in bone/BM varies 
in CR, and especially in 11-HSD1 KO mice, would be favourable to further 
understand the role of 11-HSD1 and BMAT expansion/bone loss. A previous 
publication examined the BM in the distal femur and proximal tibia in adolescent girls 
with AN (Ecklund et al., 2010). The MRI scans showed that girls with AN have 
decreased red marrow compared to controls, suggesting premature conversion of red 
marrow to adipocytes. The adipocyte expansion could have hindered osteoblast 
differentiation, resulting in increased BMAT and bone loss. It is possible that these 
findings could equally mirror what is happening during CR.  
Further work on CR also needs to be conducted on a molecular level to understand 
the pathway(s) that leads to BMAT expansion and bone loss. Although, primary 
osteoblast can respond to corticosterone (Bellows, Ciaccia and Heersche, 1998), 
confirming that bone can directly respond to GCs. It has also been published that 11-
HSD1 activity in osteoblastis increased by GCs (Cooper et al., 2001). This further 
confirms the role of 11-HSD1 in bone. While no research has been conducted on 
11-HSD1 KO mice during CR, bone morphology was analysed on the hypomorphic 
KOs during normal conditions. It was found that no differences were detected 
between the WT and hypomorphic KOs with regards to bone morphology (Justesen 
et al., 2004). Compared to my AL-fed WT and KO mice, my results further confirm 
Justesen et al., findings, although the KO models differ. However, my study is more 
consistent between the groups of mice as I quantified bone morphology on 15-week-
old mice in all groups, whereas, Justesen et al., studied bone in male mice at ~4 
months and at ~20 months of age, and in females at 7.5-11 months and ~20 months 
of age (Justesen et al., 2004). The difference in age could affect the end-results of 
the hypomorphic KOs. Moreover, they also reported the lack of BMAT in these KOs, 
which I have proved otherwise. Thus, more research has to be conducted to 
determine the effects of 11-HSD1 on bone, especially with CR.  
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5.3.4. Future directions  
 
Due to time constraints, GC target genes were not examined in the bones from the 
10-week-CR cohorts. Similarly, the femurs from the 15-week-old CR were not 
optimised for LC-MS/MS quantification. For future analysis, these two experiments 
could be performed to compare results between the bone, BM and plasma. 
Static and dynamic histomorphometry could be performed to assess rates of bone 
formation and possibly resorption. Together, it would allow the quantification of bone 
cells (osteoblast and osteoclasts) as well as bone formation rates. Furthermore, a 
new three-dimensional approach to measure bone remodelling has been published 
(Slyfield et al., 2012). Compared to the traditional histomorphometry, this new 
approach can also measure the number and size of individual resorption cavities and 
bone forming sites. However, it is important to notice that there are limitations to this 
new approach, hence it cannot be assumed it is flawless. For example, osteoclasts 
are not visualised, hence resorption cavities are identified based on surface 
irregularities. The serum markers for bone formation and resorption, Propeptides of 
type 1 collagen (P1NP) and C-terminal telopeptide (CTX-1) respectively, have been 
proposed to be used as reference markers (Vasikaran et al., 2011). In addition to 
P1NP, other common bone formation markers are alkaline phosphatase (ALP) and 
osteocalcin. ALP is an enzyme in osteoblast membranes and it is important for bone 
mineralisation, hence it can be measured as a marker of mineralisation (Shetty et al., 
2016). Osteocalcin is synthesised by osteoblast, and it can be quantified by an ELISA 
in mouse serum and also from cell culture supernatants (Ferron, Wei, Yoshizawa, 
Ducy, et al., 2010). Besides CTX-1, different bone resorption markers include TRAP 
and Cathepsin K. They are both expressed by osteoclasts. TRAP is increased during 
for example osteoporosis, and Cathepsin K is secreted during active bone resorption 
(Shetty et al., 2016).  
 
Although there might be an association between the effect of CR and GCs on bone, 
there is no experimental data in this study that can confirm it. Therefore, correlations 
between bone, BMAT and GCs and further in vitro experiments would be of interest 
and necessary to establish these associations. In vitro work would answer further 
questions regarding the cortical bone loss and trabecular maintenance/increase, for 
example to isolate and differentiate BMSCs. Osteogenic cells can be compared to 
adipose-derived cells, especially from mice on CR. Moreover, colony-forming unit 
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(CFU) assays to measure how many progenitors are present and viable to proliferate 
in a given population of cells. Hence, primary cells would be preferred instead of cell 
lines, to have the option to study bone cells from genetically altered mice. Additionally, 
cells from AL mice can be treated with dexamethasone and compared between 
genotypes. The increase in corticosterone in females and WT males, but not KO 
males, might also indicate that the loss in cortical bone might be affected due to GCs 
enhancing osteoclast differentiation and regulation of RANK and osteoprotegerin 
(Swanson et al., 2006; He et al., 2016). This is something that could be further 
investigated if the aim is to determine if CR-induced bone loss is induced by an 
increase in osteoclasts or a decrease in osteoblasts. RANKL and osteoprotegerin can 
be measured by ELISA in whole bone (Swanson et al., 2006).  
To summarise this chapter, trabecular bone mass was maintained, whereas, cortical 
bone mass was lost with CR in all mice, but less so in the CR-fed KO males. Since 
the cortical results are not as robust as with the BMAT volume, more numbers could 
be added to the groups to see if it gives more robust effects. There is no evidence 
that CR increases GC action in bones, or that the KOs resist this. However, the end-
results could be affected by the fasting/re-feeding protocol. Overall, this suggest the 
following; that the KOs do not resist the effects of CR on bone, although it seems like 
the KO males could resist cortical bone loss but not robustly, or that GCs might not 
be involved in bones loss during CR. The findings between BMAT and cortical bone 
mass in the CR-fed KO males suggest that BMAT expansion is not necessary for 
cortical bone loss, even if it is minor. However, if more mice were added to the groups, 
and it would show a clear resistance in bone loss in the KO males, it would be 
informative to measure GC concentrations in the bone to investigate if they are 
involved in the resistance, meaning decreased concentration in the KOs, and 
increased in the WTs. On the other hand, if the CR-fed KO males showed a clearer 
decrease in cortical bone, it would suggest that they do not resist the effects of CR on 
bone mass, but instead they resist CR-induced BMAT expansion. Previous research 
has showed that BMAT expansion and bone loss are not always associated, and this 
KO model would further add to it. Once again, measuring bone GC concentration 
would be informative to determine how/if big of a role GCs play a role here and to 
compare with BM GC concentration. Another option could be that these 11-HSD1 
KOs are not a suitable model to address this hypothesis. Like previously mentioned, 
I think that the osteoblast specific GR KO model would be a more suitable model 
(Rauch et al., 2010) since the KOs resisted the effects of GC excess.  
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Beyond CR, ageing also increases circulating GC concentrations. Furthermore, 
several studies have demonstrated that BMAT and bone loss also increase with 
ageing. To determine if 11-HSD1 KO mice have blunted BMAT expansion and 
bone loss with ageing, in my next chapter I investigated the effects of ageing on 
bone in WT and 11-HSD1 KO mice.  
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Chapter 6. Ageing-related corticosterone and bone 
marrow adiposity expansion are associated with bone 
loss in WT and 11-HSD1 deficient mice  
 
 
6.1. Introduction  
 
My results from the previous chapters revealed that CR-fed 11-HSD1 KO females 
do not resist CR-induced BMAT expansion, whereas KO males do. Moreover, for WT 
males and for females of each genotype, CR increased circulatory and BM 
corticosterone concentration. Cortical bone loss was evident in females (both 
genotypes) but CR-fed KO males resisted the cortical bone loss compared to WT 
males. These results suggest that, in KO males only, resistance to increased 
circulatory and BM corticosterone may then limit BMAT expansion and bone loss 
during CR. This raises the possibility that deficiency of 11-HSD1 might also 
influence bone loss and BMAT expansion in other conditions of GC excess. 
One such condition, of great relevance to public health, is ageing. It is well 
established that ageing is associated with GC excess (Purnell et al., 2004), BMAT 
expansion and bone loss (Ambrosi et al., 2017), which can result in osteoporosis. 
Ageing-related osteoporosis is a major public health burden and therefore 
understanding the mechanism behind it could reveal new therapeutic strategies of 
benefit to human health. 
Age-related osteoporosis is often associated with increased BMAT, including 
increased number and size of BMAds. This increase in BMAT is inversely correlated 
with trabecular bone volume (Justesen et al., 2001). Furthermore, vertebral cortical 
bone loss also occurs with ageing, but this is predominantly observed in women rather 
than men (Chen et al., 2010; Christiansen et al., 2011). In addition to bone 
morphology, BMAT accumulation is also sex-dependent with ageing. Thus, in males 
BMAT increases with age at a gradual and consistent rate, whereas in females BMAT 
more rapidly accumulates between 55 and 65 years of age. Consequently, above 60 
years of age females have increased BMAT volume compared to age-matched males 
(Griffith et al., 2012; Roldan-Valadez et al., 2013). Perhaps unsurprisingly, this age-
associated BMAT expansion in females is associated with menopause and decreased 
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oestrogen. Oestrogen directly decreases BMAT (Limonard et al., 2015); hence, as 
oestrogen concentration decreases during menopause, BMAT expands.  
Based on these findings, one hypothesis that has attracted a relatively large amount 
of interest is that BMAT contributes to age-related bone loss (Devlin and Rosen, 2015; 
Veldhuis-Vlug and Rosen, 2018). Given that ageing is also associated with GC excess 
(Purnell et al., 2004), in the present chapter I investigated the hypothesis that that 
age-related increases in GC action drive age-associated BMAT expansion and bone 
loss. Justesen et al., analysed bone morphology in male and female WT and 
hypomorphic 11-HSD1 KO mice (Justesen et al., 2004). Here, bone morphology was 
studied in male mice at ~4 months and at ~20 months of age, and in females at 7.5-
11 months and ~20 months of age (Justesen et al., 2004). Age-induced bone loss 
was evident in both genotypes, with similar bone formation and resorption 
parameters, but no differences were observed between the genotypes. They also 
showed that young 11-HSD1 KO males lacked BMAds, which were present in age-
matched WTs. However, there are several limitations to their study: BMAT was not 
analysed in the older mice; the ‘young’ mice (~4-months for males, and 7.5-11 months 
for females) were not particularly young; the ages of the ‘young’ and ‘old’ mice differ 
between the sexes; and the KO model used is hypomorphic, rather than a complete 
KO. These limitations are likely to confound the BMAT and bone phenotype results. 
Indeed, Justesen et al., concluded that the young KO male mice lack BMAT, whereas 
my results have shown that BMAT development is normal in young, AL-fed KO mice. 
Furthermore, another independent study confirms that BMAds are present in the 
hypomorphic 11-HSD1 KO mice (Coutinho et al., 2012). However, the effect of 11-
HSD1 KO on age-related BMAT expansion or bone loss has not been tested using 
the null 11-HSD1 KO mice. Thus, to determine whether age-related increases of 
GCs drive age-associated BMAT expansion and bone loss, I examined bone 
morphology and BMAT in 42-and 70-week-old WT and 11-HSD1 KO mice. The 
reason for using 42-and 70-week-old mice, rather than much older mice, is due to 
tumour formation and additional health issues that arise beyond 18 months of age. 
This has been observed in WT and 11-HSD1 KO mice, and also in other transgenic 
models in our group; hence, it is independent of genotype. Therefore, the concern 
with using much older mice is that it would introduce confounding pathological effects, 
which I wanted to avoid. The practical work in this chapter was completed with 
assistance from two undergraduate students. The first student, Iris Pruñonosa, 
contributed to this chapter by examining 42-week-old and 70-week-old female mice 
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(first cohorts, designated as 42.1 and 70.1, respectively). The second student, Rachel 
Bell, continued the work by further examining 42-week-old male and female mice. I 
co-supervised both students and continued the research by adding to the numbers of 
the 42-week-old mice (second cohort, referred to as 42.2) and also including a new 
cohort of 70-week-old mice (referred to as 70.2). Mice in cohort 1 (42.1 and 70.1) 
were analysed separately to mice in cohort 2 (42.2 and 70.2) because, in the first 
cohort, all of the WTs were in one cage and all of the KOs were in a separate cage, 
and therefore any genotype effect may simply have resulted from cage effects. In 
contrast, in the second cohort the genotypes were mixed together among the various 
cages (Summarised in Table 6.1). Therefore, to determine if their housing had an 
impact on age-related body weight gain, fat mass, BMAT expansion and bone loss, 
the cohorts were examined separately but they are presented alongside each other 
to aid in the comparison and interpretation of these results. 
 





Cohort 1  Cohort 2 
 15 42.1 70.1 42.2 70.2 
Number of mice 15 WT and 13 
KO 
 
4 WT and 
3 KO  








Sex of aged 
mice 
Mixed. All females. Mixed. 
Cage set up  
Single housed. 
Genotypes were 
separated: WT and KO 
in separated cages. 
Genotypes were 
mixed in cages. 
Body mass Yes Yes Yes Yes Yes 
TD-NMR 
measurements 
Yes Yes No Yes Yes 
Adipose depots 
mass 
Yes Yes Yes Yes Yes 
Adrenal glands 
mass  
Yes Yes No Yes Yes 
Corticosterone 
ELISA 
Yes Yes Yes Yes Yes 
BMAT analysis Yes Yes Yes Yes No 
Bone analysis  Yes Yes Yes Yes No 
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6.2. Results  
 
6.2.1. 11-HSD1 KO influences ageing-associated increases in body 
mass 
 
Before characterising the effects of the 11-HSD1 KO on age-related GC excess, 
bone loss and BMAT expansion, I first addressed if lack of 11-HSD1 influences the 
increases in body mass and changes in body composition that occur with ageing. The 
rationale for this was two-fold. Firstly, it is unclear if ageing-related increases in body 
mass or development of obesity are influenced by GC excess or are altered in the null 
11-HSD1 KO mice. Secondly, weight gain and obesity, as well as GCs, can influence 
BMAT and bone architecture; hence, if the former are influenced by 11-HSD1 KO 
then this might contribute to any skeletal phenotypes observed.  
Cohort one comprised females only, whereas cohort two included both males and 
females. At necropsy the KO mice differed in size to their WT counterparts, but this 
effect was strikingly different between the two cohorts. Thus, for cohort one the KOs 
were much smaller than WTs, whereas in cohort two the opposite phenotype was 
apparent. This was confirmed by the body masses of the mice (Figure 6.1). A 
significant age effect was detected by 2-way ANOVA, with the 70-week-old mice 
having a consistent increase in body weight compared to the 15-week-old (control) 
mice. The KO females also showed a decrease in body weight gain at 70-weeks of 
age compared to the WTs in the first cohort only (Figure 6.1.A). Figure 6.1.B shows 
the body weight of the second cohort of 42 and 70-week-old mice, male and female, 
compared to control mice. A significant age effect was detected by 3-Way ANOVA, 
with both male and female mice having increased body weight with ageing. A clear 
sex effect was similarly detected, with the male mice being heavier. The 70-week-old 
KO female mice from the second cohort (70.2) showed a minor trend for being heavier 
compared to the WT, although this was not statistically significant ((p=0.27) Figure 
6.1.B). The first cohort (70.1), showed the opposite result. This striking difference 
between the cohorts suggests that cage effects may have contributed to the 
phenotype, because for cohort 1 the WT and KO mice were housed in separate cages 
throughout. Therefore, the remainder of the results in this chapter will be presented 




Figure 6.1. Ageing increases body weight in male and female mice. 15- (control), 
42-and 70-week-old C57BL/6JOlaHsd (WT, transparent box) and 11-HSD1 KO (KO, 
patterned box) male (black) and female (red) mice were fed AL chow diet (15-week-
old mice) and/or standard chow diet (42-and 70-week-old mice) until appropriate age. 
The morning prior to termination, the 42-and 70-week-old mice were fasted for one 
hour and weighed thereafter. The control mice were fasted overnight and weighed in 
the morning. First cohort (stated as 42.1 and 70.1) were all females, with the 
genotypes separated in each cage. The second cohort (stated as 42.2 and 70.2) 
consisted of male and female mice with mixed genotypes in each cage. The 15-week-
old control mice were single-housed. Body weight of the first (A) and second (B) 
cohort. Data points are presented with median, interquartile range and range shown 
by box and whisker plot and were analysed by 2-Way (A) or 3-Way (B) ANOVA with 
Sidak’s multiple comparison test. The interaction from 3-Way ANOVA is between all 
three variables. First cohort: n (15 WT female) = 8. n (15 KO female) = 5. n (42.1 WT 
female) = 4. n (42.1 KO female) = 3. n (70.1 WT female) = 3. n (70.1 KO female) = 4. 
Second cohort: n (15 WT male) = 7. n (15 KO male) = 8. n (15 WT female) = 8. n (15 
KO female) = 5. n (42.2 WT male) = 9. n (42.2 KO male) = 6. n (42.2 WT female) = 4. 
n (42.2 KO female) = 7. n (70.2 WT male) = 10. n (70.2 KO male) = 8. n (70.2 WT 








Males and females body weight - 2 nd cohort
Age effect: p<0.0001
Sex effect: p<0.0001
Genotype effect: p = 0.002
















Female body weight - 1st cohort
Age effect: p<0.0001
Genotype effect: p = 0.0001
Interaction: p = 0.0001
A
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6.2.2. 11-HSD1 KO influences ageing-associated changes in body 
composition 
 
To determine the basis for these genotypic differences in total body mass, TD-NMR 
was used to assess body composition. Ageing is associated with increased fat mass 
(He et al., 2018) and can further influence BMAT and bone morphology and therefore 
I postulated that 11-HSD1 KO influences body mass primarily through effects on fat 
mass.  
 
Figure 6.2 shows the fat mass data obtained by TD-NMR in both cohorts, presented 
both as absolute mass (Figure 6.2.A-B) and as % of body mass (Figure 6.2.C-D). For 
the first cohort of females, TD-NMR was not done in the 70-week-old mice and 
therefore only data from the 15.1 and 42.1 females is presented. Here, 2-Way ANOVA 
confirmed significant age, genotype and interaction effects (Figure 6.2.A, C), with 
multiple comparisons showing a decrease in the 42.1 KO females compared to the 
WTs. For the second cohort there were significant effects of age, sex and genotype, 
both for absolute fat mass (Figure 6.2.B) and % body fat (Figure 6.2.D). Thus, the 
older mice had increased fat mass compared to young mice; males had increased fat 
mass compared to the females; and an overall genotype effect was also detected, 
with KO mice generally having greater fat mass than WT at 42 and 70 weeks of age. 
These observations support the possibility that the KO mice have altered body mass 
because of differences in fat mass. However, as shown in Figure 6.3, changes in lean 
mass were also detected. In the first female cohort, both for absolute lean mass 
(Figure 6.3.A) and % lean mass (Figure 6.3.C) there were overall age, genotype and 
interaction effects detected by ANOVA. Absolute lean mass increased with age, 
whereas % lean mass decreased. Lean mass was also significantly higher in KO vs 
WT females at 42 weeks of age (Figure 6.3.A, C). Similar age effects were also 
observed in the second cohort of mice, in which sex effects were also apparent 
(Figure 6.3.B, D). However, unlike in the first cohort, in the second cohort no genotype 
effects were detected for absolute lean mass (Figure 6.3.B) while % lean mass was 
significantly lower in KO vs WT mice at 42 or 70 weeks of age (Figure 6.3.D). These 
differences in lean mass are generally the opposite to the differences in fat mass and 




Figure 6.2. Older 11-HSD1 KO mice do not resist age-induced adiposity 
compared to control mice. 15- (control), 42-and 70-week-old C57BL/6JOlaHsd 
(WT, transparent box) and 11-HSD1 KO (KO, patterned box) male (black) and 
female (red) mice were fed and fasted as described in Figure 6.2. The day prior to 
termination, the mice were scanned for fat mass by TD-NMR. The 70-week-old female 
mice from the first cohort were not scanned due to the uncertainty of how stressful it 
would have been for aged mice to be scanned in a tight tube. However, after additional 
ageing studies in the lab, it was decided that it was safe to scan the aged mice. Fat 
mass of the first (A) and second (B) cohort shown in grams. Fat mass of the first (C) 
and second (D) cohort shown as % of body mass. Data points are presented with 
median, interquartile range and range shown by box and whisker plot and were 
analysed by 2-Way (A and C) or 3-Way (B and D) ANOVA with Sidak’s multiple 
comparison test. Numbers of mice per group, and presentation of statistically 






Male and female fat mass (g) - 2 nd cohort
Age effect: p<0.0001
Sex effect: p<0.0001
Genotype effect: p = 0.009





























Female fat mass (%) - 1st cohort
Age effect: p<0.0001
Genotype effect: p = 0.0012



















Female fat mass (g) - 1st cohort
Age effect: p<0.0001
Genotype effect: p = 0.0025







Male and female fat mass (%) - 2nd cohort
Age effect: p<0.0001
Sex effect: p = 0.0011
Genotype effect: p = 0.004
Interaction: p = 0.1
D
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Figure 6.3. Older 11-HSD1 KO mice do not resist lean mass loss compared to 
control mice. 15- (control), 42-and 70-week-old C57BL/6JOlaHsd (WT, transparent 
box) and 11-HSD1 KO (KO, patterned box) male (black) and female (red) mice were 
fed and fasted as described in Figure 6.2. The day prior to termination, the mice were 
scanned for lean mass by TD-NMR. Lean mass of the first (A) and second (B) cohort 
shown in grams. Lean mass of the first (C) and second (D) cohort shown as % of body 
mass. Data points are presented with median, interquartile range and range shown 
by box and whisker plot, and were analysed by 2-Way (A and C) or 3-Way (B and D) 
ANOVA with Sidak’s multiple comparison test. Numbers of mice per group, and 
presentation of statistically significant differences between groups, are as described 








Male and female lean mass (%) - 2 nd cohort
Age effect: p<0.0001
Sex effect: p = 0.002
Genotype effect: p = 0.0034




























Female lean mass (%) - 1st cohort
Age effect: p<0.0001
Genotype effect: p = 0.0012


















Female lean mass (g) - 1st cohort
Age effect: p = 0.006
Genotype effect: p = 0.008








Male and female lean mass (g) - 2 nd cohort
Age effect: p<0.0001
Sex effect: p<0.0001
Genotype effect: p = 0.25







6.2.3. Age-associated sex differences in WAT 
 
My previous results (Chapter 4) show that certain WAT depots contribute 
disproportionately to changes in total-body fat mass. Therefore, I next analysed the 
masses of different WAT depots in the two cohorts of 15-, 42-and 70-week-old mice. 
Figure 6.4 shows the absolute mass of iWAT (Figure 6.4.A-B) and as % of body mass 
(Figure 6.4.C-D). ANOVA detected age, genotype and interaction effects for the 
female iWAT in the first cohort, with the KOs having significantly less iWAT than WTs 
at 42 and 70 weeks of age (Figure 6.4.A, C). On the other hand, in the second cohort, 
ANOVA detected age, sex and genotype effect, without an interaction between the 
factors. No significant differences were detected between the genotypes either 
(Figure 6.4.B). iWAT as % of body mass showed overall age and genotype effect, 
with the mass increasing with age and the KOs generally having increased % iWAT 
mass compared to WTs (Figure 6.4.D).  
 
Figure 6.5 shows the absolute mass of gWAT (Figure 6.5. A-B), and as % of body 
mass (Figure 6.5.C-D). Overall age and genotype effects were detected by ANOVA 
in both cohorts, with the depot increasing with age. In the first cohort, gWAT was 
decreased in the older KO female mice (Figure 6.5.A, C). Whereas, in the second 
cohort, an overall genotype effect by ANOVA confirmed higher gWAT mass in the 
KOs than in the WTs. Figure 6.6 shows the mass of mWAT as absolute mass (Figure 
6.6.A-B), and as % of body mass (Figure 6.6.C-D). Both cohorts showed an age effect 
detected by ANOVA, with the older mice having increased mWAT mass. The results 
of mWAT were similar to iWAT and gWAT, with less mWAT in the first cohort of the 
older KO female mice (Figure 6.6.A, C), and increased mWAT in KO vs WT for each 
sex in the second cohort (Figure 6.6.B, D). KO males of the second cohort showed 
an increase in mWAT at 15 weeks of age (Figure 6.6.B).  
 
Overall, these results confirm the changes in fat mass observed with TD-NMR and 
further reveal that the genotype effects are greatest for the visceral depots of gWAT 
and mWAT, with smaller effects on iWAT.  
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Figure 6.4. iWAT increases with age in male and female mice. 15- (control), 42-
and 70-week-old C57BL/6JOlaHsd (WT, transparent box) and 11-HSD1 KO (KO, 
patterned box) male (black) and female (red) mice were fed and fasted as described 
in Figure 6.2. Post termination, iWAT was collected and weighed. iWAT of first (A) 
and second (B) cohort shown in grams. iWAT of first (C) and second (D) cohort shown 
as % of body mass. Data points are presented with median, interquartile range and 
range shown by box and whisker plot, and were analysed by 2-Way (A and C) or 3-
Way (B and D) ANOVA with Sidak’s multiple comparison test. Numbers of mice per 
group, and presentation of statistically significant differences between groups, are as 











































































Male and female iWAT - 2nd cohort
Age effect: p<0.0001
Sex effect: p = 0.0026
Genotype effect: p = 0.03













Male and female iWAT - 2nd cohort
Age effect: p<0.0001
Sex effect: p = 0.2
Genotype effect: p = 0.033
Interaction: p = 0.3
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Figure 6.5. gWAT increases with ageing in male and female mice. 15- (control), 
42-and 70-week-old C57BL/6JOlaHsd (WT, transparent box) and 11-HSD1 KO (KO, 
patterned box) male (black) and female (red) mice were fed and fasted as described 
in Figure 6.2. Post termination, gWAT was collected and weighed. gWAT of first (A) 
and second (B) cohort shown in grams. gWAT of first (C) and second (D) cohort 
shown as % of body mass. Data points are presented with median, interquartile range 
and range shown by box and whisker plot, and were analysed by 2-way (A and C) or 
3-way (B and D) ANOVA with Sidak’s multiple comparison test. Numbers of mice per 
group, and presentation of statistically significant differences between groups, are as 





















Female gWAT - 1st cohort
Age effect: p<0.0001
Genotype effect: p<0.0001




























Female gWAT - 1st cohort
Age effect: p<0.0001
Genotype effect: p = 0.0011










Male and female gWAT - 2nd cohort
Age effect: p<0.0001
Sex effect: p<0.0001
Genotype effect: p = 0.005











Male and female gWAT - 2nd cohort
Age effect: p<0.0001
Sex effect: p = 0.0016
Genotype effect: p = 0.005
Interaction: p = 0.35
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Figure 6.6. mWAT increases with ageing in male and female mice. 15- (control), 
42-and 70-week-old C57BL/6JOlaHsd (WT, transparent box) and 11-HSD1 KO (KO, 
patterned box) male (black) and female (red) mice were fed and fasted as described 
in Figure 6.2. Post termination, gWAT was collected and weighed. gWAT of first (A) 
and second (B) cohort shown in grams. gWAT of first (C) and second (D) cohort 
shown as % of body mass. Data points are presented with median, interquartile range 
and range shown by box and whisker plot, and were analysed by 2-way (A and C) or 
3-way (B and D) ANOVA with Sidak’s multiple comparison test. Numbers of mice per 
group, and presentation of statistically significant differences between groups, are as 



























































Female mWAT - 1st cohort
Age effect: p<0.0001
Genotype effect: p<0.0001










Male and female mWAT - 2nd cohort
Age effect: p<0.0001
Sex effect: p = 0.0005
Genotype effect: p = 0.0011














Male and female mWAT - 2nd cohort
Age effect: p<0.0001
Sex effect: p = 0.3
Genotype effect: p = 0.0013







6.2.4. 11-HSD1 KO exerts subtle effects on age-related changes in 
adrenal mass and circulating corticosterone 
 
To next determine if the increased adiposity was associated with age-related changes 
in GC action, at necropsy adrenal glands were collected and weighed (Figure 6.7) 
and end-point plasma was collected for quantifying plasma corticosterone 
concentration by ELISA (Figure 6.8). In the first cohort of mice the adrenal glands 
were analysed from 15-week and 42-week-old groups only, because the adrenals 
from the 70-week-old mice were not collected at the time. ANOVA confirmed that 
adrenals were heavier in the 42-week-old compared to 15-week-old mice, regardless 
of genotype (Figure 6.7.A). Significant age effects were also detected in the second 
cohort, except that here, compared to the 15-week-old mice, adrenal masses were 
lower in the 42.2 mice but similar in the 70.2 mice (Figure 6.7.B). For the adrenal 
masses as % of body mass in the second cohort, there were strongly significant 
differences between the sexes, with female mice having heaver adrenals compared 
to the males in proportion to their body mass (Figure 6.7.D); this is consistent with the 
literature (Bielohuby et al., 2007). Whether expressed as absolute mass or % body 
mass, ANOVA confirmed a significant interaction between age, sex and genotype for 
the second cohort of mice (Figure 6.7.B, D). However, no interaction was present 
between genotype x age, nor genotype x sex (p=0.5 and p=0.8, respectively). This 
indicates that the genotype does not influence the complex effects of age and sex on 
adrenal mass.  
 
Figure 6.8 shows the circulating corticosterone concentration in both cohorts. ANOVA 
detected an age effect in the first cohort, with the older females having increased 
plasma corticosterone (Figure 6.8.A). In the second cohort a similar age effect was 
detected while a genotype effect was also apparent, with KOs having greater 
corticosterone concentration than WTs at 42 and 70 weeks of age (Figure 6.8.B). 
Overall, these results show that circulating corticosterone concentrations are 
increased with age in both genotypes.  
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Figure 6.7. Adrenal glands in older WT and 11-HSD1 KO male and female mice. 
15- (control), 42-and 70-week-old C57BL/6JOlaHsd (WT, transparent box) and 11-
HSD1 KO (KO, patterned box) male (black) and female (red) mice were fed and fasted 
as described in Figure 6.2. Post termination, adrenal glands was harvested and 
weighed. Adrenal glands of first (A) and second (B) cohort shown in grams. Adrenal 
glands of first (C) and second (D) cohort shown as % of body mass. Data points are 
presented with median, interquartile range and range shown by box and whisker plot, 
and were analysed by 2-way (A and C) or 3-way (B and D) ANOVA with Sidak’s 
multiple comparison test. First cohort: n (15 WT female) = 8. n (15 KO female) = 5. n 
(42.1 WT female) = 4. n (42.1 KO female) = 3. Second cohort: n (15 WT male) = 7. n 
(15 KO male) = 8. n (15 WT female) = 8. n (15 KO female) = 5. n (42.2 WT male) = 9. 
n (42.2 KO male) = 6. n (42.2 WT female) = 4. n (42.2 KO female) = 7. n (70.2 WT 































Female adrenal glands - 1st cohort
Age effect: p = 0.14
Genotype effect: p = 0.3








Male and female adrenal glands - 2 nd cohort
Age effect: p = 0.013
Sex effect: p = 0.15
Genotype effect: p = 0.4

























Female adrenal glands - 1st cohort
Age effect: p = 0.0026
Genotype effect: p = 0.16







Male and female adrenal glands - 2 nd cohort
Age effect: p<0.0001
Sex effect: p<0.0001
Genotype effect: p = 0.7
Interaction: p = 0.046
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Figure 6.8. Circulating corticosterone concentration was increased in older 
mice. 15- (control), 42-and 70-week-old C57BL/6JOlaHsd (WT, transparent box) and 
11-HSD1 KO (KO, patterned box) male (black) and female (red) mice were fed and 
fasted as described in Figure 6.2. Post termination, blood was sampled and quantified 
by corticosterone ELISA as described in methods (2.4). (A) Circulatory corticosterone 
concentration in first (A) and second (B) cohort of mice. Data points are presented 
with median, interquartile range and range shown by box and whisker plot, and were 
analysed by 2-way (A) or 3-way (B) ANOVA with Sidak’s multiple comparison test. 
Numbers of mice per group, and presentation of statistically significant differences 












Female [corticosterone] - 1st cohort
Age effect: p<0.0001
Genotype effect: p = 0.23















Male and female [corticosterone] - 2 nd cohort
Age effect: p = 0.0008
Sex effect: p = 0.9
Genotype effect: p = 0.032








6.2.5. 11-HSD1 deficiency does not prevent ageing-associated BMAT 
expansion  
 
I next investigated if these age-associated increases in circulating corticosterone are 
related to increased BMAT and whether this relationship is altered in the 11-HSD1 
KO mice. To do so, I quantified BMAT volume by osmium tetroxide staining; owing to 
time constraints, BMAT in the second cohort of 70-week-old mice could not be 
measured.  
 
Figure 6.9 shows the analysed BMAT in the proximal and distal regions of the tibiae 
of male and female mice, as well as total BMAT in the tibiae. In the proximal BMAT of 
the first cohort, ANOVA detected age and genotype effects. The older mice had 
increased proximal BMAT compared to young mice, and the 42.1 KO females had 
decreased BMAT compared to WT females (Figure 6.9.A). In contrast, in the second 
cohort no genotype effects were detected although significant age and sex effects 
were apparent, as well as a significant interaction between age, sex and genotype. 
Thus, the older mice had increased BMAT, and the 42.2 females had greater proximal 
BMAT volume than the males (Figure 6.9.B). Furthermore, ANOVA detected age 
effects for both cohorts in the distal BMAT (Figure 6.9.C-D). The second cohort also 
had a sex effect present, with less distal BMAT in the females than the males (Figure 
6.9.D). Finally, for total BMAT, ANOVA detected significant age effects, with the older 
mice having increased BMAT in both cohorts (Figure 6.9.E-F). However, unlike for 
proximal BMAT, genotype had no significant effect on distal BMAT or total BMAT.  
Based on my previous results showing that corticosterone is increased in older mice, 
and the BMAT results showing expansion with ageing, these observations suggest 
that age-associated hypercorticosteronaemia might contribute to the expansion of 
BMAT. Although genotype significantly influences the effect of age and sex on 
proximal BMAT in the second cohort of mice (Figure 6.9.B), these effects are complex, 




Figure 6.9. Older mice have increased BMAT expansion compared to young 
controls. 15- (control), 42-and 70-week-old C57BL/6JOlaHsd (WT, transparent box) 
and 11-HSD1 KO (KO, patterned box) male (black) and female (red) mice were fed 
and fasted as described in Figure 6.2. Post termination, bones were decalcified and 
stained with osmium tetroxide staining for 48 hours, and thereafter washed for 24 
hours in Sorensen’s buffer. Tibiae were then embedded in layers in 1% agarose in a 
universal tube, followed by being scanned at 12m by uCT and analysed by CTan for 
BMAT (mm3). Proximal BMAT in first (A) and second (B) cohort. Distal BMAT in first 
(C) and second (D) cohort. Total BMAT in first (E) and second (F) cohort. Data points 
are presented with median, interquartile range and range shown by box and whisker 
plot, and were analysed by 2-way (A, C and E) or 3-way (B, D and F) ANOVA with 
Sidak’s multiple comparison test. First cohort: n (15 WT female) = 8. n (15 KO female) 
= 5. n (42.1 WT female) = 4. n (42.1 KO female) = 3. n (70.1 WT female) = 3. n (70.1 
KO female) = 4. Second cohort: n (15 WT male) = 7. n (15 KO male) = 8. n (15 WT 
female) = 8. n (15 KO female) = 5. n (42.2 WT male) = 9. n (42.2 KO male) = 6. n 












Proximal BMAT in female tibiae - 1st cohort
Age effect: p = 0.0007
Genotype effect: p = 0.015












Distal BMAT in female tibiae - 1st cohort
Age effect: p<0.0001
Genotype effect: p = 0.7










Total BMAT in female tibiae - 1st cohort
Age effect: p<0.0001
Genotype effect: p = 0.34













Proximal BMAT in male and female tibiae - 2 nd cohort
Age effect: p = 0.04
Sex effect: p = 0.04
Genotype effect: p = 0.3









Distal BMAT in male and female tibiae - 2nd cohort
Age effect: p<0.0001
Sex effect: p = 0.0009
Genotype effect: p = 0.3









Total BMAT in male and female tibiae - 2nd cohort
Age effect: p<0.0001
Sex effect: p = 0.96
Genotype effect: p = 0.17
Interaction: p = 0.25
F
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6.2.6. 11-HSD1 KO does not protect against age-associated bone loss 
 
All 42-and 70-week old mice showed increased circulating corticosterone 
concentrations, as well as BMAT expansion. However, based on qPCR for GC target 
genes, only KO females showed an increase in GC action in whole bone (data not 
shown). To determine whether increased GCs and/or BMAT expansion are 
associated with bone loss in the older mice, and whether the KOs resist these ageing-
related effects, tibiae were analysed for trabecular and cortical morphology; owing to 
time constraints, these parameters in the second cohort of 70-week-old mice could 
not be measured.  
 
Figure 6.10 shows the trabecular bone morphology of 15-, 42-and 70-week old mice. 
ANOVA detected a strong age effect for the first (Figure 6.10.A) and second (Figure 
6.10.B) cohorts, with the older mice having decreased trabecular bone volume. 
Furthermore, the second cohort also showed a sex effect, with the females having 
less trabecular bone volume than males. Trabecular thickness was increased at 70-
weeks of age in the first cohort (Figure 6.10.C), but no age effects were present 
between 15-week-old and 42-week-old mice in the first or second cohorts (Figure 
6.10.C, D). ANOVA detected an age effect for trabecular number in the first (Figure 
6.10.E) and second (Figure 6.10.F) cohorts, with the older mice having decreased 
trabecular number. Furthermore, the second cohort also showed sex effects, with the 
females having less trabecular number than the males (Figure 6.10.F). Finally, 
trabecular separation was increased with age in the first cohort (Figure 6.10.G), but 
unaltered in the second cohort (Figure 6.10.H). However, an overall sex effect was 
detected by ANOVA for the second cohort, with females having increased trabecular 
separation compared to the males (Figure 6.10.H). Overall, these data show that 
ageing is associated with trabecular bone loss but that this is not influenced by 11-
HSD1 KO. Figure 6.11 shows the cortical bone morphology of 15-, 42-and 70-week 
old mice. In the first cohort of mice there were no significant age or genotype effects 
on cortical thickness, whereas in the second cohort ANOVA confirmed an age and 
sex effect, with cortical thickness decreasing with ageing but being greater in females 
than in males (Figure 6.11.B). In both cohorts, ANOVA confirmed that mean total 
cross-sectional bone area decreased with ageing, regardless of sex (Figure 6.11.C-
D). Similar to the trabecular parameters, no genotype effects were found, indicating 








Trabecular bone volume - 1st cohort
Age effect: p<0.0001
Genotype effect: p = 0.7









Trabecular thickness - 1st cohort
Age effect: p<0.0001
Genotype effect: p = 0.4











Trabecular number - 1st cohort
Age effect: p<0.0001
Genotype effect: p = 0.6











Trabecular separation - 1st cohort
Age effect: p<0.0001
Genotype effect: p = 0.7







Trabecular bone volume - 2nd cohort
Age effect: p<0.0001
Sex effect: p<0.0001
Genotype effect: p = 0.3











Trabecular thickness - 2nd cohort
Age effect: p = 0.25
Sex effect: p = 0.2
Genotype effect: p = 0.8








Trabecular number - 2nd cohort
Age effect: p<0.0001
Sex effect: p<0.0001
Genotype effect: p = 0.5









Trabecular separation - 2nd cohort
Age effect: p = 0.18
Sex effect: p<0.0001
Genotype effect: p = 0.6
Interaction: p = 0.04
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Figure 6.10. Trabecular bone is lost with ageing in WT and 11-HSD1 KO mice. 
15- (control), 42-and 70-week-old C57BL/6JOlaHsd (WT, transparent box) and 11-
HSD1 KO (KO, patterned box) male (black) and female (red) mice were fed and fasted 
as described in Figure 6.2. Post termination, bones were fixated in 10% formaldehyde 
for seven days. Tibiae were then embedded in layers in 1% agarose in a universal 
tube, followed by being scanned at 6m by uCT and analysed by CTan. Trabecular 
bone volume (%) in first (A) and second (B) cohort. Trabecular thickness (mm) in first 
(C) and second (D) cohort. Trabecular number (1/mm) in first (E) and second (F) 
cohort. Trabecular separation (mm) in first (G) and second (H) cohort. Data points are 
presented with median, interquartile range and range shown by box and whisker plot, 
and were analysed by 2-way (A, C, E and G) or 3-way (B, D, F and H) ANOVA with 
Sidak’s multiple comparison test. Numbers of mice per group, and presentation of 



















Figure 6.11. Age-related cortical bone loss is not influenced by 11-HSD1. 15- 
(control), 42-and 70-week-old C57BL/6JOlaHsd (WT, transparent box) and 11-
HSD1 KO (KO, patterned box) male (black) and female (red) mice were fed and fasted 
as described in Figure 6.2. Post termination, bones were fixated in 10% formaldehyde 
for seven days. Tibiae were then embedded in layers in 1% agarose in a universal 
tube, followed by being scanned at 6m by uCT and analysed by CTan. Average 
cortical thickness (mm) in first (A) and second (B) cohort. Mean total cross-section 
bone area (mm2) in first (C) and second cohort (D). Data points are presented with 
median, interquartile range and range shown by box and whisker plot, and were 
analysed by 2-way (A, C) or 3-way (B, C) ANOVA with Sidak’s multiple comparison 
test. Numbers of mice per group, and presentation of statistically significant 





















Average cortical thickness - 1st cohort
Age effect: p = 0.35
Genotype effect: p = 0.6









Average cortical thickness - 2nd cohort
Age effect: p = 0.0021
Sex effect: p = 0.009
Genotype effect: p = 0.4












Mean total cross-sectional bone area - 2 nd cohort
Age effect: p = 0.017
Sex effect: p = 0.78
Genotype effect: p = 0.46















Mean total cross-sectional bone area - 1 st cohort
Age effect: p = 0.035
Genotype effect: p = 0.096
Interaction: p = 0.44
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6.2.8. Ageing-associated corticosterone and BMAT expansion are 
associated with bone loss  
 
The above results show that 11-HSD1 deficiency does not prevent BMAT expansion 
or protect against bone loss with ageing. To further understand the relationship 
between BMAT expansion and bone loss in this context, and if circulating 
corticosterone might influence these parameters, linear regression analysis was 
performed for the 15-, 42.2-and 70.1-week-old mice. The remaining 70-week-old mice 
(70.2) were not included because there was not enough time to complete the µCT 
bone analysis for this group. 
 
Table 6.2 shows the linear regression analysis of male mice. Circulating 
corticosterone was not significantly associated with BMAT volume or with any other 
trabecular or cortical parameters in WT or KO males. Unlike circulating corticosterone, 
BMAT volume was significantly and inversely associated with trabecular bone volume 
fraction (BV/TV) and number (Tb.N) in both genotypes and showed a significant 
positive association with trabecular spacing (Tb.Sp) in KO mice only. Indeed, the 
strength of these associations between BMAT and trabecular bone was greater in the 
KO than in the WT mice, suggesting that lack of 11-HSD1 may influence the 
relationship between BMAT and trabecular bone remodelling. In contrast, BMAT was 
not significantly associated with cortical bone parameters in either genotype. Table 
6.3 shows the linear regression analysis of female mice. Unlike in males, a significant 
positive association was found between corticosterone and total BMAT, regardless of 
genotype. Similarly, in each genotype trabecular bone volume fraction (BV/TV) and 
trabecular number (Tb.N) were negatively associated with corticosterone as well as 
BMAT. Cortical bone area (Ct.Ar) was also negatively associated with BMAT in WT 
females. In addition, corticosterone and BMAT were positively associated with 
trabecular spacing (Tb.S) and thickness (Tb.Th), although, for corticosterone, the 
latter was significant only for WT mice. Unlike in males, the strengths of these 
associations were generally greater in WT than in KO mice, suggesting that 11-
HSD1 may contribute to the ability of corticosterone and/or BMAT expansion to 
modulate skeletal remodelling with ageing. Overall these results suggest that age-
associated BMAT expansion in males might not be associated with corticosterone, 
whereas in females it is. Furthermore, bone loss, particularly for trabecular bone, is 
associated with increased corticosterone concentration and BMAT expansion.  
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 Linear regression analysis for male mice with ageing 








 R2 P value R2 P value R2 P value R2 P value 
T.BMAT 0.136 0.159 0.002 0.909     
BV/TV 0.016 0.645 0.001 0.923 0.392 0.010 0.619 0.012 
Tb.Th  0.028 0.533 0.159 0.288 0.006 0.768 0.309 0.120 
Tb.N  0.002 0.860 0.050 0.564 0.321 0.022 0.815 0.001 
Tb.S  0.019 0.609 0.190 0.241 0.201 0.081 0.453 0.047 
    















Table 6.2. Linear regression analysis of WT and KO male mice, with circulating corticosterone (ng/mL) and total BMAT volume 
(mm3) in tibiae as constant variables. Data from 15-and 42-week old male mice was pooled together to observe changes with ageing. 
BV/TV = % Bone volume fraction (Segmented bone volume to the entire volume of the region of interest). Tb.Th = Trabecular thickness 
(Average thickness of trabeculae). Tb.N = Trabecular number (Average number of trabeculae per unit length). Tr.S = Trabecular 
separation (Average distance between trabeculae). Ct.Th = Average cortical thickness (mm). Ct.Ar = Mean total cross-section bone area 
(mm2). P values in bold represent statistical significance. Direction of association is indicated by cell colour: Green = positive and Red = 
negative, with darker shades used for statistically significant values. n (15 WT male) = 6. n (15 KO male) = 5.  n (42.2 WT male) = 9. n 
(42.2 KO male) = 4. 
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 Linear regression analysis for female mice with ageing 








 R2 P value R2 P value R2 P value R2 P value 
T.BMAT 0.725 0.0001 0.622 0.001     
BV/TV 0.567 0.003 0.534 0.003 0.651 0.001 0.540 0.003 
Tb.Th  0.624 0.001 0.182 0.128 0.658 0.001 0.404 0.015 
Tb.N  0.624 0.001 0.581 0.002 0.718 0.0003 0.670 0.0003 
Tb.S  0.782 <0.0001 0.558 0.002 0.726 0.0002 0.749 <0.0001 


















Table 6.3. Linear regression analysis of WT and KO female mice, with circulating corticosterone (ng/mL) and total BMAT volume 
(mm3) in tibiae as constant variables. Data from 15,42-and 70-week old female mice was pooled together to observe changes with 
ageing. BV/TV = % Bone volume fraction (Segmented bone volume to the entire volume of the region of interest). Tb.Th = Trabecular 
thickness (Average thickness of trabeculae). Tb.N = Trabecular number (Average number of trabeculae per unit length). Tr.S = Trabecular 
separation (Average distance between trabeculae). Ct.Th = Average cortical thickness (mm). Ct.Ar = Mean total cross-section bone area 
(mm2). Statistical significance and the direction of the associations are indicated as for table 6.1. n (15 WT female) = 7. n (15 KO female) 
= 4. n (42.2 WT female) = 4. n (42.2 KO female) = 7. n (70.1 WT female) = 3. n (70.1 KO female) = 4. Please note, for 70-week-old total 




6.3.1 Cohort-dependent variability in the phenotypes of 11-HSD1 KO 
mice.  
 
The aim with this chapter was to investigate if ageing-associated GC excess mediates 
BMAT expansion and bone loss in null 11-HSD1 KO mice, with the hypothesis that 
the increased GCs with ageing contribute to BMAT expansion and bone loss. 
Furthermore, as mentioned in the introduction, the analysis of two cohorts were 
presented side-by-side in this chapter for comparison due to possible cage and/or 
cohort effects. The WT and KO mice in the first cohort were caged separately, 
whereas the second cohort had mixed genotypes in each cage. My results showed 
clear differences between the two cohorts, and due to the first cohort having the WT 
and KO mice in separate cages, it is impossible to distinguish between cage and 
genotype effects within this cohort. Several studies have investigated how different 
cage parameters, for example temperature, nesting material, space, shelter and 
provision of gnawing sticks, affect mice (Latham and Mason, 2004; Bailoo et al., 
2018). Furthermore, besides housing, different facilities can also impact the mice, for 
example their gut microbiota (Spychala et al., 2018), which can also further change 
with ageing (Spychala et al., 2018). In addition, null 11-HSD1 KO mice have an 
altered gut microbiome compared to WT counterparts, and this differs between 
normal chow and Western diet (Johnson et al., 2017). Therefore, it is possible that 
the cohorts were exposed to a somewhat different environmental factors throughout 
their lifetime which influenced them in such ways that our end-results differed between 
the cohorts. In addition, the cages containing the separate genotypes could have 
been in different parts of the room, which could have further influenced the cage 
effects. Therefore, the second cohort allows more trustworthy and robust conclusions 
to be drawn, because (1) mice in the first cohort had WT and KO mice in separate 
cages, and (2) the numbers for the second cohort are larger.  
 
6.3.2. Effect of 11-HSD1 KO on age-related changes in body mass and 
composition 
 
Mice at 42 and 70 weeks of age, in both cohorts, had increased body weight 
compared to the 15-week-old controls. The older mice also had increased fat mass, 
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including the female mice. Although female mice resist fat loss during CR (Chapter 
3), they did not resist fat mass gain with ageing. It has previously been reported in 
humans that ageing is associated with obesity (Hajek et al., 2015), and especially that 
obesity predominantly increases among women between 30-65-years of age (von 
Ruesten et al., 2011).  
 
A different study also demonstrated that with ageing, total fat tissue increases in 
women only, whereas percentage body fat increases in both men and women (He et 
al., 2018). Based on these results, it is clear that increased body weight with ageing 
is due to increased fat mass. In my study, the older mice also had decreased lean 
mass as percentage of body mass, which is common with ageing unless regular 
exercise is performed (Abizanda et al., 2016). Overall, these findings suggest that 
11-HSD1 deficiency does not protect against increases in age-associated adiposity; 
in contrast, the data from the second, more-robust cohort, indicate that lack of 11-
HSD1 may exacerbate increased adiposity with ageing. Compared to previous 
studies investigating 11-HSD1 KO mice and adiposity, my results are the opposite, 
at least for the second cohort. One previous study showed that overexpression of 
11-HSD1 in AT results in increased adiposity (Masuzaki, 2001), whereas the 
hypomorphic 11-HSD1 KO mice on HFD exhibit reduced fat mass compared to age-
matched controls (Morton et al., 2004; Wamil et al., 2011). However, it is worth 
remembering that the 11-HSD1 KO model used in these latter studies is the 
hypomorphic KO. Therefore, the difference in adiposity resistance in these two KO 
models could differ.   
 
 
6.3.3. Effect of 11-HSD1 KO on BMAT expansion and bone loss with 
ageing 
 
As discussed in the introduction to this chapter, Justesen et al., previously reported 
that the hypomorphic 11-HSD1 KO mice lack BMAds (Justesen et al., 2004). Herein, 
I show that 42-and 70-week old null 11-HSD1 KO male and female mice do not lack 
BMAT. Instead, the KOs had age-related increases in BMAT. However, in the 
proximal BMAT in the KO females from the second cohort, BMAT was significantly 
decreased compared to the WT females, although it was still present. Based on the 
knowledge that the first cohort had the genotypes separated in different cages, and 
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that the body composition, adipose depots and BMAT volume vary significantly 
between the genotypes, it suggests that these results could reflect cage effects, as 
discussed above. Interestingly, the BMAT phenotype tracks with the overall 
adiposity/obesity phenotype. This confirms previous studies suggesting that obesity 
is associated with increased BMAT, including with ageing (Patel et al., 2018). It also 
highlights the need to measure body composition if robust conclusions are to be 
drawn about any BMAT phenotype. Therefore, based on the differences in the first 
cohort, the results from the second cohort are more robust and informative regarding 
possible influences of 11-HSD1 with ageing. There are several possible 
explanations for these different results, and also several reasons why my present 
findings allow firmer conclusions to be drawn. For example, as described in the 
introduction, the Justesen et al., (2004) study used a hypomorphic KO, whereas I 
studied a null KO model (Vandermosten et al., 2017; Zhang et al., 2017; Verma et al., 
2018). Furthermore, Justesen et al., (2004) analysed BMAT by static 
histomorphometry, with six sections of bone per animal, and in the proximal tibiae 
only. Conversely, I used osmium tetroxide-staining with CT to quantify BMAT in the 
entire tibia. This method, which was not available in 2004, allows far more 
comprehensive and robust BMAT quantification. Thus, my findings show that null 11-
HSD1 KO mice do not lack BMAT and that they still undergo age-related BMAT 
expansion. 
 
6.3.4. Influence of 11-HSD1 KO on the relationships between circulating 
corticosterone, BMAT expansion and bone loss with ageing 
 
Despite these differences in the BMAT phenotype, both my findings and those of 
Justesen et al., (2004) show that hypomorphic and null 11-HSD1 KO does not affect 
trabecular or cortical parameters. However, I found that the age-associated changes 
in trabecular and cortical bone are associated with increased corticosterone 
concentration and BMAT expansion in both sexes. Several previous studies also 
found increased circulating corticosterone concentration in the hypomorphic 11-
HSD1 KO mice compared to age-matched controls (Kotelevtsev et al., 1997; Harris 
et al., 2001; Yau et al., 2001), but on a different background compared to my null KOs. 
However, other publications did not find this difference in circulating corticosterone 
concentrations in 11-HSD1 exon 5 and the null KO mice (Abrahams et al., 2012; 
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Morgan et al., 2014; Verma et al., 2018), nor did one study that used hypomorphic 
11-HSD1 KO mice (Joyce L. W. Yau et al., 2015). This means that the end results 
between the KOs with the different background strains do vary, as previously 
published (Carter et al., 2009). The correlations between BMAT volume and bone 
parameters were predominantly negative, suggesting that age-related BMAT 
expansion is associated with increased bone loss, supporting previous findings 
(Devlin and Rosen, 2015; Veldhuis-Vlug and Rosen, 2018). Indeed, the strength of 
these associations between BMAT and trabecular bone was greater in the KO than 
in the WT mice, suggesting that lack of 11-HSD1 may influence the relationship 
between BMAT and trabecular bone remodelling. The association between BMAT 
and cortical bone was insignificantly positive for KOs and negative for WTs. This 
suggests that the lack of 11-HSD1 might protect against cortical bone loss with 
subsequent BMAT expansion.  
 
Previous work on the hypomorphic 11-HSD1 KO mice following 21 days of induced 
arthritis showed similar trabecular bone loss, and less cortical bone loss, compared 
to WT mice (Coutinho, 2009). No changes were observed two days following the 
induced arthritis, suggesting that the results observed at the later time point were not 
due to initial differences between the genotypes. This is similar to the lack of skeletal 
differences reported by Justesen et al., (2004) and between the AL-fed WT and KO 
mice in Chapter 5. However, these arthritis studies used young WT and KO mice 
between 8 and 12-weeks of age, and therefore they do not inform about the potential 
impact of the KO on bone with ageing. In addition, in my studies in 15-, 42-and 70-
week old mice, further parameters could be included to determine in greater depth 
the effect of BMAT expansion on cortical bone. 
 
In contrast to the males, the associations between corticosterone/BMAT and bone 
parameters were generally greater in the females. This suggests that 11-HSD1 may 
contribute to the ability of corticosterone and/or BMAT expansion to modulate skeletal 
remodelling with ageing in females. In addition, a previous publication showed that 
trabecular bone loss in females can occur independently of oestradiol, suggesting it 
is potentially more susceptible to GCs (Syed et al., 2010). To address this, mass 
spectrometry would need to be performed on plasma to determine GCs and sex 
hormone concentrations, while markers of oestrogen action within bone and BM could 
be assessed.  
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Surprisingly, corticosterone and total BMAT were not associated in males but were 
positively associated in females. From these results, one interpretation is that, in both 
sexes, bone loss during ageing could be influenced by increased corticosterone 
concentrations and BMAT expansion, and that increased circulating corticosterone 
may contribute to BMAT expansion in females, but not in males. However, other 
factors could also influence this shift, such as sex hormones (i.e. progesterone, 
testosterone). Besides bone loss and BMAT expansion, the older mice, regardless of 
genotype, also had increased circulating corticosterone concentration compared to 
the 15-week-old mice. Further work would need to be conducted to add to the 
numbers, and additional experiments to determine if other hormones could be 
involved in these effects. For example, mass spectrometry could be performed to 
determine the concentration of the hormones in the circulation and BM between the 
genotypes.  
 
A factor that could explain the bone mass loss in the null KOs could be the age. It is 
possible that the mice do lose some bone mass throughout their life, but after a certain 
age they maintain it compared to the WTs. The mice used in this chapter were 42- 
and 70-weeks old (~10 and 16 months old, respectively). Compared to previous 
studies on the hypomorphic 11-HSD1 KO mice with regards to ageing, mice around 
18-26-months of age have been used to investigate the role of 11-HSD1 in other 
age-related conditions (Yau et al., 2001; Sooy et al., 2010; Joyce L.W. Yau et al., 
2015). However, none of these analysed the bone phenotype, and therefore future 
studies should use older mice to further test the role of null 11-HSD1 in age-related 
bone loss and BMAT expansion.  
 
Since most of the studies involving 11-HSD1 KO mice involve the hypomorphic 
model, many gaps in knowledge remain that could be addressed using null 11-HSD1 
KO model. Based on previous publications, the inhibition of 11-HSD1 protects 
against the deleterious effects of excess GCs (Morgan et al., 2014). Moreover, 
increased expression and activity of 11-HSD1 in bone has been shown to cause 
age-induced bone loss and increase the risk of GIO (Cooper et al., 2002). Since the 
hypomorphic model often showed improved results, one would expect the null KO 
model to potentially exhibit even greater improvements due to having a complete lack 
of Hsd11b1 expression. However, a different publication showed that 11-HSD1 plays 
a protective role in the suppression of joint destruction and bone loss in inflammatory 
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diseases (Hardy et al., 2018). Based on this, and if aged null 11-HSD1 KO mice 
have increased inflammation, they might exhibit bone loss, either to a similar or 
greater extent compared to age-matched WT controls. Therefore, more research is 
necessary to understand the mechanism behind age-induced BMAT expansion and 
bone loss, and if other factors such as sex hormones and/or inflammation further 
aggravate the effects.  
 
6.3.3. Limitations and future directions  
 
To further understand how ageing affects null 11-HSD1 KO mice in regards to BMAT 
expansion and bone loss, the addition of more mice would be necessary. Although, 
since the KOs did not resist circulatory effects of GCs with regards to BMAT 
expansion and bone loss, it potentially undermines the reasoning for adding more 
mice to the groups. To further understand how GCs affect BMAT and bone with 
ageing, the BM should be flushed out to examine GC target genes, as well as in the 
bone. In addition, performing mass spectrometry on plasma and BM would be 
important to determine if there are any differences between systemic and tissue-
specific GC concentration. Due to time constraints, the bones from the 70-week-old 
mice from the second cohort were not analysed. Therefore, bone analysis and BMAT 
quantification needs to be done on the 70-week-old mice from the second cohort to 
determine if BMAT does increase with ageing in the second cohort, as found in the 
first cohort, and if bone loss is consistent with ageing. In humans, femoral neck 
fracture is common with ageing (Woolf, 2003), and associations between BMAT and 
fracture risk have also been reported (Wehrli et al., 2000; Justesen et al., 2001; 
Schwartz et al., 2013). This suggests that the older mice might have decreased 
femoral bone mass. Based on my hypothesis, the KO mice should resist the age-
induced bone loss. However, the older mice did not resist tibial bone loss, and might 
therefore not resist femoral bone loss either. Past publications have either shown an 
inverse association between BMAT and bone loss, or no changes, as previously 
discussed in the introduction. However, a more recent publication showed that greater 
BMAT is not associated with bone density/strength in men, but is associated with 
trabecular bone loss in older women (mean age of 80.9) (Woods et al., 2019). It would 
therefore be scientifically and clinically beneficial to scan and analyse the proximal 
femurs of the mice to determine if deficiency of 11-HSD1 protects against femoral 
bone loss as well as to determine the association between BMAT and bone loss with 
 202 
ageing. The findings of Woods et al., (2019) could be explained by the decrease in 
sex hormones, which might cause BMAT expansion and bone loss. However, they 
adjusted for circulatory oestradiol and testosterone concentration, but did not come 
across any associations between BMAT and bone loss (Woods et al., 2019). Instead, 
a different publication found that trabecular bone loss in female mice is not associated 
with oestradiol, but potentially with GCs (Syed et al., 2010). Therefore, the work of 
Woods et al., (2019) would benefit from measuring circulatory GCs, as they could be 
significantly increased in the women and therefore influence the associations with 
bone loss. 
 
As mentioned above, the lack of resistance in BMAT expansion and bone loss with 
ageing undermines the reasoning for adding more mice to the groups. The reason for 
the KOs not resisting BMAT expansion is still to be explored. Since the KO model still 
has circulating active corticosterone, a more efficient model that lacks complete GC 
action might be more efficient to test my hypothesis (further discussed below). In the 
CR study, only the male KOs resisted BMAT expansion with CR, which could 
potentially be due to altered progesterone. However, since mass spectrometry was 
not performed on the ageing mice in this chapter, it cannot be concluded if 
progesterone is involved in the effects on BMAT and bone. A decrease in 
progesterone has shown to inversely correlate with bone mass (Seifert-Klauss et al., 
2012), suggesting that the female mice might have decreased concentrations 
regardless of genotype. In addition, ageing has also been shown to be associated 
with inflammation, termed inflammaging (Franceschi and Campisi, 2014; Franceschi 
et al., 2018). This causes an increase in circulatory GC concentrations (Sergio, 2008; 
Baylis et al., 2013), potentially contributing to the pathological effects observed such 
as bone loss, increased BMAT and body adiposity. To determine if the observed 
results are due to age-induced GCs and/or inflammaging, inflammatory markers could 
be measured in the plasma such as IL-1, IL-6/12/18, TNF-, IFN- (pro-
inflammatory) and TGF- and IL-10 (anti-inflammatory). Corticosteroid binding 
globulin (CBG) could also be measured in the plasma to determine the amount of 
corticosterone that is bound by this protein. However, the corticosterone ELISA used 
in this thesis is provided with a steroid displacement reagent to release bound 
corticosterone to CBGs. Although, to compare between free and bound 
corticosterone, one could use a different ELISA to measure the free corticosterone 
and also do the assay for CBG measurement, if there would be enough plasma for 
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both assays. This would further address the hypothesis in this chapter by being able 
to draw more-accurate conclusions regarding GC availability and action. One could 
also assay 11-HSD1 enzymatic activity in the BM from the control and older WT and 
KO mice, for example using assays that have previously been reported (Hardy et al., 
2007; Patel et al., 2012; Morgan et al., 2014; Loerz et al., 2017).   
 
Instead of adding more numbers to the 11-HSD1 KOs, it would be interesting and 
potentially more productive to work on a different mouse model that robustly resists 
the effects of GCs, especially within the skeleton. For example, compared to WT mice, 
mice with conditional KO of the GR in osteoblasts resist the effects of GCs on bone 
formation (Rauch et al., 2010); however, BMAT was not analysed in these mice. 
Furthermore, mice with a mutation that disrupts GR dimerization did not resist bone 
loss, and neither did mice lacking the GR in osteoclasts (Rauch et al., 2010). Bone 
resorption was not changed in the osteoblast-specific GR KO mice, suggesting that 
GC-induced bone loss occurs by suppression of GC action in osteoblasts, reducing 
bone formation, rather than increasing bone resorption. Based on these results, I 
would not expect increased BM adiposity in the osteoblast-specific GR KO mice 
compared to the WT mice, although this remains to be determined. In addition, if 
BMAT would not differ between the genotypes in normal conditions, it would be 
interesting put these KOs on CR and quantify BMAT. Additional models that can resist 
the effect of excess GC could also be used to further address the hypothesis, for 
example 11-HSD2 overexpression in mice on CR, or adrenalectomy to block 
circulating GCs. These options would further help to understand the function of BMAT 
with ageing, and potential inhibitors of 11-HSD1 and/or GR, or overexpression of 
11-HSD2 for age-related bone loss. In addition, the correlation data in this Chapter 
are associations and do not imply cause and effect, but they do indicate that these 
are all related (GCs, bone and BMAT). Whether the same correlations would be 
expected for the CR cohort is still to be defined at a later point. It is also possible that 
these correlations have less to do with ageing, but more with the overall results and 
the link between GCs, BMAT and bone, either direct or indirect through factors such 









The mechanism regulating BMAT expansion and bone loss during CR and with 
ageing remains incompletely understood. Therefore, the focus of this thesis was to 
investigate if GCs are mediators of CR- and/or ageing-induced BMAT expansion and 
bone loss.  
 
In Chapter 3, I show that CR increases circulating and BM GC concentration. 
Furthermore, GC target genes are upregulated with CR in AT and BM. This suggests 
that GC action is increased with CR in AT and BM. In addition, Hsd11b1 was 
significantly increased in the BM of 15-week-old, but not 10-week-old CR-fed WT 
mice. Moreover, Hsd11b1 was not altered in the BM-free bones of the 15-week-old 
mice, suggesting that Hsd11b1 could be a potential marker of increased BM adiposity, 
as BMAT was not increased in the 10-week-old mice (R. Sulston, unpublished data). 
Furthermore, Hsd11b1 expression is highly expressed in subcutaneous WAT 
compared to stromal vascular fraction in obese patients. However, after weight loss, 
the expression is non-detectable in WAT, but unaltered in stromal vascular fraction 
(Methlie et al., 2013). Moreover, other publications similarly showed increased 
Hsd11b1 expression in subcutaneous and intraabdominal WAT compared to stromal 
vascular fraction (Gesta et al., 2006), as well as increased Hsd11b1 expression with 
adipogenesis (Cheung et al., 2007). This supports my finding that Hsd11b1 
expression might be a marker of increased BM adiposity.  
 
In Chapter 4, the main finding was that 11-HSD1 activity is required for CR-induced 
BMAT expansion in males but not in females. In Chapter 5 I found that CR causes 
cortical bone loss in males and females, with ANOVA showing a genotype effect, 
pointing towards greater cortical mass in KO males compared to WTs. However, an 
insignificant p value (p=0.0629) was detected between the CR-fed males. Based on 
the results, it is difficult to say whether the CR-fed KO males resist CR-induced bone 
loss or not, as the effects are not that robust. Therefore, further work is necessary to 
determine the effect of CR and 11-HSD1 on cortical mass in KO males. If more mice 
are added to the groups, and the KO males do resist bone loss with CR, then it 
suggests that BMAT expansion might be required for CR-induced bone loss, at least 
in mice. If not, then it would suggest that BMAT expansion is not necessary for bone 
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loss. As previously mentioned, BMAT volume and bone loss are not always 
associated, for example rabbits on CR had bone loss without increased BMAT 
(Cawthorn et al., 2016). The 15-week-old mice did not show increased GC action nor 
increased GC concentration, presumably due to fasting/re-feeding. The 10-week-old 
KOs did not resist increased GC target genes either. Overall, these findings suggest 
that the 11-HSD1 KO model does not resist excess GCs. Therefore, based on my 
findings, progesterone was considered as an additional potential regulator of BMAT 
and bone during CR, which will be further discussed below in section 7.2. 
 
Finally, in Chapter 6 I found that BMAT volume increases with ageing, regardless of 
genotype. Furthermore, BMAT was positively associated with plasma corticosterone 
in females, but not males. Age-associated changes in trabecular and cortical bone 
were however associated with increased corticosterone concentration and BMAT 
expansion in both sexes. This suggests that GCs might be necessary for BMAT 
expansion in older females, but not in males.  
 
Based on my overall findings, in the following sections I will discuss whether GCs are 
potential regulatory of BMAT expansion and bone loss during CR and ageing, as well 
as if the 11-HSD1 KO model is the best model to test my hypothesis.  
 
7.2. GCs as potential mediators of CR-and age-induced BMAT expansion and 
bone loss 
 
Based on the findings in this thesis, further research is necessary to determine if GCs 
do or do not mediate CR-induced BMAT expansion and bone loss. Although an 
association was found between corticosterone and BMAT in KO males, this was not 
observed in females. Interestingly, the CR-fed KO males on one-week CR resisted 
increased corticosterone in the BM, suggesting a potential resistance to GC action 
and that tissue-specific corticosterone production might be necessary for BMAT 
expansion. Subsequently, for the older mice, I found an association between BMAT 
and corticosterone in female mice only. An explanation for the resistance in the 
increased corticosterone in the CR-fed KO males is that the AL-fed KOs already have 
CR-like concentrations of corticosterone. Therefore, if GCs drive BMAT expansion, 
the AL KO males should have greater BMAT volume than the AL-fed WT males. 
Based on the BMAT quantification, there is a near-significant p value (p=0.0881) 
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between the AL-fed males, with the KO males having a slightly greater BMAT volume 
than the WTs. Furthermore, the KOs did not resist the up-regulation of the GC target 
genes. For the older mice, LC-MS/MS was not performed. This would however be 
informative to do in the future to determine if the older mice have increased GCs in 
the plasma compared to the BM, and if the KO males maintain the increased 
progesterone with ageing. Although, since the KO males were heavier and fatter than 
the WTs, and obesity is associated with increased BMAT volume (Patel et al., 2018), 
the increased body adiposity could explain the greater BMAT in the AL KO males. 
Overall, both the CR and ageing study revealed novel sex differences with regards to 
BMAT expansion and bone loss. 
 
Based on the presented results, there is contradicting evidence for the KOs resisting 
CR-induced GCs and for GCs increasing BMAT with CR. Therefore, I thought the 
progesterone findings might explain some of the results since the GR and PR share 
a number of target genes (Wan and Nordeen, 2002) and also GCs and 
mineralocorticoids cross-talk with the PR to induce effects of progesterone in vitro 
(Leo et al., 2004). Interestingly, progesterone was significantly increased in the 15-
and 10-week-old KO males compared to females and WT males. This suggests that 
that progesterone might play a role in regulating CR-induced BMAT expansion and 
bone loss, dependently or independently of GCs, as previously discussed in Chapter 
4. On the contrary, progesterone was also increased in CR-fed WT males in 10-week-
old mice, and 15-week-old males showing a similar trend. Compared to the findings 
in the KOs, this supports the conclusion that progesterone might stimulate BMAT 
expansion, rather than suppressing it. However, no formal correlations were drawn 
between progesterone and other factors in Chapter 4, and no in vitro work was 
performed. Therefore, it cannot be concluded that progesterone does regulate BMAT 
expansion. Instead, it can be hypothesis that it plays a role, but further work is 
necessary to determine this. Although, for progesterone to stimulate BMAT 
expansion, it would suggest bone mass might decrease, or it might not be affected. 
This is in contrast to previous publications that have shown that progesterone 
promotes bone formation (Verhaar et al., 1994; Seifert-Klauss and Prior, 2010) and is 
used to treat osteoporosis in menopausal women (Seifert-Klauss et al., 2012; Prior, 
2018). Thus, the idea that it would also stimulate BMAT formation would be intriguing, 
as to my knowledge no model or regulator has been proposed to subsequently 
expand BMAT and induce bone formation. Progesterone is the precursor to oestrogen 
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(Hanukoglu, 1992), and since oestrogen blocks BMAT expansion (Limonard et al., 
2015) and both hormones decrease in menopausal women, it would be postulated 
that progesterone would have similar effect on BMAT. However, that might be with 
ageing when the hormones decrease, but the effect of progesterone on BMAT in 15-
week-old mice might differ with CR. Furthermore, progesterone predominantly 
stimulates osteoblast formation (Verhaar et al., 1994; Seifert-Klauss and Prior, 2010) 
instead of adipocyte differentiation, which might explain the resistance in BMAT 
expansion in the KO males, and the minor bone loss resistance. Since the KO males 
had increased progesterone concentration, even compared to the females, it would 
explain why the females did not resist CR-induced bone loss. Progesterone also 
increases the number of alkaline phosphatase-expressing cells (marker of bone 
formation) in the lumbar vertebrae of both male and female rats (Ishida and Heersche, 
1997). Although, progesterone did exert greater adipocyte differentiation in the female 
rats compared to the males (Ishida and Heersche, 1997). Overall, these findings 
suggest that progesterone is important for bone formation and this might explain the 
minor bone loss in the KO males. However, it does not explain the increased BMAT 
volume in the CR-fed WT mice with increased progesterone concentration compared 
to the AL-fed WT mice. Furthermore, osteoblasts express PR (Eriksen et al., 1988; 
Wei et al., 1993) and oestrogen can stimulate the PR (Ekka et al., 1987; Quadros and 
Wagner, 2008). This suggests that certain effects on bone that are thought to be 
regulated by oestrogen, might be regulated by progesterone. Whether it is the same 
for BMAT expansion with CR and ageing in humans, or for ovariectomised animals, 
remains to be determined. Moreover, to understand the possible relationship between 
GCs, progesterone and oestrogen, it would be informative to quantify the expression 
of GR, MR, PR and ER by qPCR as well as in vitro experiments to determine the 
differentiation between the genotypes, diets and ageing and the addition of these 
hormones to the differentiated adipocyte and osteoblast cells. Based on this, it is 
possible that the decreased progesterone in the CR-fed females and WT males might 
have targeted the BMAds instead of the bone cells, and/or perhaps the progesterone 
was not significantly increased to target either in the AL-fed mice. On the other hand, 
the KO males had increased progesterone, unaltered BMAT and relatively unaltered 
bone mass.  
 
Recent findings revealed different patterns of GC-androgen crosstalk in various 
metabolic tissues, for example in WAT and BAT, where the AR can stimulate 
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expression of GC target genes (Spaanderman et al., 2019). These findings suggest 
that the expression of GC target genes, which were increased with CR, and the BMAT 
outcome could have been influenced by androgens. Herein, such GC-androgen 
crosstalk was not investigated in bone or BM, hence it can only be assumed that if it 
had an impact on WAT and BAT, it might also affect BMAT and its microenvironment 
since BMAT has been reported to have endocrine functions. Although several studies 
have confirmed the presence of both AR and ER in BM (Gruber et al., 1999; Oreffo 
et al., 1999; Mantalaris et al., 2001; Bonnelye and Aubin, 2002), and AR KO mice 
have decreased bone formation and increased BMAT  (Russell et al., 2018). AR was 
not quantified in our study, hence, no conclusions can be drawn in regards to CR and 
11-HSD1 ablation in the BM. Although, testosterone concentration in plasma and 
BM was increased in CR-fed females, but decreased in CR-fed males. The 10-week-
old KO males showed a greater decrease in testosterone concentration with CR 
compared to WTs, suggesting that testosterone might be necessary for BMAT 
expansion with CR. However, the results of Russell et al., suggest that the lack of 
androgens allows for BMAT expansion. It is worth noting that the lack of AR might 
affect other hormones besides testosterone, hence the contradicting results. In 
addition, previous research has revealed that osteocalcin release stimulates 
testosterone proliferation which further stimulate bone growth and maintenance in 
male mice, but not females (Oury et al., 2011). Therefore, the maintenance of 
trabecular bone mass, and very minor cortical bone loss with CR could have been 
maintained by increased circulatory osteocalcin. However, to determine whether this 
is the case, circulatory osteocalcin needs to be measured in CR mice. The same 
experiment could be implemented in the older mice, to determine if osteocalcin 
decreased with ageing and whether that is or is not associated with bone loss and 
increased BMAT. A key question arising from these findings regarding steroid 
hormones is whether GCs are indeed mediating CR-and age-induced BMAT 
expansion and, if so, are they doing it dependently or independently of other 
hormones such as progesterone?  
 
7.3. Implications of BMAT expansion in disease 
 
As previously reviewed in the introduction, increased BMAT and bone loss often 
coincide in different physiological and disease contexts (Section 1.2.2). Based on my 
findings, blocking 11-HSD1 in men with AN and/or osteoporosis might be an option 
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to prevent BMAT expansion and potentially bone loss, since the KO males showed a 
potential resistance to bone loss. Pharmacological agents could be used for this 
(further discussed in section 7.4). Although, since the KO female mice did not resist 
BMAT expansion nor bone loss, this approach might not benefit women. However, it 
is important to note that the effects on mice with CR and ageing, are not always 
corresponding to humans. For example, the effects of GCs on BAT differ between 
human and mouse (Ramage et al., 2016). An additional factor to consider is the 
progression of the disease, as the inhibition of 11-HSD1 might be more beneficial 
prior to the disease becoming more adverse. The more adverse the disease is, the 
inhibition of 11-HSD1 could worsen the side-effects. For example, the lack of 11-
HSD1 during rheumatoid arthritis enhances inflammation (Hardy et al., 2018).  
 
Furthermore, the role of BMAT during CR is still not fully known. Besides the 
associations with bone, where BMAT expansion and bone loss often coincide (but not 
always as previously mentioned), it remains to be explored if BMAT contributes to 
other effects of CR. Based on a recent study, it is possible that the effects of CR on 
immunity could be mediated by BMAT. Under basal conditions, WAT is the 
predominant hub for memory T cells, but during CR it declines. BMAT however 
expands during the same condition, promoting memory T cell accumulation within the 
BM (Collins et al., 2019). While circulatory GCs were elevated, BM GC concentration 
was much lower at baseline and CR, similar to our findings. The high concentration 
of circulating GCs and the interaction between GCs and the GR on T cells could have 
affected the downfall of memory T cells in the circulation. Therefore, the lower 
concentration of GCs in the BM, could have promoted the T cell accumulation in the 
BM to protect the cells from the detrimental effects of GCs. An increase in red blood 
cells was also observed in the BM during CR, suggesting that this increase could have 
influenced the accumulation of memory T cells (Collins et al., 2019). These findings 
highlight potential roles of BMAT expansion during CR and immunological memory 
preservation and function. BMAT has previously been reported to act as an endocrine 
organ due to the release of adiponectin (Cawthorn et al., 2014). Now, these recent 
findings of Collins et al., further confirm the BM as an endocrine organ responding to 
stress aimed at immunological memory. However, further work is necessary to 
understand the mediators involved in this process and how BM adiposity affects it 
during CR.  
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7.4. Future directions  
 
There are several further lines of investigation that could be pursued to overcome 
some of the technical limitations and/or further address the conclusions of my thesis. 
In terms of experiments, quantifying circulating and BM oestradiol concentration 
would have aided interpretation of the progesterone data. Since progesterone was 
increased, I would expect similar results for oestradiol as progesterone ultimately 
converts into oestrogen, as well as other hormones (Hanukoglu, 1992). If so, this 
might also explain the minor lack in cortical bone loss in the CR-fed KO males, as 
BMAT volume and bone mass are often inversely correlated (Justesen et al., 2001; 
Devlin et al., 2010; Di Iorgi et al., 2010; Fazeli et al., 2013; Fazeli and Klibanski, 2019), 
and oestrogen inhibits BMAT expansion (Limonard et al., 2015). Furthermore, Syed 
et al., demonstrated that trabecular bone loss in female mice occurs independently of 
oestradiol, suggesting it is potentially more susceptible to GCs (Syed et al., 2010). 
Compared to my results, based on the findings of Syed et al., it suggests that the 
oestradiol concentration in the CR females might be low. Therefore, measuring 
plasma and BM oestradiol concentration in male and female mice would allow us to 
make a firmer conclusion regarding what is allowing the CR-fed KO males to resist 
BMAT expansion and possibly cortical bone loss. If BM oestradiol is not increased 
during CR, it could instead point towards progesterone as an independent regulator 
of BMAT expansion and bone loss. Although, it has been published that the 
combination of oestrogen and progesterone is more effective to prevent bone loss 
than oestrogen alone (Issar et al., 2006; Seifert-Klauss et al., 2012; Prior, 2018), but 
BMAT was not investigated. In addition, the relationship between circulatory 
progesterone and GC concentration has been reported during stress (Kalil et al., 
2013), with an increase in both hormones compared to non-stressed rats. This 
suggests that oestradiol might also be increased in conditions of stress, such as CR, 
mirroring the increased progesterone concentrations. To further test the progesterone 
finding, one could administer progesterone antagonists to the KO males. If such 
antagonists restore bone loss and BMAT expansion, this would support the 
identification of progesterone as a regulator of BMAT and bone loss. One caveat is 
that such antagonists might also indirectly influence the concentration and/or 
functions of GCs and/or oestradiol; hence, mass spectrometry would also need to be 
performed on plasma and BM to determine the concentrations of such hormones, to 
determine if they were influencing the BMAT and bone phenotype post-antagonism 
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of progesterone. In the older mice, corticosterone and BMAT were each correlated 
with age-induced bone loss. However, the lack of LC-MS/MS analysis in plasma and 
BM limits our ability to determine if progesterone also plays a part in this. Overall, in 
the CR study the increased BM and plasma progesterone concentrations in the KO 
males raises the possibility that, in this context, progesterone might have a protective 
effect to limit bone loss and BMAT expansion with CR. However, no correlations were 
drawn between bone parameters and the progesterone, and neither between 
progesterone/corticosterone and fat/lean mass. That could further give us more 
insight into the relationship between these hormones and adiposity and bone.  
 
A disadvantage to using 11-HSD1 KO mice is that they still have GCs. The 
intracellular regeneration of corticosterone is absent, but adrenal production of 
circulatory corticosterone is not. To overcome this, either a different KO model could 
be used, for example osteoblast GR KO model that has previously shown to resist 
effects of excess GCs on bone (Rauch et al., 2010), as previously discussed in 
Chapter 4 and 6 (4.3.2 and 6.3.4, respectively). Adrenalectomy could also be 
performed. By removing the adrenal glands, the synthesis of corticosterone would 
stop and circulatory concentration would drop. This would allow us to investigate if 
BMAT expands during CR in the absence of circulatory and intracellular GCs and, 
perhaps even more importantly, if the adrenalectomised KO mice would survive on 
calorie deficit.  
 
In the past our lab’s protocol for qPCR from bone involved grinding up the whole bone 
and then assessing expression of adipocyte markers as a readout of BM adiposity 
(Cawthorn et al., 2014; Sulston et al., 2016). However, this does not distinguish gene 
expression between BM and bone. Therefore, in my PhD I optimised the protocol to 
flush out the BM and do qPCR on the BM alone, followed by the bone itself. This way, 
the results are more accurate for the gene expression in each tissue. However, there 
is one more possible optimisation that could be performed which includes isolating 
the BMAds and stromal cells from the BM. This would allow for even more precise 
quantification of target gene expression. A limitation with this is that a mouse bone is 
very small and several mouse bones might have to be pooled together for each group, 
which means more experimental mice and higher costs. Although, it is not impossible 
as it has been previously performed (Fan et al., 2017). An additional experiment that 
would be intriguing to do would to sort and analyse the nuclei from BMAds (Wu et al., 
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2019). Such single-cell approaches to characterise BMAds from AL- vs CR-fed mice 
would be interesting, as it would give us more information about BMAd function, 
potentially identify further BMAd subtypes, and reveal how CR impacts not just the 
amount of BMAT, but also the properties of BMAds on a single-cell level.  
 
Pharmacological approaches could also be used to further address my hypothesis 
and strengthen my conclusions. For example, metyrapone, a steroidogenesis inhibitor 
that has previously been used to block adrenal GC production (Lorivel, Gras and 
Hilber, 2010; Murphy et al., 2017). This drug could be used to inhibit GC synthesis in 
WT animals, and simultaneously have them on CR to investigate BMAT volume and 
bone morphology. A second option would be the GR antagonist RU486, which has 
previously been used to deteriorate adrenal steroidogenesis in patients with CS (Leo 
et al., 2004; Johanssen and Allolio, 2007). Based on these agents, I would expect 
BMAT expansion to be blocked with CR and ageing, if indeed GCs are strong 
regulators of BMAT expansion. However, RU486 also targets the PR and AR, hence 
the results can once again be reflecting more than the effect of one hormone (Zhang, 
2006; Raaijmakers, Versteegh and Uitdehaag, 2009). Moreover, progesterone 
antagonists could also be used to test the role of progesterone on CR-and ageing-
induced BMAT expansion and bone loss as previously discussed in Chapter 4, 
section 4.3.3.  
 
Regarding using a more robust KO model that lacks complete GC action would 
include the GR KO in osteoblasts, as previously discussed in Section 4.3.2 and 6.3.4. 
Briefly, this KO model resists the effects of GCs on bone loss (Rauch et al., 2010). 
Using this KO model would benefit our current understanding and findings regarding 
the relationship between GCs, BMAT expansion and bone loss. A different model to 
consider would be the global knockout of Osx, which has previously been reported to 
suppresses adipogenesis via PPAR in vitro (Han et al., 2016). Furthermore, BM 
adipocytes have been reported to derive from progenitor cells expressing Osx (Chen 
et al., 2014). Therefore, Osterix-Cre x Pparg-floxed KO mice may be one way to 
specifically ablate BMAT, but not other AT depots. If successful, this could be an ideal 
model to investigate the formation of BMAds and if Osx expressing cells are part of 
the BMAds formation. Furthermore, based on my findings that BMAT expansion might 
be necessary in CR-fed KO males to lose bone mass, I would also want to address if 
the lack of BMAT in Osterix-Cre x Pparg-floxed KO mice would prevent bone loss.  
 213 
A recent publication used an Osx-Cre mouse model to investigate the role of GCs on 
BMAT during CR (Pierce et al., 2019). However, there are some limitations to this 
study, which raises questions to how interpretable their results are. The mice had the 
GR deleted in the BM osteoprogenitors (Osx-Cre), and the control groups they used 
did not include a non-floxed Cre+. Since the Osx-Cre model already has a skeletal 
phenotype of delayed bone formation (Huang and Olsen, 2015; Wang, Mishina and 
Liu, 2015; Dallas et al., 2018) the results of this study are difficult to interpret without  
including the non-floxed Cre+ controls. The authors argued this by saying that the 
skeletal phenotype is not present past 12 weeks (Davey et al., 2012), and the mice 
they used were 6 months old. They reported that the AL-and CR-fed GR KO mice had 
reduced bone mass, but significantly increased BMAT compared to the controls. 
These results are contradicting every publication regarding GCs and BMAT volume, 
and regarding GC therapy in patients that show increased BMAT (Vande Berg et al., 
1999). Due to their results being the opposite of all previous publications, and their 
lack of use of an appropriate non-floxed Cre+ control group, it is difficult from this 
study to draw reliable conclusions about the role of GCs in CR-induced bone loss and 




The most notable finding of my PhD research is that 11-HSD1 KO confers resistance 
to CR-induced BMAT expansion in male mice, but not in females. However, it remains 
unclear if this is through blockade of GC action, or if other mechanisms are involved. 
Based on the CR and ageing study, the overall results suggest that there is an 
association in between GCs and BMAT expansions. However, considering some of 
my findings, such as the lack of increased GC action in WAT and BM with CR and 
ageing, as well as bone loss in all mice, less so in the CR-fed KO males and the 
increased progesterone concentration in the KO males, it is possible that GCs might 
not induce these effects alone and that other factors such as progesterone, oestradiol 
and/or testosterone are involved that might further influence the physiological and 
pathological implications of BMAT. From a clinical research perspective, it is important 
to investigate and disclose these mediators and pathways as they can be used to 
improve bone health in patients with AN, CS, osteoporosis and other bone diseases. 
Furthermore, targeting BMAT instead of the bone itself could be an alternative that 
might include less side effects, as bone loss. 
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